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Abstract
The cascade linking growth factor receptors and G-protein coupled receptors (GPCRs) to 
the regulation of p42/44 mitogen-activated protein kinase (p42/d4^P^) has been 
described in some detail and involves numerous steps of phosphorylation and protein- 
protein interaction. There is a remarkable degree of similarity in the pathways initiated by 
these two receptor families, although some degree of cell/receptor specificity exists. In 
this study, the regulation of p42/44^^P^ by the 02A adrenoceptor and the ô opioid 
receptor following transfection into Rati fibroblasts to different receptor densities was 
quantitatively measured and compared to the regulation by endogenous G-protein 
(lysophosphatidic acid: LPA) and tyrosine kinase (epidermal growth factor: EGF) 
coupled receptors.
The wild type 02A adrenoceptor was expressed at a high (clone TAGWT 17: 5600 
fmol/mg protein) and low density (clone TAGWT 3: 460 fmol/mg protein) which 
permitted greater G-protein activation in clone TAGWT 17 cells as measured by agonist 
(UK14304)-mediated stimulation of high affinity GTPase activity and cholera toxin- 
catalysed [32p]ADP-ribosylation of Gi-like proteins. Greater maximal activity and lower 
half-maximal agonist concentrations (EC50 values) were determined for clone TAGWT 
17. The greater signalling ability was also determined at the level of inhibition of 
adenylyl cyclase. Previous studies had demonstrated the activation of p42/44^ ^ E  by 
the «2A adrenoceptor, UK14304 treatment of cells of both these clones phosphorylated a 
significant proportion of p44MAPK^  demonstrating that there was no requirement for high 
level expression to observe this coupling. This response was dose-dependent with 
TAGWT 3 clone displaying a 10-fold greater EC50 value than clone TAGWT 17.
An Asn'^  ^mutation of the oc2A adrenoceptor (Asp^ ^^  changed to Asn) substantially 
reduced the G-protein coupling efficiency of the receptor, previously demonstrated as a 
complete or partial loss of signalling capacity. This mutant receptor expressed in
fibroblasts (clone ASN79 4: 3000 fmol/mg protein; ASN79 9: 4300 fmol/mg protein) 
demonstrated an attenuated, but not eliminated, ability to stimulate G-protein activation, 
inhibit adenylyl cyclase and phosphorylate p42/44^^^. This indicated that the coupling 
efficiency to the MAPK cascade was not exceptionally poor, as even a severely limited 
G-protein activation substantially stimulated this pathway. However, the time course of 
phosphorylation of p44^ ^ K  was significantly more delayed and transient which would 
indicate that the kinetics of this regulation is dependent on the level of stimulation of the 
G-protein-coupled pathway.
The Ô opioid receptor was also expressed to a low (clone DOE : 170 fmol/mg protein) 
and high density (clone D2 : 6400 fmol/mg protein), and the ability of this receptor to 
regulate Gi-like proteins (as determined by agonist (DADLE: [D-Ala^, D-Leu^] 
enkephalin)-mediated stimulation of high affinity GTPase activity, P^SjGTPyS binding 
and cholera toxin-catalysed [^^P]ADP-ribosylation) again conelated with the receptor 
level in the two clones: higher maximal activities and lower EC50 values were detennined 
for clone D2. DADLE-mediated adenylyl cyclase inhibition and phospholipase D 
activation was also greater in clone D2. Consistent with the similarities of signalling 
capacity of the « 2A adrenoceptor, DADLE treatment phosphorylated and activated 
p42MAPK and p44MAPK via Gi-proteins in both of these clones. This result added 
another GPCR to the list which can regulate p 4 2 /4 4 ^^^  and again demonstrated that 
there was no requirement for receptor overexpression. Activation by DADLE was dose- 
dependent and a 40 fold higher concentration of DADLE was required for half-maximal 
activation in clone DOE compared with clone D2. This difference was much more 
pronounced than that detected at the level of G-protein activation and indicated the 
presence of a large receptor and stimulated G-protein reserve for the activation of 
p42/44^P^^ in both clone D2 and DOE, although the magnitude of this reserve was 
greater in clone D2. These DADLE-mediated concentration-response curves also 
demonstrated that the activation of p42/44^PI^ was co-operative in nature for both 
clones (indicated by Hill coefficients greater than 1.0), suggesting that there may be more
ii
than one input point into the p 4 2 /4 4 ^ ^ ^  cascade for the ô opioid receptor. This co- 
operativity was not obseiwed for the response to UK14304 in clone TAGWT3 or 17 or to 
LPA in any clone, demonstrating that this is not a universal feature of GPCRs.
The time course of DADLE-mediated activation of p 4 2 /4 4 ^^^  followed a similar 
pattern in both opioid receptor expressing clones, however, the activation was 
significantly more sustained in clone D2. The time course of activation in clone D2 was 
more delayed and more transient with lower concentrations of DADLE. This confirms 
that the time course of activation is dependent on the level of G-protein stimulation.
These conclusions were confirmed by the ability of ligands with a range of intrinsic 
activities at this receptor to phosphorylate p44MAPK Even ligands which displayed vei^ 
limited intrinsic activity in GTPase activity measurements significantly phosphorylated 
p44MAPK jjj clone D2, although the time course was more delayed and transient than 
with a full agonist. Only the more efficacious ligands stimulated phosphorylation of 
p44MAPK in clone DOE, and again they displayed a more delayed and transient time 
course than for DADLE.
The influence of other signalling pathways and kinases on the regulation of p42/44^^^^ 
phosphorylation by both the (%2A adienoceptor and ô opioid receptor was also examined. 
Both of these responses were sensitive to inhibition by cAMP elevating agents and may 
suggest a secondary input into the MAPK cascade. The lack of any significant effect of 
butan-l-ol or chelerythrine pretreatment indicated that phospholipase D and protein kinase 
C were not involved in the DADLE-medated phosphorylation of p44MAPK in clone D2. 
Similarly, genistein displayed no inhibitory effect on the activation of p44^ P K  by either 
of these GPCRs. However, tyiphostin AG1478 and wortmannin attenuated the response 
to DADLE in clone DOE, although the higher level of receptor expression in clone D2 
permitted this inhibition to be overcome. This would appear to indicate that the EGF
111
receptor kinase and the phosphatidylinositoi 3-kinase are involved in the pathway initiated 
by the ô opioid receptor leading to the phosphorylation of p44MAPK
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Chapter 1: Introduction
Chapter 1: Introduction
The problem of how cells convey a signal from the binding of an extracellular ligand to 
an intracellular effect is central to modern biology. In this field, an increasing amount of 
attention is being given to intracellular signalling pathways which transduce signals 
which regulate cellular growth and differentiation. Of these pathways, those stimulated 
by growth factors acting on tyrosine kinase-linked receptors were historically the first to 
be discovered and much of the early information about these pathways aiose from studies 
on these systems. Many of the early signalling events leading to mitogenesis have been 
discovered and found to involve numerous kinases and protein-protein interactions. 
Receptors which make use of the heterotrimeric guanine nucleotide-binding proteins (G- 
proteins) to transduce their signals were also found to stimulate mitogenesis. The 
similarities and differences between the signalling pathways initiated by these two 
categories of receptors has been an area of intense study in recent years.
These studies have discovered the importance of an increasingly large and complex 
family of enzymes involved in mitogenic pathways: the mitogen-activated protein kinase 
(MAPK) family. The work which is described in this thesis is focused on the regulation 
of a subset of this family, namely p42 and p44 mitogen-activated protein kinase 
(p42MAPK and p44MAPK^  by receptors which couple to the G{ family of G-proteins.
1.1 G-proteiii coupled receptors
Many external signals such as hormones, neurotransmitters, light, and odorants produce 
their effects by interacting with transmembrane receptors which transduce the 
extracellular' signals to effector molecules in the interior of the cells by means of 
heterotrimeric G-proteins. Many of these receptors (the G-protein coupled receptors - 
GPCRs) have been cloned and sequenced and found to share common structural features 
(which are explained in more detail in Dohlman etaL, 1991), Hydropathy plots 
suggested that GPCRs contained seven hydrophobic, membrane spanning regions and all
receptors of this family are believed to fit this model with an extracellular- amino-terminus 
and an intr acellular carboxy-terminus. The transmembrane spanning regions are thought 
to be composed of a  helices based on structural similarities with bacteriorhodopsin. The 
agonist binding region has been determined in many of the receptors to be formed at least 
in part by the transmembrane region of the receptor. An important feature is that 
antagonists often display a distinctly different binding site from the naturally occurring 
agonists.
Site-directed mutagenesis, deletions and chimeric receptor studies have been performed 
in order to identify regions of the receptor which ar e important for coupling to their G- 
proteins (Dohlman etal., 1991 ; Exton, 1996). It is thought that the important regions for 
this function ar e the car boxy-terminal end of the third intracellular loop and the proximal 
part of the cytoplasmic tail as well as part of the second intracellular loop. However, this 
work has not been able to detemiine specific amino acid sequences required for coupling 
to selective G-proteins and thus it appears that the overall three-dimensional structure of 
the cytoplasmic parts of the receptor is the important deteiininant for G-protein coupling.
GPCRs are post-translationally modified. These modifications may include extracellular 
N-linked glycosylation on the ami no-terminal region which might contribute to 
detennining proper distribution of the receptor and intracellular lipid modification which 
takes the foim of palniitoylation at a cysteine or cysteines in the caiboxy-terminal region. 
This palmitoylation may be dynamic and regulated by receptor activation and through 
intercalation with the membrane bilayer may create a fourth cytoplasmic loop which may 
play various roles in different receptors such as membrane anchorage, regulation of 
desensitisation or G-protein interaction (Milligan e ta l, 1995).
Prolonged stimulation of a cell often results in reduced responsiveness to subsequent 
challenge with the same stimulus in a rapid process termed desensitisation. For many 
GPCRs this process is rapid and involves serine/threonine phosphorylation of the
receptors by second messenger-regulated kinases such as protein kinase A (PKA) and 
protein kinase C (PKC) and by G-protein receptor kinases (GRKs). PKA is involved in 
heterologous desensitisation which may occur in response to elevated cAMP levels in the 
cell and leads to the modification of any receptor with an appropriate target site. The 
GRKs are involved in homologous desensitisation occurring only at high levels of 
agonist and their action is dependent on agonist binding to the receptor. The GRKs are 
apparently synergistically activated by Gpy and by the agonist-bound receptor (see later) 
and the phosphorylation permits the binding of a second factor (an arrestin) which 
uncouples the receptor from its G-protein (Dohlman etal, 1991). A longer-term process 
is that of down-regulation which is characterised by a reduction in the total number of 
receptors present in the cell and this occurs over several hours.
1.2 Heterotrimeric G-proteins
The large family of heterotrimeric G-proteins plays an important role in transducing 
signals at the cell surface to effector proteins within the cell in all eukaryotic organisms 
(Hepler and Gilman, 1992; Neer, 1995; Rens-Domiano and Hamm, 1995). These 
proteins are heterotrimeric, being composed of three distinct subunits: ot, p and y. The a 
subunit family is composed of over 20 members with approximate molecular masses 
ranging between 39 and 52 kDa. The a  subunits contain a single high affinity binding 
site for guanine nucleotides (GDP and GTP) and have intrinsic GTPase activity. G- 
proteins have been defined by the identity of the a  subunit which they contain. There are 
now five known mammalian p subunits of approximate 36 kDa and ten y subunits of 6-9 
kDa. p and y subunits are tightly complexed and function as a unit. The structures of 
these subunits have been extensively studied (see Neer, 1995; Rens-Domiano and 
Hamm, 1995; Gudermann etal, 1996; Exton 1996 for reviews) and recently crystal 
structures of heterotrimeric G-proteins have been described which have revealed the 
guanine nucleotide-dependent interaction of the a  and Py subunits which regulates their 
interaction with receptor and effector molecules (Wall etal, 1995; Lambright etal. , 
1996).
Although all three subunits lack any sequence which would obviously traverse a lipid 
bilayer, the heterotrimer is bound to the plasma membrane. The isoprenylation of the 
caiboxy-tenninus of the y subunit appears to be essential for the plasma membrane 
association of the Py complex, as well as for interaction with effectors and Ga subunits 
(Clapham and Neer, 1993). The role of lipid modification of the a  subunit is cuiTently 
the subject of much investigation. Members of the Gja class (see below) have been 
shown to be co-translationally myristoylated at their amino-teiminal glycine and this may 
play a role in membrane association and interaction with Gpy. Members of all the classes 
of Ga have been shown to be palmitoylated in a post-translational modification which is 
dynamic and appears to be regulated by their activation (Milligan etal., 1995). The role 
of the palmitoylation of these proteins is still somewhat controversial but may include 
some contribution to plasma membrane localisation as well as subunit and G-protein- 
receptor coupling.
The GDP bound fomi of a  is tightly bound to Py and is inactive, whereas the GTP 
bound form is dissociated from Py which permits the a  and the Py subunits to regulate 
effector proteins. The intrinsic GTPase of a  switches off this activity and allows 
reassociation with Py to occur. Receptors regulate this cycle of activation and 
deactivation of the G-proteins by inducing a confoimational change which causes GDP 
dissociation from the inactive G-protein complex (Figure 1.1).
GPCR
GDP
|— A -]
GPCR
GTP GDP
GTP
r  A - i
GPCR GPCR
GTPGDP
HTh
GPCR
E2
GTP
Figure 1.1 Transmembraiie signalling by heterotrimeric G-proteins
Agonist (A)-mediated activation of the receptor stimulates a confoiTnational change which 
favours the interaction of the receptor with the heterotrimeric G-protein (Step 1). This 
induces a confonnational change in the a  subunit which promotes dissociation of GDP 
from its binding site and permits GTP to bind (as it is present in significantly higher 
levels than GDP in normal cellular conditions). This induces the activated conformation 
of Get which dissociates from the receptor as well as from Gpy (Step 2), This releases 
the receptor to interact with further G-proteins, and the a  and (By subunits to regulate 
effector proteins (Step 3). The active state persists until the intrinsic GTPase activity of 
Ga hydrolyses the bound GTP to GDP (Step 4) and so the duration of activity is 
determined by the rate of GTPase activity. The GDP-bound form of G« favours 
reassociation with Gpy which switches off both subunits and primes the system to 
respond again (Step 5).
1.2.1 Ga-families and their function
The G-proteins were subclassified according to amino acid sequence relationships of the 
a  subunits (see Table 1.1) although functional relationships follow this system closely as 
well. Much could be discussed as to the function of each of these subfamilies and their 
members, however, only a limited introduction to each of these will be given. The 
function and effect of the members of the G12 family is still poorly understood.
Table 1.1 Classes of mammalian G^ subunits
Class Members Toxin Some Effector Functions
Gs « 8 ,  « O lf Cholera Stimulate adenylyl cyclase.
regulate Ca^+ channels
Gi Oil, ai2, 0i3, Pertussis (except a^), Inhibit adenylyl cyclase, regulate
Gto, GC(2, Ctg, Cholera (for ott and Ug Ca^+ and K+ chaimels, activate
«Z only) phospholipase C
Gq Oq, ctji, - Activate phospholipase C
«15, «16
Gi2 «12, «13 - Regulate Na+/K+ exchange
1.2.1.1 Gg family
One of the earliest second messengers to be discovered was cAMP and its production is 
catalysed by a large family of proteins called the adenylyl cyclases (Sunahara e ta l , 
1996). Although these enzymes are regulated in diverse ways (De Vivo and Iyengar, 
1994b), all of the mammalian adenylyl cyclases which have been identified thus far are 
stimulated by members of the Gg family. All members of the Gg family are sensitive to 
modification by the bacterial cholera toxin which catalyses the ADP-ribosylation of a 
specific Arg residue of the a  subunit which is thought to play a key role in the GTP 
hydrolysis mechanism ( Rens-Domiano and Hamm, 1995). This modification inhibits 
the GTPase activity thereby constitutively activating the protein.
1.2.1.2 Gi family
Pertussis toxin can catalyse the ADP-ribosylation of most members of the Gi family.
This modifies a Cys residue four amino acids from the carboxy-terminus and thus 
inhibits receptor-G-protein coupling. Pertussis toxin sensitivity is often used to implicate 
Gi-proteins in signalling pathways. The Gi family couples receptors to various effector 
proteins. The most common and widely studied is the inhibition of adenylyl cyclase, but 
others include ion channels, phospholipases and the MAPK cascade (see later). The 
mechanism of inhibition of adenylyl cyclase by Gi-proteins depends, to a great deal, on 
the type of adenylyl cyclase which is present. This can occur by means of a direct 
inhibition of the enzyme by the Gi^ subunit (especially on type V and VI isoenzymes) or 
by release of py complex which can inhibit the activity of Gga ou type 1 cyclase (see 
below).
1.2.1.3 Gq family
Members of the Gq family, all of which are insensitive to both pertussis and cholera 
toxins, have been shown to be important in the regulation of members of the 
phosphoinositide-specific phospholipase C (Pl-PLC) family (Exton, 1996). These 
enzymes catalyse the hydrolysis of phosphatidylinositol 4,5-bisphosphate to form two 
second messengers, inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 
regulates the release of intracellular Ca^+, while DAG activates many isozymes of PKC. 
Specifically, it is members of the PLCp sub-family (isozymes 1, 2, 3 and 4) which can 
be activated by Gq (Exton, 1996).
1.2.2 The role of Py complex
For a long time, the accepted viewpoint was that the py complex was present only as a 
facilitator of the activity of the a  subunits, stabilising the inactive fomi, localising it to 
membranes and presenting it to receptors. However, increasingly, the importance of the 
direct regulation of effector proteins by Py complexes has been realised (discussed in 
Sternweis, 1994; Clapham and Neer, 1995). Numerous effectors which are regulated by
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Py subunits have now been found including K+ and Ca^+ channels, adenylyl cyclase, 
PLCp, GRKs and they are implicated in the regulation of the MAPK cascade (as will be 
discussed later). It is now clear that effectors can be regulated by G^ subunits alone, by 
Gpy alone, by both subunits acting independently of each other, or by both subunits 
acting synergistically or antagonistically. This presents a great potential for complexity in 
the regulation of effector molecules by GPCRs, especially when the ability of one 
receptor to interact with more than one type of G-protein (see next section) is also 
considered. Selectivity between the different possible effects probably relies heavily 
upon the cell-specific expression of different isoforms of the signalling components.
The different isoforms of adenylyl cyclase are regulated by some of these mechanisms 
involving Py and a  subunits (Sternweis, 1994; Sunahara etal, 1996). For example, . 
type I adenylyl cyclase is susceptible to direct inhibition by Gpy and activation by Gga 
whereas types 11 and IV are only modestly activated by Gga but are synergistically 
activated further by Gpy. In contrast type 111 is neither activated nor inhibited by Gpy but 
is still regulated by Gga-
PLCp2 and 3 are stimulated by Py subunits as well as by Gqp (as mentioned above) 
although these effects are selective with regard to the preferred isoforms (Exton, 1996). 
The py subunit acts independently of Gq^ and activation is not conditional on priming by 
either subunit. This implies that these subunits act at distinct sites within the PLC 
molecule. The pertussis toxin-sensitive regulation of PLC activity by GPCRs is thought 
to occur by py-mediated activation of PLCp .
In addition to enhancing receptor interaction with Ga, the Py complex has also been 
shown to regulate receptor desensitisation by localising GRKs (such as the p-adienergic 
receptor kinase (PARK)) to the plasma membrane (Pitcher etal, 1992) through a direct 
interaction mediated by the carboxy-terminal region of pARK (which includes a 
plecksti'in homology domain (see later)). Activation of the GRKs is achieved by a
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synergy between the agonist-activated receptor and Gpy to stimulate phosphorylation and 
desensitisation of the agonist-bound receptor (Haga etal, 1994). This mechanism may 
suggest a general model of membrane localisation and co-activation for the function of 
Gpyin regulating other effectors.
1.3 Multifunctional signalling by GPCRs
The mechanisms by which any one GPCR can regulate multiple effector pathways and 
how specificity in these pathways is achieved aie of considerable interest (Milligan,
1993, Guderman etal, 1996). There is a potential problem of proving experimentally 
that multiple effectors aie regulated by a single receptor expressed in its physiological 
setting as there can be many genetic subtypes of one receptor which respond to the same 
ligand but activate distinct effector pathways. A frequent strategy to circumvent this 
problem involves heterologous expression of receptors in cells which do not usually 
contain them. If this technique is used, it must be taken into account that expressing the 
receptors in foreign genetic backgrounds to levels which are frequently considerably 
higher than in the cells which endogenously express the receptors may lead to non- 
physiological interactions of signalling components while the physiological situation may 
represent greater specificity; of coupling (see Guderman etal, 1996 for examples).
Nevertheless, heterologous expression has indeed demonstrated the coupling of a single 
receptor to multiple effector proteins and examples of such will be seen in this thesis.
The mechanisms by which receptors produce these effects are currently under study but 
may involve the ability of one receptor to couple to distinct G-proteins which can then 
activate distinct signalling pathways, or both the a  and py subunits released from one G- 
protein regulating distinct effectors. Some of the mechanisms can be clearly seen in the 
regulation of the MAPK cascade by GPCRs.
1.4 THE MAPK CASCADE
MAPKs ai e important intennediates in signal transduction pathways that are initiated by 
many types of cell surface receptors. This family of MAPKs has been extensively 
studied over the past decade and is composed of three main groups: p42 /p44^^^  
(ERKs), JNK/SAPK and p38/RK (Davis, 1994, Cano and Mahadevan, 1995). It is 
with the classical MAPKs or ERKs (extracellular regulated kinases) that this thesis will 
mainly deal, although the other subfamilies will be mentioned later in this Introduction. 
p42MAPK and p44MAPK are important enzymes involved in mitogenesis and 
differentiation and were initially described as regulated by growth hormones acting at 
tyrosine kinase-linked receptors. Subsequently it was realised that cytokines, antigens 
and GPCR agonists could also regulate their activity (for examples see Pelech and 
Sanghera, 1992; Pelech, 1993; Malarkey etaL, 1995). Numerous GPCR agonists have 
since been demonstrated to activate these enzymes via endogenously expressed receptors 
(including those for thrombin (van Corven etal., 1993) and lysophosphatidic acid (LPA) 
(Hordijk etal, 1994)) and via heterologously expressed receptors (including the 
muscarinic m2 acetylcholine receptor (Winitz e ta l , 1993) and a 2A-adrenergic receptor 
(Alblas etal, 1993)). Regulation of these MAPKs is achieved by means of intricate and 
complex cascades involving phosphorylation and protein-protein interactions which will 
be described in some detail (reviewed in Blenis, 1993; Crews and Erikson, 1993; 
Burgering and Bos, 1995; Malai'key e?a/., 1995). Although the tyrosine kinase linked 
receptors and the GPCRs were originally thought to use largely distinct pathways in 
order to regulate these enzymes (Crews and Erikson, 1993), cuixent research has 
increasingly suggested considerable similarity in the two cascades. It should be noted 
that there is great diversity in the pathways used by different receptors and cells and 
therefore some of the generalisations which will be mentioned will not be true in every 
system. A diagram illustrating the MAPK cascade as initiated by GPCRs is shown in 
Figure 1.2.
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Figure 1,2 The G-protein coupled MAPK cascade
Schematic diagram of the regulation of p42/44^^^^ by GPCRs via Gg, Gqand Gi- 
protein families and growth factor tyrosine kinase receptors (RTK). See main text for 
details and variations from this scheme.
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1.4.1 p4 2 ^APK and p4 4 MAPK
MAPK was first identified in adipocytes as an insulin-activated soluble serine/threonine 
kinase which catalysed the phosphorylation of microtubule-associated protein 2 (Ray and 
Stui'gill, 1987). Two proteins of approximate molecular mass 42 kDa had previously 
been observed to be phosphorylated on tyrosine residues in response to growth factors 
and phorbol esters (Gilmore and Martin, 1983; Cooper etal, 1984) and these proteins 
were found to mediate the activity observed by Ray and Sturgill (Rossomando et al, 
1989). Cloning and characterisation of these proteins (Boulton etal,  1990 and 1991) 
demonstrated a family of kinases with two main isofonns, p42 and p44 (also called ERK 
2 and 1 respectively but from now on these will be denoted as p42^^^P^ and p44MAPK) 
These two forms of MAPK are coactivated by a variety of stimuli as will be seen later, 
however it should be noted that although selective activation of p 4 2 ^ ^ ^  but not 
p44MAPK been demonstrated in platelets (Papkoff etal, 1994), this is thought to be 
unique to this system. Much of the work in this field was aided by the observed 
similarity in the MAPK cascade in signal transduction pathways in all eukaryotes. For 
example, genetic analysis of the pheromone-induced signalling pathways in yeast has 
been applied to the study of the MAPK pathway in mammalian systems (see Blumer, 
1994; Nishida and Gotoh, 1993),
1.4.2 Regulated by phosphorylation
An early obseiwation of the ability of phosphatase inhibitors to preserve the activity of 
MAPK suggested the importance of phosphorylation in the activation of MAPK (Ray and 
Sturgill, 1987). It is now known that the MAPK family is activated by dual 
phosphorylation on both threonine and tyrosine residues (Anderson etal, 1990). This 
occurs in a TEY sequence for both p42^^^^ and p44MAPK (Thr^^ and Tyr^^^ in the 
mammalianp42^^^) (Nishida and Gotoh, 1993; Her etal, 1993) and this defines 
these enzymes from the other members of the MAPK family (Cano and Mahadevan,
1995 and see later). Phosphorylation on both of these residues is essential for activity as 
shown by the loss of MAPK activity on mutation of either the phosphorylated threonine
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or tyrosine residue (Alessandrini etal., 1992). The phosphoiylation of the TEY 
sequence is catalysed by a single dual specificity enzyme called MAPK kinase or MEK 
(MAPK or ERK Kinase) (Gomez and Cohen, 1991). Tyrosine and threonine residues 
can be phosphorylated by MEK independently of each other and in either order (Her et 
al., 1993), and although autophosphorylation of the regulatory tyrosine residue can 
occur, MEK can catalyse the dual phosphoiylation of a kinase-inactive MAPK (Nakielny 
etal., 1992), demonstrating that this protein is indeed a dual specificity kinase. Control 
of the activity is also achieved by the action of phosphatases, both in the nucleus 
(CLIOO) and cytoplasm (Pystl) and these will be discussed later.
The three-dimensional structure of p 4 2 ^ ^ ^  was determined in its unphosphorylated 
low-activity conformation (Zhang etal., 1994). This revealed that Thr^^ is on the 
surface of the molecule while T y r ( t h e  residue which is suggested to be 
phosphorylated first) is buried in a largely hydrophobic pocket and may interfere 
sterically with substrate binding. It is assumed that p 4 2 ^ ^ ^  undergoes an initial 
confonnational change on MEK binding in order to permit phosphorylation which occurs 
first on tyrosine and subsequently of thieonine. Both global and local conformational 
changes are thought to be involved in the activation of p42MAPK
1.4.3 MAPK substrates
p42/44MAPK jg ^ serine/threonine kinase with an optimal substrate consensus sequence 
of Pro-Xaa-Ser/Thr-Pro (hence the description of MAPK as a proline-directed kinase) 
(Davis, 1993). Following activation of MAPK, an important step is thought to be the 
translocation of a proportion of this enzyme to the nucleus (Chen etal., 1992) and the 
activation of various transcription factors (Edwards, 1994; Cano and Mahadevan, 1995; 
Hill and Treisman, 1995). There are also important substrates of p 4 2 /44^P ^  which are 
located in the cytoplasm such as cytosolic phospholipase A% winch can be activated by 
GPCRs by a complex mechanism involving regulation by Ca^+, PKC and MAPK (Lin et 
ah, 1993; Kiamer etal., 1993) and perhaps a further factor (Winitz etal, 1994). Other
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substrates of p 4 2 /4 4 ^ ^ ^  include p90 ribosomal S6 kinase (p9CP®^ ) which can also 
activate transcription factors in the nucleus (Chen etal., 1992; Blenis, 1993), MAPK 
activated protein (MAPKAP) kinase-2, as well as other kinases upstream of MAPK 
which perhaps function in a feedback pathway (reviewed in Davis, 1993).
1.4.4 MEK and its regulation
Two main mammalian isoforms of MEK have been identified and cloned, MEKl and 
MEK2 (Seger etal,  1992; Zheng and Guan, 1993a). These ubiquitous enzymes show 
remai'kable selectivity for p42 /44^^^; no other in vitro substrates for this enzyme have 
been discovered. The sufficiency of the MAPK cascade for cell growth was 
demonstmted by the ability of constitutively active MEK to transfonn mammalian cells 
(Mansour etal, 1994, Cowley etal, 1994). MEK was inactivated on treatment with 
phosphatases specific for phosphoserine/threonine, but not phosphoty rosi ne, 
demonstrating that these enzymes are regulated by serine/threonine phosphorylation 
(Crews and Erikson, 1992; Nakielny etal, 1992). MEK and p 4 2 /4 4 ^ ^ ^  were 
constitutively activated in NIH 3T3 cells expressing the oncogene v-r<^(the transfonning 
gene of the murine sarcoma virus), and recombinant v-Raf could also phosphorylate and 
activate MEK in vitro (Dent etal, 1992). Activation and phosphorylation on Ser/Thr 
residues of MEK by the cellular counterpart of this oncogene, c-Raf, was subsequently 
demonstrated (Kyriakis etal,  1992; Howe etal, 1992) and phosphorylation at both 
Serais and Ser^^^ which is required for activation of human MEKl can be catalysed by 
c-Raf (Zheng and Guan, 1994; Alessi etal, 1994). In addition, MEK can also be 
phosphorylated by Mos and MEK kinase (Blumer and Johnson, 1994).
Raf-1 is a 72-76 kDa serine/threonine protein kinase which is activated by numerous 
growth factors. Its requirement in the activation of p42^ P ^  and p44MAPK (Schaap et 
al, 1993) and cellular transformation (Troppmair 1994) induced by growth 
factors, serum and oncogenes has been demonstrated by the overexpression of dominant 
negative mutants of Raf-1 made from the N-terminal regulatory domain. The activation
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of in response to LPA was also blocked by the expression of dominant
negative mutants of Raf-1 and potentiated by overexpression of wild type Raf-1 in COS- 
1 cells (Howe and Marshall, 1993). The expression of a dominant negative mutant of 
Raf-1 also blocked the activation of p44MAPK various GPCRs expressed in COS-7 
cells (Hawes etal, 1995) suggesting a general function for this enzyme. Three 
mammalian isofonns of Raf have been identified (c-Raf-1, A-raf and B-raf), of which c- 
Raf-1 is ubiquitous while they others display some tissue specificity (Daum et al, 1994),
Raf may have other additional signal transduction roles involving the phosphorylation of 
substrates other than MEK. Recent work has implicated Raf-1 in a pathway leading to 
activation of p70®^k (gee later) by a MAPK-independent mechanism (Lenormand e ta l , 
1996). At present these observations are poorly understood.
1.4.5 Ras
For many years, p2F^® has been known to play a role in cell growth and transformation 
having been implicated in the formation of a considerable proportion of human tumours. 
This protein is the product of a proto-oncogene and one of a large number of small 
GTPase enzymes which are present in mammalian cells. Mammalian cells express four 
true Ras proteins and these proteins cycle between the active GTP-bound and the inactive 
GDP-bound forms and the ratio of Ras-GTP/Ras-GDP is thought to be the key 
determinant of downstream signalling from Ras proteins. This is regulated by guanine 
nucleotide exchange factors (GEFs) which stimulate the release of GDP and by 
stimulation of the low intrinsic GTPase activity by GTPase activating proteins (GAPs) 
(Boguski and McCormick, 1993),
Expression of oncogenic Ras was found to constitutively activate p42^^*^ and 
p44MAPK (Leevers and Marshall, 1992; Cook etal, 1993), although this appears to be 
cell-specific as this was not always observed in transfected Rati fibroblasts (Gupta e ta l , 
1992, Gardner etal, 1993 contrasts with Hordijk etal, 1994a). Ras has also been
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implicated in the control of other transcriptional regulators (Deng and Karin, 1994). 
Overexpression of dominant negative mutants of p2F^® (Asn^ ^^  to Ser, which might 
compete for a required GEF) in various cells blocked p 4 2 ^ ^ ^  and p44MAPK activation 
by growth factors and GPCR agonists but not by phorbol esters (de Vries-Smits etal. , 
1992; Cook etal., 1993; Hawes etal, 1995) which implicated a Ras-dependency of 
these pathways, although some GPCRs act by an apparently Ras-independent 
mechanism (Honda, etal., 1994; Hawes etal., 1995). Experiments with the 
heterotrimeric G-protein activator A1F“4 apparently also indicated that certain G-proteins 
may control this pathway in a Ras-independent manner (Robbins etal., 1992).
1.4.6 Ras and Raf interaction
Experiments in which active Ras was shown to activate Raf-1 (Williams etal., 1992), 
and dominant negative Raf prevented the effect of oncogenic Ras on the MAPK cascade 
(Schaap etal, 1993; Troppmair etal, 1994), positioned Ras upstream of Raf. These 
observations were taken further by the discovery of a direct interaction in vitro between 
the effector region of Ras and the amino-tenninal regulatory domain of c-Raf, but only 
when Ras was present in its active GTP-bound state (Wame et al, 1993). Specific 
interaction between Ras and Raf in intact mammalian cells in response to stimuli that 
cause Ras to be GTP-bound (phorbol esters and growth factors) was subsequently 
shown (Hallberg etal, 1994). The native structure of Raf is a large multi-subunit 
complex made up of Raf and at least the chaperone proteins hsp90 and p50, and this 
complex was recruited to the membrane by Ras where Raf was found to be activated and 
interact with MEK (Waitmann and Davis, 1994). This led to the idea that the role of Ras 
was that of recmiting the inactive form of Raf to the membrane whereupon some other 
activation event occurs. The most convincing proof of this was presented by the loss of 
Ras-dependency when Raf was mutated to include the cai boxy-terminal membrane 
localisation signal from K-ras (Stokoe etal, 1994; Leevers etal, 1994). This Raf- 
CAAX mutant was constitutively membrane localised and active, although growth factor 
treatment could further activate this protein. These activities were completely Ras-
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independent, and so it is now thought that Ras acts as a regulated Raf membrane- 
recruiting agent, and then Raf is activated by some other means and anchored to the 
membrane (perhaps by cytoskeletal proteins) in a Ras-independent fashion.
The co-operation of Ras with other signals was indicated by experiments using an insect 
expression system which showed that p2R^ ® and y-src could independently activate Raf- 
1 but only to a very limited extent. Maximal activation of Raf-1 required the 
coexpression of both genes (Williams etal,, 1992). Coexpression of Raf-1, pp60®^ '^  and 
c-Ras was shown to be able to phosphorylate and activate recombinant MEK in a similar 
expression system (Dent etal., 1994).
1.4.7 Phosphorylation of Raf
It would appear that phosphorylation of Raf is an important step in the activation of this 
kinase as physiological activation of Raf is paralleled by its hypeiphosphorylation. 
Phosphorylation occurs on serine, threonine and tyrosine residues to various extents 
depending on the stimulus and the cell type involved (Daum etal, 1994; Avruch etal,
1994). Morrison and co-workers demonstrated that three serine residues (Seri^ ,^ Ser^59 
and Ser^^l) are the major in vivo phosphorylation sites of Raf-1 in mammalian cells and 
Sf9 insect cells expressing human Raf-1 (Monison etal, 1993). These sites varied in 
their basal level of phosphorylation, the level of phosphorylation in response to growth 
factors, and the functional consequences of their mutation to unphosphorylated residues.
1.4.7.1 PKC and Raf
PKCa has been a candidate Raf kinase due to the action of PKC-activating phorbol 
esters. Indeed, PKCa can activate Raf-1 by direct phosphoiylation in vitro and in vivo 
(Kolch etal,  1993) and the important sites in this regulation appeal* to be Ser^^ (and 
Ser^^^, although this is possibly an autophosphorylation site). However, although 
mutation of either of these residues impedes activation of Raf-1 by PKCa, this does not 
affect Ras/Src-mediated activation, implying that there is a complex activation of Raf-1.
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Subsequent work also suggested that although the phosphorylation of Raf-1 by PKCa 
did stimulate the autokinase activity of Raf-1, it did not stimulate its ability to 
phosphorylate MEK (MacDonald et al., 1993), Therefore PKCa -mediated 
phosphoiylation of Raf-1 may activate this kinase for a specific, as yet unidentified, 
substrate.
1.4.7.2 Tyrosine phosphorylation of Raf
Although the phosphorylation on tyrosine residues of Raf is very limited in many cell 
systems, coexpression in the Sf9 insect expression system of activated tyrosine kinases 
(y-src) and Raf-1, produced phosphorylation on Tyr^^ and Tyr^^l of Raf-1 and 
activated its autokinase activity (Fabian etal., 1993). This phosphorylation appears to 
have a functional role as a mutant Raf-1 in which these residues are altered to a negatively 
charged residue (presumably mimicking the effect of phosphorylation) has a higher basal 
activity and can transfonn mammalian cells and induce the meiotic transformation of 
Xenopus oocytes. Phosphorylation on tyrosine residues of Raf-1 has also been seen in 
vivo, in aT-cell line after treatment with interleukin 2 (Turner etal., 1993). Treatment of 
immunoprecipitated Raf-1 from these cells with tyrosine-specific phosphatases, which 
selectively removed phosphate from the tyrosine residues, reduced the activity of Raf to 
near basal levels, Serine/thi'conine-specific phosphatases produced a much more modest 
reduction in Raf activity, and so this would suggest that phosphorylation of Raf-1 on 
tyrosine residues plays an important role in the interleukin 2-mediated activation of this 
kinase in these cells.
1.4.8 Other regulators of Raf
Other molecules which can phosphoiylate Raf include MAPK (in a proposed feedback 
loop, but the physiological significance of this is unknown), and PKA (which will be 
discussed in detail below). Other proteins have been shown to bind to Raf proteins such 
as Rapl which is a small Ras-related GTPase which may exert its inhibitory effect on
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growth factor-mediated MAPK activation and stimulation of DMA synthesis by 
interrupting the interaction of Ras with Raf (Cook etal, 1993).
Whether the phosphorylation of Raf is the initiating event in Raf activation is still a matter 
of some controversy. Therefore other candidates for the Raf-activator have been 
investigated. It has been suggested that some isofonns of the 14-3-3 family of proteins 
play a role in the regulation of Raf in mammalian systems, possibly through a 
stabilisation of the Raf kinase or through some interaction with PKC (Aitken, 1995).
1.4.9 Raf-independent MEK kinase activity
MEK can also be regulated by a MEK kinase (MEKK) activity which is independent of 
Raf. The similarity of signal transduction cascades in yeast and mammalian systems led 
to the discovery of a mouse MEKK (73 kDa) which was shown to be ubiquitously 
expressed and could phosphorylate and activate MEK independently of Raf-1 (Lange- 
Carter etal, 1993). However, both MEKK and Raf appear to regulate MEK activity by 
phosphorylation on common residues (Gardner etal,  1994). This MEKK was initially 
proposed to explain a number of observations in which G-protein-mediated activation of 
the MAPK cascade was not Ras/Raf dependent. For example, a Ras-independent 
activation of the MAPK cascade was stimulated by the G-protein activator AIF‘4 
(Robbins etal, 1992), and thrombin activated MEK activity in fibroblasts without any 
detectable Raf activation (Gardner etal, 1993). However, these are not general 
observations as, for example, Ras and Raf-dependent GPCR agonist-mediated 
p42/44MAPK regulation has subsequently been demonstrated for LPA in COS-1 cells 
(Howe and Marshall, 1993), and for the a 2A receptor expressed in COS-7 cells (Hawes 
etal, 1995). Also, agonist-stimulation of the muscaiinic m2 acetylcholine receptor 
activated Ras, Raf, MEK and MAPK in heterologously transfected Rati fibroblasts 
(Winitz etal, 1993). Further variation was seen in the activation of p 4 2 /4 4 ^ ^ ^  by the 
a  IB adrenergic and the m2 muscarinic acetylcholine receptors expressed in COS-7 cells 
which was Raf-dependent, but Ras independent (Hawes etal, 1995).
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Raf-independent p42/44^^^^ activation has also been implied with other growth factors. 
Epidennai growth factor (EGF) and phorbol ester were shown to be able to utilise a Raf- 
independent pathway in order to activate p 4 2 /4 4 ^^^  in murine fibroblasts (Chao etal. ,
1994). In adipocytes, insulin-stimulated activation of Raf-1 which was Ras-dependent 
was not upstream of MAPK, but was required for insulin-mediated differentiation 
(Porras etal., 1994). Insulin in these cells can activate (probably by serine/thieonine 
phosphorylation) another member of the MEKK family distinct from c-Raf which can 
phosphorylate and activate MEK (Haystead etal., 1994). Regulation of a MEKK by 
growth factors was also demonstrated in PC 12 cells and this occuned in parallel with Raf 
activation, and both kinases were activated in a Ras-dependent fashion (Lange-Carter and 
Johnson, 1994). These results would indicate the presence of different paiallel 
p42/44MAPK pathways which may regulate diverse cellular functions. The role of 
MEKK in these cascades is not fully understood. In 293 cells, MEKK could indeed 
phosphorylate and activate MEK but this did not lead to a significant activation of 
p42MAPK (Xu etal., 1995) suggesting that additional, unidentified mechanisms were 
also involved in the activation of the p42/44^^^K
However, the physiological role of MEKK may be in another MAPK pathway - the 
JNK(c-Jun NH2"terminal kinase)/SAPK(stress-activated protein kinase) cascade (see 
later). In NIH 3T3 cells, MEKK has been shown to be able to phosphoiylate and 
activate the kinase and activator of SAPK (SEKl) but be unable to activate p42 /44^P ^  
(Yan etal, 1994). Around the same time it was discovered that MEKK participated in 
the Ras-dependent activation of JNK by EGF and nerve growth factor (NGF), but only 
contributed to the activation of p42MAPK when overexpressed. Raf-1 contributed to the 
Ras-dependent activation of p 4 2 ^ ^ ^  but not of JNK by these same growth factors 
(Minden etal., 1994). Therefore this suggested that there are two distinct Ras-dependent 
pathways with one initiated by Raf-1 leading to p42/44^P ^ activation and the other 
involving JNK activation mediated by MEKK. Raf-independent MEK kinase activity
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may also be achieved by c-Mos which can activate MEK and p 4 2 /4 4 ^ ^ ^  in Xenopus 
oocytes (Blumer and Johnson, 1994; Nebreda and Hunt, 1993).
1.4.10 Effect of cAMP on the MAPK cascade
It has been known for some time that cAMP can affect the mitogenic response in 
numerous cells. Understanding the MAPK cascade has provided a molecular basis to the 
effects on growth of cAMP. Agents which elevated intracellular cAMP levels blocked 
the stimulation of DNA synthesis induced by growth factors in Rati fibroblasts (Cook 
and McCormick, 1993; Hordijk etal, 1994a) and the activation of Raf-1, MEK and 
p42/44MAPK By growth factors acting on tyrosine kinase receptors, GPCR agonists and 
phorbol esters in Rati and NIH 3T3 fibroblasts (Wu etal, 1993; Cook and McConnick, 
1993; Burgering etal., 1993). cAMP, however, did not affect the stimulation of GTP 
loading of p2P^ or any of the other upstream proteins (Cook and McCormick, 1993; 
Burgering etal., 1993). This indicated that the site of action was downstream of Ras but 
upstream of Raf, a conclusion which was strengthened by the ability of elevated 
concentrations of cAMP in ras transformed Rati and NIH 3T3 cells to deactivate 
constitutively active p 4 2 /4 4 ^^^  and reverse the transformed phenotype, without 
altering the p2P^GTP level (Hordijk etal, 1994a; Chen and Iyengar, 1994). A model 
of competition for binding to Raf between a cAMP regulated protein and Ras was 
suggested by work which demonstrated that the block in the MAPK cascade could be 
overcome by increasing the total number of p2P^®GTP molecules by overexpression 
(Burgering 1993).
The involvement of PKA in the effect of cAMP in these cells was demonstrated by the 
loss of this effect in cells expressing a dominant negative form of PKA (Chen and 
Iyengar, 1994). Elevated cAMP levels in Rati fibroblasts were found to stimulate the 
phosphorylation of Raf-1 on SeiA3, which is the main site of PKA-directed 
phosphorylation of Raf-1 in vitro and in vivo. This residue is present in the regulatory 
amino-terminal domain of Raf-1 which binds to Ras and this phosphorylation
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significantly reduced the affinity of binding of GTP-bound Ras for Raf-1 (Wu e ta l , 
1993). Therefore the PKA-directed phosphorylation of Raf-1 may contribute to the 
cAMP-mediated blockade of the MAPK cascade. Other mechanisms of cAMP-mediated 
inhibition of the MAPK cascade have been suggested including a role for members of the 
p2 frap family.
In other cell lines, elevated cAMP levels have distinctly different effects on growth 
factor-induced MAPK activation. In PC 12 cells (a neuroendocrine cell line) cAMP 
elevating agents stimulated the activity of p42 d^APK and p44MAPR and MEK, and 
potentiated neurite formation induced by NGF (Frodin etal, 1994). However, another 
study in PC 12 cells described cAMP as having no effect on MEK and p 4 2 ^P R  
activation in the absence of growth factors but potentiating the effect of growth factor- 
mediated activation of MEK and p42^ P R  (y  aillancourt et aL, 1994). Surprisingly, an 
inhibitory effect of cAMP on growth factor-activated Raf-1 and B-Raf was demonstrated 
in this same study. Similarly, in COS-7 (Faure etal., 1994) and Swiss-3T3 cells (Faure 
and Bourne, 1995), elevated cAMP levels stimulated p42 /44^P ^  activity and did not 
inhibit LPA or EGF-mediated activation of p 4 2 ^ ^ ^  or MEK. However, elevated 
cAMP levels did prevent mitogen-mediated Raf-1 activity, as was seen with Rati cells 
(Faure and Bourne, 1995). These studies would suggest that in these cells, growth 
factors can trigger a MAPK pathway which is both Raf-1-independent and cAMP- 
insensitive in addition to the Raf-regulated cascade. MEKK is not thought to be involved 
in this cAMP-insensitive pathway as its activation is blocked by cAMP as well (Lange- 
Carter and Johnson, 1994).
1.4.11 MAPK phosphatases
In contrast to the mechanisms of activation of p42/44^^^ , and the pathway which 
controls this, the inactivation of these enzymes is poorly understood. The 
phosphorylation and activation of p 4 2 /4 4 ^^^  in most instances is a transient response 
and so there seems to be a requirement for a switch off mechanism, which could most
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obviously be met by specific phosphatases. Indeed a family of apparently selective 
MAPK phosphatases has been discovered (Nebreda, 1994). 3CH134 was discovered as 
an immediate early gene which was rapidly and transiently expressed in mouse embryo 
fibroblasts during the GO/Gl transition and induced by various mitogens (Lau and 
Nathans, 1985). The product of this gene was a short-lived protein which displayed no 
similarity to any protein except a vaccinia virus tyrosine/serine phosphatase (Charles et 
aL, 1992). This led to the discovery that this protein displayed intrinsic protein tyrosine 
phosphatase activity with selectivity for p42^'^^^^ in vitro (Charles etal., 1993) and 
subsequently to the identification of this protein as MKP-1 (MAPK phosphatase-1), a 
dual-specificity phosphatase in vitro and in vivo with remarkable specificity for 
p42MAPK and p44MAPK (§nn etal., 1993). Other members of this family were 
discovered including the human homologue of 3CH134 called CLIOO or HVHl (Keyse 
and Emslie, 1992; Zheng and Guan, 1993b). CLIOO is highly inducible by oxidative 
stress and heat shock in skin cells (Keyse and Emslie, 1992) and is a highly MAPK- 
specific tyrosine/thieonine phosphatase (Alessi etal., 1993). Another similar MAPK 
phosphatase is PAC-1 which like 3CH134/CL100 is localised to the nucleus and induced 
by mitogens, but displays a distinctly different and limited tissue distribution (Rohan et 
al., 1993). These enzymes can also be induced by agonists of GPCRs as demonstrated 
by the ability of angiotensin II (and thrombin) to induce expression of 3CH134 in 
vascular smooth muscle cells in a PKC and Ca^+-dependent manner (Duff etal., 1993).
The physiological relevance of this family of phosphatases have been demonstrated. The 
kinetics of MAPK deactivation coincided with the appearance of 3CH134 and treatment 
with cycloheximide (a protein synthesis inhibitor) led to a persistent activation of 
p42MAPK ( S u n  etal., 1993), and constitutive expression of 3CH134, CLIOO or PAC-1 
blocked mitogen or oncogenic Ras and Raf-mediated activation of p42 /4 4 ^P ^  and 
MAPK-regulated reporter gene expression (Sun etal., 1993; Alessi etal., 1993; Ward et 
al, 1994).
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These enzymes were discovered to be localised to the nucleus and to have some, but 
lower, activity towaids other members of the MAPK cascade (see later). However, 
recently discovered novel members of this family (called Pystl and Pyst2) are 
constitutively expressed in the cytoplasm of human skin fibroblasts and are much more 
selective for the p42/44^^^^ members of the MAPK family (Groom etal., 1996). 
Therefore the MAPK may be regulated by different MAPK phosphatases depending on 
their subcellulai* location.
Phosphatases would also be expected to act at other levels of the MAPK cascade. For 
example, protein phosphatase 2A (PP2A - a serine/threonine selective phosphatase) was 
implicated in the dephosphorylation and inactivation of MEK by the ability of SV40 small 
tumour antigen to activate MEK and p44^ ^ K  through an interaction with PP2A (Sontag 
etal, 1993). These examples underline the importance of controlling phosphorylation- 
signalled pathways by phosphatases as well as kinases (see Feng and Pawson, 1994;
Sun and Tonks, 1994).
1.4.12 Growth factor receptors
The cascades initiated by growth factors and GPCR agonists were thought to converge at 
the level of the activation of Ras. However, there is striking similarity in some of the 
pathways which are used to couple the primary receptor events and the activation of the 
MAPK cascade indicating that convergence occurs at an earlier step. The early steps in 
the growth factor-mediated cascade will be explained briefly and then compared and 
contrasted with the pathways for various GPCR agonists (Schlessinger and Bar-Sagi, 
1994; Malarkey et a l , 1995).
Growth factor receptors are characterised by an extracellular binding domain, a single 
tiansmembrane spanning region and a large intracellular catalytic domain. It is the 
autophosphoi-ylation of these receptors on specific tyrosine residues and their associated 
dimérisation which are the essential events following growth factor binding. For the
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EGF receptor (EGFR), the main sites of phosphorylation are in the carboxy-temiinal tail, 
however, other receptors (e.g. the platelet derived growth factor (PDGF) receptor) 
contain kinase insert domains which aie also phosphorylated. These receptors are called 
tyrosine kinase receptors because of their catalytic activity.
Phosphorylation of the receptor on tyrosine promotes the interaction of numerous 
proteins and enzymes including PLCy, phosphatidylinositol 3-kinase (PI3-kinase), GAP, 
the growth-factor-receptor binding protein (Grb2), and members of the non-receptor Src 
family of tyrosine kinases. This interaction is mediated by Src homology-2 (SH2) 
domains (Feller etal, 1994; Pawson, 1995) which are defined by approximately 100 
amino acids which show considerable homology to the non-catalytic region of the Src 
family. The specificity of these various domains determine the specificity of the binding 
of these proteins with selective tyrosine residues of the receptors (Songyang and Cantley,
1995). It is the association of the adaptor protein Grb2 to the phosphorylated receptor 
which is the initial step in the p2P^-MAPK cascade initiated by growth factor receptors 
(Gale etal., 1993; McCormick, 1993). Some of the other proteins have been implicated 
in this cascade and will be dealt with later.
1.4.12.1 Grb2 and mSos
In addition to an SH2 domain, Grb2 contains two Src homology-3 (SH3) domains 
which are composed of approximately 60 amino acid residues and mediate binding to 
proline rich sequences (Feller a/., 1994; Pawson, 1995). The SH3 domains of Grb2 
mediate its binding to a proline rich sequence of the carboxy-terminal domain of mSos 
(the mammalian homologue of Drosophila Son of sevenless) (Li e ta l , 1993 ; Egan et a l ,
1993). mSos is a RasGEF, which activates Ras by stimulating guanine nucleotide 
exchange (Egan 1993; Boguski and McCormick, 1993). EGF-stimulated guanine 
nucleotide exchange of Ras was potentiated by Grb2 overexpression (Gale e ta l , 1993) 
and the constitutive Grb2.mSos complex was associated with the EGFR to form a multi­
protein complex, after EGF-mediated autophosphorylation (Li etal., 1993). The
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functional importance of mSos was demonstrated by the transforming ability of 
expression of this protein in Rati fibroblasts (Egan etal, 1993). These, and many other 
studies (McConnick, 1993), indicate that tyrosine kinase linked receptors stimulate 
Ras.GTP loading by receptor autophosphorylation which recruits (via SH2 domains) the 
cytoplasmic Grb2.mSos complex which activates Ras by stimulation of guanine 
nucleotide exchange.
The way in which mSos is activated is not fully understood, however the primary 
mechanism is thought to simply involve its localisation to the plasma membrane at the 
vicinity of its substrate. This idea was strengthened by work perfonned with modified 
mSos proteins which were constitutively located at the plasma membrane by the 
introduction of sites of lipid modification. These mSos proteins activated the Ras.MAPK 
cascade and led to oncogenic transformation without external stimuli (Aronheim et ah ,
1994). A carboxy-terminal truncated form of the plasma membrane-localised mSos 
displayed even greater activity, raising the possibility of a secondar y mechanism of mSos 
activation through the relief of an inhibitory effect exerted by the carboxy-teiminal 
region. Phosphorylation of mSos has been demonstrated but this is thought to be 
explained by MAPK-mediated feedback rather than by a primar y activating stimulus 
(Burgering cWL, 1993).
1.4.12.2 GAP activation of Ras
Activation of Ras could also conceivably occur through inactivation of a basal GAP 
activity. Although such a decrease in GAP activity has been shown not to be the main 
mechanism of activation in a number of cell lines (e.g. Gale etal, 1993), inactivation of 
GAPs has been demonstrated to be important in the activation of p21^^ (in a PKC- 
dependent manner) on stimulation of the antigen receptor of T lymphocytes (Downward 
etal, 1990). However the physiological role of GAPs may be more to do with 
restricting the length of any Ras activity stimulated by other means.
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1.4.12.3 Src homology/collagen (She)
Alternative links between the tyrosine kinase linked receptors and downstream effectors 
can be mediated by other SH2 containing, adaptor proteins. One such protein is the 
insulin receptor substrate-1 (IRS-1) which is a major target for the insulin and insulin­
like growth factor-1 (IGF-1) receptor tyrosine kinases and is implicated in the actions of 
PI3-kinase and Grb2 (Skolnik etal, 1993). Another important adaptor protein is Src 
homology/collagen (She), which is a family of widely expressed proteins of size 46, 52 
and 66 kDa (Pelicci etal, 1992), These proteins contain an SH2 domain, a 
glycine/proline rich domain and a phosphotyrosine binding domain distinct from any 
SH2 domain, but they do not contain any detectable catalytic domain. These proteins 
were found to be complexed with, and tyrosine phosphorylated by, the activated 
epidennal growth factor receptor and the physiological involvement of these proteins in 
mammalian cell proliferation was demonstrated by the transforming and tumour creating 
ability of overexpressed She in NIH 3T3 cells and nude mice (Pelicci etal,  1992).
She's role in Ras signalling was demonsti’ated in PC 12 cells by the ability of dominant 
negative Ras to block the neurite outgrowth induced by She overexpression (Rozakis- 
Adcocke^a/., 1992). This was explained by the demonstration of Grb2 association (via 
its SH2 domain) with tyrosine phosphorylated She (Rozakis-Adcock etal, 1992), and 
the association between She and mSos (Egan etal, 1993), in src transformed Rat2 cells. 
Shc.Grb2 complexes were also found to be foiTned by, and associated with, ligand- 
activated EGFand NGFreceptors (Rozakis-Adcock etal., 1992) and insulin can also 
stimulate the formation of Shc.Grb2 complexes (Skolnik etal, 1993).
The role of She in the mitogenic response to EGF and insulin in Rati cells 
overexpressing insulin receptors was demonstrated by the inhibitoiy effect of 
microinjection of anti-Shc antibodies on DNA synthesis (Sasaoka etal, 1994b). 
However the anti-Shc antibodies did not inhibit the mitogenic effect of oncogenic ras. 
Immunoprecipitates of She from lysates of growth factor-stimulated cells removed a large 
proportion of the RasGEF activity (Sasaoka etal, 1994a and b). These results would
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therefore show that She was an important component in the mitogenic signal transduction 
cascade of insulin and EGF and appears to function upstream of Ras.
As the last piece of data suggests, the coupling of the activated EGFR to She is preferred 
over direct coupling to the Grb2.mSos complex. This was demonstrated by Sasaoka and 
co-workers who also demonstrated the presence of Shc.Grb2.mSos complexes which 
were formed on EGF stimulation but not associated with the activated EGFR (Sasaoka et 
al., 1994a). The model of activation of Ras which is thought to predominate is that on 
EGF treatment, She associates with, and is tyrosine-phosphorylated by, the EGFR 
which leads to the formation of the EGFR. She.Grb2.mSos complex. Free 
Shc.Grb2.mSos complexes also exist which aiise from the dissociation from the receptor 
or phosphorylation of She by other tyrosine kinases. In this way mSos is activated and 
the Ras.MAPK cascade is stimulated. It should be noted, however, that She has also 
been implicated in the control of other pathways in addition to the Ras.MAPK cascade 
{Bonfinietal, 1996).
1,4.12.4 The non-receptor Src family of tyrosine kinases
As noted above, c-Src binds to activated tyrosine kinase linked receptors and this binding 
leads to the activation of these Src kinases. The mechanism of activation is quite 
complex and is not fully understood but is thought to involve the displacement of an 
internal phosphotyrosine residue from Src's SH2 domain, possibly by competition from 
the receptor phosphotyrosine, subsequent dephosphorylation of the inhibitory tyrosine ■ 
residue and the autophosphorylation of another tyrosine on Src (Cooper and Howell, 
1993). These steps are thought to be under the contiol of (one or many) phosphatases 
and kinases.
Members of the Src family have been proposed to be involved in signal transduction 
pathways that control growth and cellular architecture. The physiological role of Src has 
been suggested by the ability to activate or co-operate in the activation of the MAPK
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cascade (see above; VanRenterghem etal, 1993). Src is thought to play an important 
role for growth factor receptors (Erpel and Courtneidge, 1995), especially for those 
which do not contain intrinsic tyrosine kinase activity (especially important in 
haematopoietic cells). The activation of tyrosine kinase signalling pathways by these 
receptors is thought to be mediated by members of the Src protein tyrosine kinase family. 
However, Src has been demonstrated to be essential for PDGF receptor-induced 
mitogenic signalling even although these receptors contain intrinsic tyrosine kinase 
activity (Twamley-Stein etal, 1993). Src family kinases are also essential for the 
mitogenic response of NIH 3T3 and Swiss 3T3 cells to PDGF, colony stimulating factor 
and EGF (Roche etal, 1995). The implication of c-Src in the cascades initiated by 
GPCRs will be discussed below.
1.4.13 Regulation of the MAPK cascade by G-protein coupled receptors
There aie now many agonists which act at GPCRs which have been demonstrated to 
stimulate growth and cell proliferation in numerous cells. This effect has been 
demonstrated for receptors coupling to G-proteins of the Gq, Gi, Gs and G12/13 families 
(for reviews see Post and Brown, 1996; Malarkey etal, 1995). These receptors have 
been shown to activate the p42 /44^P ^  cascade, and although activation of this cascade 
is not always sufficient and may not be required for all GPCR-mediated growth 
responses it undoubtedly plays a central role in the mediation of many growth signals 
from GPCR to the nucleus. Other kinases may also be involved in these actions for 
example the JNK cascade (see later). The activation of the p42/44^^^^ cascade by 
receptors coupling to Gg, Gqand Gi are discussed below.
1.4.13.1 Gs-coupled receptors and MAPK
Gg-coupled receptors have very different effects on p42/44^^^^ activity and mitogenesis 
in various cell lines. Agonist-stimulation of Gg-coupled receptors stimulates p 4 4 ^ ^ ^  
activity in COS-7 cells (Faure etal, 1994; Crespo etal, 1995), but reduces EGF- 
m ediatedp44^^^ activity in Rati fibroblasts (Hordijk etal, 1994a). Expression of a
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constitutively active mutant of Gga stimulates in COS-7 cells in some (Faure et
d., 1994) but not all studies (Crespo etal, 1995), but blocks the Ras-induced 
stimulation of p44^ P K  activity and DNA synthesis in NIH 3T3 cells (Chen and 
Iyengar, 1994). Stimulation of Gga with cholera toxin also displayed a cell-specific 
effect on p#MAPKactivity and DNA synthesis (Frondin etal, 1994; Cook and 
McCormick, 1993). Most of these effects can also be reproduced using other cAMP 
elevating agents and can be correlated with the diverse effects of elevated cAMP levels on 
p42/44MAPK activity in these cells (as seen above).
1.4.13.2 Gq-coupled receptor activation of MAPK
There are many honnones which activate Gq-coupled receptors which can activate the 
Ras.MAPK cascade although the signalling pathways aie less well defined than for Gi- 
coupled receptors. As seen before, the ability of Gqpcoupled receptors to activate these 
pathways appears to depend not only on the specific receptor under investigation but also 
the cellular environment in which it is expressed. For example, endothelin-1 (ET-1) 
stimulated the phosphoiylation and activation of p42/44^P ^ in mouse astrocytes 
(Cazaubon etal, 1993) and rat myocytes (Bogoyevitch etal, 1994) but not in rat 
astrocytoma cell lines (Cazaubon etal, 1993). In Rati fibroblasts, treatment with ET-1 
has been reported to activate the Ras.MAPK cascade by Daub etal (1996) but not by 
other groups (van Corven etal, 1993; Alblas etal, 1993; Hordijk etal, 1994b).
There have been conflicting reports as to the involvement of Ras in the Gq-mediated 
activation of p42/44^^l^ which may be a reflection of receptor and cell diversity. 
Agonist stimulation of the Gq-coupled prostaglandin p2a (in NIH 3T3 cells) and ai~ 
adrenergic receptors (in COS-7 cells) activated Ras.GTP loading (Watanabe etal, 1995; 
Koch etal, 1994), and m l muscarinic acetylcholine receptor-mediated MAPK activation 
(in COS-7 cells) was apparently blocked by expression of a dominant negative mutant 
Ras (Crespo etal, 1994). However, it has been reported that the p42/44^^^^ 
phosphorylation induced by the ml muscarinic acetylcholine receptor in HEK 293 cells
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(Ito etal., 1995) and the ai-adrenergic receptor expressed in CHO cells (van Biesen et 
al, 1996) or by either receptor expressed in COS-7 cells (Hawes etal., 1995) was 
unaffected by expression of the dominant negative Ras, thereby demonstrating Ras- 
independence.
1.4.13.2.1 Mediated by the a-subunit of Gq
The effect of Gq-coupled receptors is thought to be mediated by the Gqa subunit rather 
than the py complex, as shown by the lack of any effect of overexpression of Gta or the 
C-terminus of the p-adrenergic receptor kinase (PARKct) on the agonist-mediated 
activation of the Ras.MAPK cascade by the bombesin, a  1-adrenergic, or ml muscarinic 
acetylcholine receptors expressed in COS-7 and CHO cells (Faure etal., 1994; Koch et 
al., 1994; Lutti'ell etal, 1995a; Hawes etal, 1995; van Biesen etal., 1996). The ability 
of a constitutively active mutant of Gq^ to activate the Ras.MAPK cascade and DNA 
synthesis in NIH 3T3 cells (Watanabe etal., 1995) and p44MAPK activity in COS-7 cells 
(Faure etal, 1994) seemingly confirms this view.
However, opposing findings have been reported. De Vivo and coworker failed to detect 
any stimulation of p44MAPK activity or DNA synthesis on expression of a constitutively 
active mutant of Gqp in NIH 3T3 cells, although they did show that expression 
potentiated the response to PDGF treatment (De Vivo and Iyengar, 1994a).
Constitutively active mutants of Gq^ and G u a  were unable to activate the Ras.MAPK 
cascade in COS-7 and HEK 293 cells (Crespo etal, 1994; Ito etal, 1995) and 
overexpressing Gta inhibited ml muscarinic receptor-mediated activation of p 4 2 ^ ^ ^  in 
COS-7 cells (Crespo etal, 1994). This may again indicate cell/receptor specificity in the 
mechanism of activation.
1.4.13.2.2 Involvement of PKC
The strong p 4 2 /4 4 ^ ^ ^  stimulation by phorbol esters and phosphorylation of Raf-1 by 
PKC-a (see above) has implicated PKC in the control of p42 /44^^^ . The activation of
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PKC isoforms by diacylglycerol produced by PLC has been suggested as the mechanism 
for the activation of the MAPK cascade by Gq-coupled receptors (Faure etal, 1994), and 
this is supported by the observations that PKC-dowm'egulation by phorbol esters does 
attenuate the MAPK phosphorylation induced by some Gq-coupled receptors (Ito e ta l , 
1995; Hawes etal, 1995; van Biesen etal, 1996). However this does not explain all 
the available data. Although phorbol ester could stimulate p42/44^^^^ activity in 
vascular smooth muscle cells, it was not as potent as vasopressin which acts on a 
pertussis toxin-insensitive GPCR (Granot etal, 1993). This suggested the presence of 
both PKC-dependent and independent pathways leading to p 4 2 /4 4 ^ ^ ^  activation. 
Consistent with this idea is the partial block of ET-mediated activation of p42 /44^P ^ by 
downregulation of (at least some isoforms of) PKC by prolonged treatment with phorbol 
esters (Cazaubon etal,  1993; Bogoyevitch etal, 1994). This was also demonstrated 
for the activation of p 4 2 ^ ^ ^  by carbachol acting on muscarinic ml receptors in COS-7 
cells (Crespo etal, 1994). However, prostaglandin F2a-activated p 4 2 ^ P ^  by a 
mechanism which was sensitive to the protein kinase inMbitors staurosporine and H-7, 
was unaffected by prolonged phorbol ester treatment and so appears to utilise protein 
kinases independently of classical PKCs (Watanabe etal, 1995). Some of these effects 
could possibly be explained by the involvement of phorbol ester-insensitive PKC 
isoforms.
1.4.13.2.3 Calcium and PYK2
A potential mechanism has been suggested for the coupling of the activation of PKC and 
an increase in cytoplasmic calcium to the Ras.MAPK cascade (Lev etal, 1995). This 
involves a newly discovered protein tyrosine kinase, PYK2, which could be activated by 
phosphoiylation on tyrosine residues stimulated by an influx of Ca^+, and by bradykinin 
(an agonist for a Gq-protein coupled receptor) in a PKC-dependent and independent 
manner. Activated PYK2 stimulated p42MAPK apparently by phosphorylating She 
thereby recruiting the Grb2.mSos complex which is quite similar to the mechanism 
utilised by receptor tyrosine kinases (also see later). PYK2 has since been shown to play
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an important role in mediating the activation of p 4 2 /4 4 ^^^  in PCI2 cells on stimulation 
with bradykinin and with LPA in a mechanism which involves an interaction with Src 
upstream of Grb2 and mSos (Dikic etal, 1996). A role for increased cytoplasmic 
calcium in Gq-protein-mediated MAPK activation was suggested by a number of studies, 
for example the partial attenuation of the response to prostaglandin p2a  by a calcium 
chelator (Watanabe etal., 1995).
1.4.13.3 G,-protein coupled receptor activation of the MAPK cascade
Many agonists of GPCRs have demonstrated a pertussis-toxin sensitive activation of 
p42/44^ï*^ indicating that these effects are mediated by members of the Gi-protein 
family. The signalling pathway to p 4 2 /4 4 ^^^  activation has been shown to involve 
MEK, p2 P^s and Raf-1 (van Corven etal, 1993; Howe and Marshall, 1993; Winitz et 
al, 1993; Alblas etal, 1993; Crespo etal, 1994; Luttrell etal, 1995b; Ito etal, 1995; 
Hawes etal, 1995; and earlier discussions) but on the whole appears to be PKC- 
independent (van Corven etal, 1993; Hordijk 1994; Crespo etal, 1994; Luttrell 
etal, 1995b; Hawes etal, 1995; van Biesen etal., 1996). LPA and thrombin acting on 
endogenous receptors in fibroblasts have the ability to signal via members of both the Gq 
and the Gi-protein family. Coupling to DNA synthesis and the Ras.MAPK cascade, 
however, has been shown by pertussis toxin sensitivity to be solely mediated by Gi- 
proteins (Gupta etal, 1992; Gardner etal, 1993; van Corven etal, 1993; Howe and 
Marshall, 1993) and is independent of PLC pathways (van Corven etal, 1993; Hordijk 
etal, 1994b). LPA, in common with other Gq-coupled receptor agonists, stimulates the 
phosphorylation of many other substrates, such as pl25F^^, paxillin and pl30, and this 
has been shown to involve PLC activation mediated by pertussis toxin-insensitive G- 
proteins (Gq^  (Hordijk etal,  1994b; Seufferlein and Rozengurt, 1994, Moolenaar,
1995).
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1.4.13.3.1 Mediated by the Py subunits
It has been suggested that the a  subunit of Gi2 is responsible for the activation of the 
p42/44MAPK cascade because expression of a GTPase deficient form of this protein 
{gip2) in Rati fibroblasts transforms these cells (Pace etal, 1991) and constitutively 
activatesp42^^^ (Gupta etal., 1992) and MEK-1 (Gardner etal., 1993). However 
the effects of this oncogene were highly cell specific as gip2 failed to transform NIH 
3T3 cells (Pace etal, 1991) or to constitutively activate p 4 2 ^ ^ ^  or MEK-1 in these 
cells {Gallego etal, 1992; Gardner etal, 1993), COS-7 cells (Faure etal, 1994;
Crespo etal, 1994) or HEK 293 cells (Ito etal, 1995). This may reflect a cell specific 
effect of this oncogene and may also demonstrate the problems in relating the results 
from oncogene studies to the signalling of GPCRs in untransformed cells which 
stimulate p 4 2 /4 4 ^ ^ ^  in all of the above cell lines.
The Py complex derived from Gi-proteins is now thought to be the initiator of the 
Ras.MAPK cascade. The initial experiments which led to this conclusion involved the 
overexpression of p and y subunits together (specifically p ly2) which stimulated 
p 42 /44^P ^  in a Ras-dependent and PKC-independent manner in COS-7 cells (Faure et 
al., 1994; Crespo etal, 1994; Hawes etal, 1995) and stimulated p42^P^'^, Raf and 
Ras in HEK 293 cells (Ito etal, 1995). These effects were dependent on membrane 
localisation of the py complex as shown by the failure of response with isoprenylation- 
deficient y mutants.
The role of the Py complex was further demonstrated by the expression of peptides 
which function as py-antagonists by competing with effector molecules for the binding of 
py subunits. Thus overexpression of Gta inhibited the p42/44^^^^ activation induced 
by the overexpression of py subunits as well as that induced by agonist-activated Gi- 
coupledreceptors {Fauvc etal, 1994; Crespo etal, 1994). Expression of pARKct 
containing its Py-binding domain which can specifically antagonise Gpy (and not Ga) 
mediated effects inhibited the activation of Ras and p 4 2 ^ ^ ^  by LPA in Rati cells and
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by agonists acting on heterologousiy expressed a 2~adrenergic and m2 muscarinic 
receptors expressed in COS-7 cells (Koch etal, 1995; Hawes etal, 1995). EGF- 
mediated responses and pertussis toxin-insensitive G-protein-mediated effects were 
unaffected in both cell lines. pARKct contains a pleckstrin homology (PH) domain and 
expression of the PH domains of several other proteins (including PLCy, RasGAP, 
RasGRF) inhibited the stimulation of the Ras.MAPK cascade mediated by a 2-adrenergic 
receptors and py overexpression in COS-7 cells (Luttrell etal, 1995a), PH domains of 
proteins are thought to be involved as Py-subunit binding domains and so this data would 
seem to confirm the importance of the Py-subunit in the Ras.MAPK cascade. The 
presence of PH domains in many proteins involved in signal transduction and growth 
control suggests that these domains may play a major role in the assembly of membrane- 
associated protein complexes involved in signal transduction cascades (see Inglese etal.,
1995).
A variation to this mechanism of pertussis toxin sensitive G-protein-mediated MAPK 
activation was seen with m2 muscarinic acetylcholine and platelet activating factor (PAF) 
receptors (van Biesen etal, 1996). The m2 muscarinic receptor signals via Gq-proteins 
in order to stimulate p44MAPK activity when expressed in COS-7 cells in a pertussis 
toxin and pARKct-insensitive manner, (PAF does not stimulate p44MAPK jjj these cells). 
However, when expressed in CHO cells, these receptors stimulate p44MAPK a Gq- 
coupled pathway which is sensitive to pertussis toxin inhibition and PKC-dependent. 
Signalling in these cells is still insensitive to Py-antagonists and so represents a novel 
mechanism for the activation of the MAPK cascade mediated by the a  subunit of Gq. 
PAF-induced p 4 2 /4 4 ^^^  activation has been reported to occur in the absence of any 
detectable Ras activation in these cells (Honda etal., 1994). This again reinforces the 
idea of the cellular specificity of pathways used to transduce mitogenic stimuli by 
GPCRs.
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Another novel finding was that stimulation of p44MAPK induced by the IGF-1 receptor in 
Rati fibroblasts was pertussis toxin sensitive and was inhibited by the expression of 
PARKct (Luttrell etal., 1995b). This stimulation was also similar to that induced by 
LPA in that it was PKC-independent, Ras-dependent and was inhibited by protein 
tyrosine kinase inhibitors (see later). This suggests that some tyrosine kinase-linked, 
growth factor receptors employ similai’ mechanisms for mitogenic signalling as GPCRs 
involving Gpy subunits derived from pertussis toxin-sensitive G-proteins.
1.4.13.3.2 Py stimulation of Ras.MAPK cascade is mediated by She
Once the role of py in the stimulation of the Ras.MAPK cascade had been shown, the 
question of how this was achieved remained. The effect of py was not thought to be 
directly at the level of Ras because of the requirement for tyrosine kinase activity (see 
later) and is now thought to be mediated by the She adaptor protein. She was 
phosphorylated on tyrosine residues after agonist stimulation of Gi-protein coupled 
receptors in cardiac fibroblasts and COS-7 cells or by overexpressing Gpy in COS-7 cells 
(Schorb etal, 1994; Touhara eta l, 1995; van Biesen etal, 1995). The 
phosphoiylation of She was followed by an increase in the functional association 
between She and the Grb2.mSos complex and the disruption of this interaction between 
She and Grb2 blocked py-mediated activation of p42/44^P ^ (van Biesen eta l, 1995). 
These effects (but not those stimulated by EGF) were py-dependent as shown by the 
inhibitory effects of pARKct, but were not dependent on Ras or PKC activation. 
Tyrosine phosphorylation of She therefore appears to be an early step in the Py-mediated 
activation of the Ras.MAPK cascade, and the subsequent signalling pathway appears to 
be common to both growth factor, tyrosine kinase linked receptors and GPCRs.
A similar pathway may also be induced by Gq-protein coupled receptors as demonstrated 
by the tyrosine phosphorylation of She and subsequent complex formation with 
Grb2.mSos stimulated by gastrin, thrombin (in this case by a pertussis toxin-insensitive 
manner) and muscarinic m l receptors (Seva etal, 1996; Chen etal, 1996). This
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pathway was shown to be PKC-independent (Chen etal, 1996) and so may not be the 
mechanism used by all Gq-protein coupled receptors (see earlier).
Another possible role for the Gpy subunits in the MAPK cascade was suggested by the 
work of Pumiglia and co-workers which demonstrated a direct interaction between the py 
subunits and Raf-1 (Pumiglia etal, 1995). This occurred in vitro and in vivo with 
similar affinity to that of the interaction of p ARK and Py. This raises the question as to 
the role of this interaction in signal transduction pathways. Suggestions include cross­
talk mechanisms between growth factor receptor and GPCR-mediated pathways or the 
regulation of the MAPK cascade by GPCRs.
1.4.13.3.3 Tyrosine kinase activity required
The requirement for the tyrosine phosphorylation of She necessitates the activation of a 
tyrosine kinase as an early step in the GPCR-mediated activation of the Ras.MAPK 
cascade. In other systems, IRS-1 is apparently phosphorylated on tyrosine residues in 
cells stimulated by angiotensin II, suggesting its role as a different substrate for a GPCR- 
induced tyrosine kinase activity (Saad etal, 1995). This conclusion is consistent with a 
number of observations of the inhibitory effects of genistein which is a tyrosine kinase- 
specific inhibitor (Akiyama etal., 1987). Genistein inhibited LPA and thrombin- 
mediated Ras and p42^^^^ activation in Rati fibroblasts at a lower concentration than 
that required for inhibition of EGF-mediated stimulation (van Corven e ta l , 1993 ;
Luttrell etal, 1995b). Phorbol ester-activated p 4 2 ^ ^ ^  was unaffected by genistein. 
Also, genistein prevented p44MAPK activation by overexpression of py or agonist 
activation of Gi but not Gq-coupled receptors expressed in COS-7 cells (Hawes e ta l ,
1995).
The genistein-sensitive protein tyrosine kinase has been located upstream of She in the 
Ras.MAPK cascade, and possibly may be responsible for the phosphorylation of She. 
Genistein had no effect on oncogenic Ras-mediated p42/44^^PI^ activation in both Rati
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and CHO cells (Lnttiell etal, 1995b; van Biesen etal, 1995), but could inhibit the 
phosphorylation of p52 She by py overexpression and agonist stimulation of the a2A~ 
adrenoceptor in COS-7 cells (Touhara etal, 1995) and could prevent the synergistic 
effect on p 4 4 ^ ^ ^  activation of Gp y and mSos expression in CHO cells (van Biesen et 
al, 1995). As usual there is some receptor specificity in this effect as the effect mediated 
by the muscarinic m2 receptor in Rati fibroblasts was not susceptible to inhibition by this 
agent (Winitz etal, 1993). Other inhibitors of tyrosine kinases (but with less selectivity) 
e.g. staurosporine, have also been shown to have an inhibitory effect on this cascade 
(Hordijk 1994; Luttrell 1995b).
1.4.13.4 Receptor tyrosine kinases and GPCR-mediated p42/44^^^^  
activation
It has been proposed that receptor tyrosine kinases may play a role as downstream 
mediators in GPCR signalling to the Ras.MAPK cascade. In Rati fibroblasts, various 
GPCR agonists stimulated the phosphoiylation of the EGFR and subsequent association 
of this receptor with the She adaptor proteins (which was tyrosine phosphorylated) and 
Grb2 (Daub etal, 1996). Inhibition of EGFR function by either tyrphostin AG1478 (a 
selective EGFR kinase inhibitor (Levitzki and Gazit, 1995)) or a dominant negative 
mutant EGFR, suppressed these interactions as well as the stimulation of p42/44^P^^ 
activity and DNA synthesis mediated by the GPCRs. EGF-mediated p 4 2 /4 4 ^^^  
activity was less sensitive to inhibition by tyrphostin A G1478 and the actions of the 
dominant negative EGFR on EGF-mediated signalling could be overcome by a higher 
EGF concentration (PDGF-mediated responses were reported as insensitive to either 
inhibition). Therefore, this work suggests that the EGFR tyrosine kinase can act as a 
downstream mediator in the GPCR-mediated activation of the Ras.MAPK cascade. How 
this kinase activity would itself be activated independently of ligand-binding by the 
release of py subunits (at least in the case of LPA and thrombin) is not known. This 
work suggests that the point of convergence between the pathways by which GPCRs and
38
growth factor receptors activate p42/44^^P^ is at a much earlier step than previously 
proposed.
Similarly, the PDGF receptor has been implicated in the signalling pathway stimulated by 
angiotensin II in smooth muscle cells (Linseman etal, 1995). Angiotensin II treatment 
of these cells phosphorylated the PDGF receptor on tyrosine residues and stimulated the 
association of this receptor with tyrosine phosphorylated Shc.Grb2 complex and also Src 
kinases. Therefore this GPCR may stimulate a pathway involving both a receptor 
(PDGF receptor) and the non-receptor (Src) tyrosine kinases.
1.4.13.5 Src and GPCR-mediated p42/44^^*’®^ activation
The Src family of tyrosine kinases was also implicated by the inhibitory effect of 
herbimycin A (an inhibitor of Src-family kinase (Levitzki and Gazit, 1995)) on GPCR 
and Py-mediated activation of p 4 4 ^ P ^  and tyrosine phosphorylation of She (Hawes et 
al, 1995; Touhara etal, 1995). The role of Src in the stimulation of Shc.Grb2.mSos 
complexes was discussed earlier and this would seem to present a possible route to 
activation of the Ras.MAPK cascade. Activation of Src has been demonstrated by 02 - 
adrenergic, muscarinic ml and thrombin receptors expressed in CCL39 cells acting 
through pertussis toxin sensitive, insensitive and partially sensitive pathways respectively 
(Chen etal, 1994). Data has been reported which supports a role for Src in the GPCR- 
mediated activation of p42/44^ ^ K  poi- example, angiotensin II acting at AT 1 receptors 
in smooth muscle cells has been shown to stimulate Ras.GTP loading and Ras.Raf-1 
complex foiination in a pathway which is dependent on selective members of the Src 
kinase family (Schieffer etal, 1996). In PC 12 cells, Src has been shown to act with 
PYK2 to link Gi- and Gq-coupled receptors (for LPA and bradykinin) to the cascade at a 
point upstream of Grb2 and Sos in order to activate p 4 2 /4 4 ^ ^ ^  (Dikic eta l, 1996).
Again there appears to be a measure of diversity depending on the cell type studied 
because although the Src kinases were activated by LPA and bombesin treatment in
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Swiss 3T3 cells, they were shown not to be involved in the mitogenic responses to LPA 
and bombesin (Roche etal., 1995). It has been suggested that Src may play a role in the 
cytoskeletal rearrangements which accompany stimulation by LPA and thrombin in this 
case (Ei*pel and Courtneidge, 1995). Further studies aie required to determine if the Src 
kinases aie widely used as a mechanism of GPCR-mediated stimulation of the 
Ras.MAPK cascade.
1.4.13.6 Other tyrosine kinases and GPCR-mediated p42/44^^^^  
activation
Other tyrosine kinases have also been shown to be required for the GPCR-mediated 
activation of the Ras.MAPK cascade. Avian B cells were shown to require the Src- 
related tyrosine kinase Lyn to permit the activation of p44^^^^ and MEK by a 
transiently transfected Gq-coupled ml muscarinic acetylcholine receptor (Wan etal. ,
1996). This kinase was not required for the Gpcoupled m2 muscarinic receptor to 
activate this cascade. However, another tyrosine kinase called Syk was essential for the 
activation by both types of receptors. This again illustrates that the pathway for GPCR- 
mediated Ras.MAPK activation depends upon both the receptors involved and their 
cellular environment,
1.4.14 PI3-kinase
PI3-kinase catalyses the formation of phosphatidylinositol 3,4,5-trisphosphate 
(PI(3 ,4 ,5)P3) by direct phosphorylation of phosphatidylinositol 4,5-bisphosphate, and 
the first identified fonn of this enzyme was a heterodimer composed of an 85 kDa 
regulatory subunit and a 110 kDa catalytic subunit. This enzyme has been implicated in a 
number of intracellular signalling pathways, for example the activation of p7Q ribosomal 
S6 kinase (p70^^^) which is thought to play an important role in cellular regulation 
(Proud, 1996). However, the tai'gets for the product of the enzyme (PI(3 ,4 ,5)P3) are 
still being sought, although the serine/threonine kinase, Akt/PKB, has been suggested 
(Bos, 1995). The study of this enzyme has been greatly aided by the use of wortmannin
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(and other similar inhibitors such as LY294002) which is a selective inhibitor of PI3- 
kinase (Ui etal, 1995), although other effects have been reported (see Cross etal. ,
1995). PI3-kinase can be activated by numerous receptors of both the tyrosine kinase 
family and the GPCR family (Ui etal., 1995) and this enzyme is of particular interest to 
this discussion because of the recent implication of the role of PI3-kinase in the 
p42/44MAPK pathway induced by GPCRs.
1.4.14.1 PI3-kinase and the p42/44^^^^ cascade
The involvement of PI3-kinase in the activation of the Ras.MAPK cascade was 
suggested by the ability of wortmannin to inhibit insulin and serum-mediated activation 
of p42/44^^F"K and p9Œ^  ^in CHO cells overexpressing the insulin receptor (Welsh et 
al., 1994). Wortmannin was thought to act at an early step in the pathway as Raf-1, 
MEK and p42^^^^ activation by IGF was blocked by this compound, although it did 
not appear to inhibit Ras-GTP loading (Cross etal, 1994). In both these studies, 
rapamycin, (an inhibitor of the p70®^  ^pathway (MacKintosh and MacKintosh, 1994)) 
had no effect on the MAPK pathway.
The use of wortmannin has also implicated PI3-kinase in the GPCR-mediated activation 
of p42/44^'^P^. PAF activates p42/44^'^^^ through two distinct pathways in 
neutrophils, both of which are required for full activation. One is a Ca^+-dependent 
pathway (inhibited by an intracellular Ca^+ chelator) and the other is a Ca^+-independent 
but wortmannin-sensitive pathway (Ferby etal., 1994). However this PAF-activated, 
wortmannin-sensitive MAPK pathway in a macrophage cell line appeared not to involve 
the p85/pl 10-type PI3-kinase (Ferby etal., 1996), indicating that a different PI3-kinase 
isoform or a different wortmannin-sensitive protein was involved in this pathway. In 
COS-7 cells, the tyrosine phosphorylation of She stimulated by Py overexpression (but 
not by EGF) was inhibited by wortmannin (Touhara etal., 1995) which would implicate 
the wortmannin-sensitive step early in the GPCR-mediated MAPK cascade. Agonist 
activation of a i  adrenoceptors in vascular smooth muscle cells stimulated p42/44^P^^,
4 1
DNA synthesis and p85/pl 10 PI3-kinase activity in a wortmannin-sensitive but PKC- 
and Ca^+-independent manner (Hu etal, 1996). Stimulation was blocked by pertussis 
toxin pretreatment, implying that the receptors in this instance aie coupled to proteins of 
the Gi family. Also reported was that the a i  adrenoceptor-activated PI3-kinase was 
associated with an increase in the GTP loading of Ras and activation of some protein 
tyrosine kinase activity.
The activation of Ras and p42/44^ P K  stimulated by LPA, agonist stimulated 0 .2  
adrenoceptors and py overexpression in COS-7 and CHO cells (but not by phorbol ester 
or EGF) was also inhibited by wortmannin, LY294002 and a dominant negative p85 
subunit of PI3-kinase (Hawes etal, 1996). PI3-kinase inhibitors did not affect 
p42/44MAPK activation by overexpression of mSos, constitutively active Ras or MEK. 
All of these results would indicate that PI3-kinase activity is required in the Gpy-mediated 
MAPK signalling pathway at a point upstream of She, Sos and Ras activation.
There remains the question of how PI3-kinase is activated by GPCRs. A novel 110 kDa 
PI3-kinase subunit (pllOy) which is stimulated by thrombin via Gpy but does not bind to 
the p85 subunit has been cloned and expressed. In human platelets, this isoform of P13- 
kinase was detected and was shown to be regulated by thrombin in a Gpy-dependent 
manner (Zhang etal, 1995). However, in addition, these cells also stimulated p85/pll0 
PI3-kinase activity and this was independent of Gpy subunits, but was appai'ently 
regulated by Rho. ADP-ribosylation of p21^^° by the Clostiidium botulinum C3 
exoenzyme has been shown to inhibit LPA-mediated PI3-kinase activation in Swiss 3T3 
cells, although this did not totally block p42^^^^ activation (Kumagai e ta l , 1993).
The Rho proteins form a subgroup of the Ras family of low-moleculai* weight G- 
proteins. These proteins were initially implicated in the reorganisation of the 
cytoskeleton stimulated by growth factors and GPCR agonists (Takai eta l, 1995). 
However, more recently these proteins have been shown to be involved in various 
multiple pathways including those transducing growth regulatory signals using MAPK-
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like cascades (Symons, 1996). It has been suggested that the effect of the dominant 
negative p85 PI3-kinase subunit on Gpy-mediated p42/44^^^^ activation which would 
apparently point to the involvement of p85/pl 10 P13-kinase in this pathway, may not rule 
out the involvement of the pi lOy subunit but rather be the result of the binding of a 
substrate common to both isoforms (Hawes etal., 1996). Therefore the regulation of 
PI3-kinase activity may involve multiple kinase isoforms activated by distinctly different 
mechanisms. Src has also been suggested to play a role in coupling GPCR to PI3-kinase 
activity.
1.4.15 Functional outcome of MAPK activation
The importance of the p42/44^PI^ cascade in the regulation of mitogenesis has been 
illustrated throughout this chapter in numerous ways, such as the ability of agents whieh 
activate p42/44^^P^ to also stimulate DNA synthesis (for example van Corven etal., 
1989; Seuwen etal, 1990; Gupta etal., 1992; van Corven etal., 1993; Hu etal, 1996), 
by the correlation between the inhibition of the p42/44^^^^ cascade and the inhibition of 
DNA synthesis by cAMP (Cook and McCormick, 1993; Hordijk etal., 1994a; Frondin 
etal., 1994), wortmannin (Hu etal, 1996) and tyrphostin AG1478 (Daub etal, 1996). 
This has also been demonstrated by the ability of constitutively active members of the 
cascade to transform mammalian cells (Dent etal., 1992; Pelicci etal, 1992; Mansour et 
al, 1994; Aronheim a/., 1994, Cowley etal, 1994).
The role of p42/44^^^^ in the mitogenic response has been more clearly demonstrated 
by the expression of kinase deficient mutants of p42^ P ^  ^nd p44MAPK Using this 
method, the requirement for functional p42 /44^P ^  was demonstrated in the growth of 
quiescent cells infected with the SV40 small tumour antigen (Sontag etal, 1993), the 
transformation of NIH 3T3 cells by y-rafÇVroppmair etal, 1994), the stimulation of 
gene transcription and cell proliferation by thrombin, fibroblast growth factor (FGF) or 
serum in lung fibroblasts (Pages eta l, 1993), and in the induction of AP-1 activity by 
Ha-Ras, phorbol ester, and serum in rat embryo fibroblasts (Frost etal, 1994). The last
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two conclusions were also reached by use of RNA antisense expression and 
microinjection of specific substrate peptide inhibitors. Similai' conclusions were achieved 
by the expression of dominantly interfering mutants of MEKl (whose only known 
substrate is that of p42/44^PK.) which reverted v-src- and mj-transformed NIH 3T3 
cells (Cowley etal, 1994). Therefore the growth factor-mediated activation of 
p42/44MAPK jg absolute requirement for the triggering of proliferative responses in
many cells.
In other cells, the functional response to the activation of p42/44^^^^ is not that of DNA 
synthesis and cellular prolifemtion, but sometimes that of differentiation or protein 
synthesis and hypertrophy. A constitutively active mutant of MEKl stimulated the 
differentiation of PC 12 cells, and a dominantly interfering mutant of the same enzyme 
inhibited growth factor-mediated differentiation of these cells (Cowley eta l, 1994). 
Agonist activation of the thromboxane A2 GPCR in rat aortic smooth muscle cells 
stimulated p 4 2 ^ ^ ^  activation by a pathway involving She and Grb2, but this did not 
result in the stimulation of DNA synthesis. However, protein synthesis was stimulated 
as measured by an increase in the incorporation of [l^CJleucine (Jones etal, 1995). The 
absolute requirement for the p42 /44^P ^  cascade in the stimulation of protein synthesis 
by tyrosine kinase growth factors (insulin and FGF) and GPCR agonists (angiotensin II 
and thrombin) in smooth muscle cells was demonstrated by the inhibition by a MEK 
inhibitor (PD 98059) of protein synthesis and p42/44^P ^ activation (Servant etal. ,
1996). However, the p 4 2 /4 4 ^ ^ ^  cascade is not sufficient for protein synthesis 
activation as demonstrated by the inhibition by rapamycin (a pVO®*^  ^cascade-selective 
inhibitor) and the additive effects of rapamycin and PD 98059. It appears that both of 
these distinct pathways operate to increase protein synthesis.
It should be noted that the activation of the MAPK cascade and protein synthesis by the 
one agonist does not necessarily indicate a functional connection between these two 
effects. This was seen in the activation of p 4 2 /4 4 ^^^  by various GPCR agonists in
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neonatal ventricular myocytes (Post etal., 1996). In these cells, GPCR agonists which 
could stimulate hypertrophy stimulated p42 /44^P ^ with similar kinetics to agonists 
which were not hypertrophic. Also expression of dominantly-interfering mutants of 
p42MAPK and p44MAPK and treatment with PD 98059 failed to block the atrial natriuretic 
factor (ANF) expression of the hypertrophic GPCR agonists, but did inhibit Ras-induced 
gene expression and p42/44^^^^ activation. Therefore p42/44^^^^ activation is 
apparently not sufficient for GPCR-mediated induction of cai’diac cell growth and gene 
expression (Gq-coupled PLC activation correlates better with hypertrophy) and is not 
required for transcriptional activity of the ANF gene. This would again illustrate the cell 
and stimulus-specificity which can occur in these pathways especially at this level of 
functional output.
1.4.15.1 Duration of activation and response
The picture of the functional outcome of activation of the MAPK cascade is more 
complex as it depends not only upon the extent of stimulation of p 4 2 /44^^^ , but also 
on the duration of the activation of these enzymes (Schlessinger and Bar-Sagi, 1994; 
Marshall, 1995). It is thought that a more sustained activation permits time for nuclear 
translocation and transcriptional activation of genes which are not regulated by a more 
transient activation (Edwards, 1994; Hill and Treisman, 1995). NGF promoted the 
differentiation of PC12 cells whereas EGF treatment led to a proliferative signal, even 
although both growth factors activated p 4 2 /4 4 ^^^  (Marshall, 1995). However, in 
these cells, NGF stimulated a prolonged activation of p 4 2 /4 4 ^^^  and MEK for several 
hours and a significant translocation of p42 /44^P ^  to the nucleus, wliile EGF-mediated 
activation was significantly more transient and translocation was not detected (Traverse et 
al., 1992). The sustained activation of p42/44^^^^ permitted nuclear tianslocation and 
supposedly phosphorylation of transcription factors which produced the differentiation. 
This idea was strengthened by the observation of a differentiative response on EGF 
treatment of PC 12 cells which overexpressed the EGFR. In this case, EGF stimulated 
the activation of p 4 2 /4 4 ^ ^ ^  with a significantly more prolonged time course and its
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translocation to the nucleus was clearly seen (Traverse etal., 1994). The opposite effect 
was seen by reducing the level of expression of NGF receptors in these cells thereby 
converting a differentiation response to one of proliferation by a more transient 
p42/44MAPK activation (Marshall, 1995). Therefore the quantitative difference in 
activation of p42/44^^P^ was translated into a qualitative difference in transcription 
factor activation and cellular response.
A similar model can be used to explain observations in other cells with GPCR agonists 
where the sustained activation of p 4 2 /4 4 ^ ^ ^  is apparently important in producing a 
proliferative response. In CCL39 (hamster lung fibroblasts), thrombin was strongly 
mitogenic and stimulated cell proliferation presumably through its ability to stimulate 
p 7 Q s6 k  and p44MAPK with a biphasic time course of an initial transient peak of activity 
followed by a delayed, sustained peak over many hours (Kahan etal., 1992; Meloche et 
al., 1992). Treatment with pertussis toxin or a thrombin inhibitor nearly totally 
prevented the mitogenic activity and the sustained activation of p44MAPK yy thrombin, 
but only partially inhibited the initial transient phase (Meloche etal., 1992). Activation of 
a serotonin receptor or a transfected ml muscaiinic receptor was not sufficient to induce 
full mitogenesis and could only stimulate the initial transient peak of activity. Therefore, 
there appears to be a correlation between the ability of a growth factor to stimulate a 
sustained phase of p44MAPK activity and its mitogenic potential.
The duration of MAPK activation can also determine between a hyperplastic (cell 
proliferation) and hypertrophic (cell growth) response. In rat mesengial cells, PDGF 
stimulated a prolonged activation of p42/44^P^, MEK and Raf and stimulated DNA 
synthesis (pH]thymidine incorporation) and protein synthesis (pH]leucine 
incorporation). In contrast, angiotensin II stimulated a significantly less potent and more 
transient activation of the MAPK cascade coupled with an inability to stimulate DNA 
synthesis, although protein synthesis was still stimulated (Huwiler eta l, 1995).
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Therefore the critical determinant between a hyperplastic and a purely hypertrophic 
response appears to be the magnitude and duration of the stimulation of p42/44NAPK
1.4.16 Other MAPK cascades
As stated eaiiier there are three distinct groups of mammalian MAPKs (see Davis, 1994; 
Cano and Mahadevan, 1995). The JNK/SAPK family has limited homology to 
p42/44MAPK and its members are activated by UV iiradiation, protein synthesis 
inhibitors, heat shock and cellular stress. The defining property of these kinases is that 
they contain the TPY sequence which must be phosphorylated on threonine and tyrosine 
in order to be activated (this is TEY in p42/44^^^). This can be achieved by a dual 
specificity kinase called SEK which is thought to be regulated by MEKK in a Ras- 
dependent manner (see eaiiier; Yane? a / . ,  1994; Minden etal., 1994), although at present 
the pathway of regulation is not as well defined as that for p42/44^^P^. The 
JNK/SAPK cascade can also be activated by mitogens and recent evidence has 
demonstrated their activation by Gq and Gpcoupled receptors in Rat la  cells (Mitchell et 
al., 1995) and NIH 3T3 cells (Coso etal., 1995). Like the p42/44^^^^ cascade, the 
JNK/SAPK cascade is thought to play an important role in the induction of the 
transcription factors c-fos and c-jun (Cano and Mahadevan, 1995).
The third member of the MAPK family is p38 which was discovered as a kinase which 
was tyrosine phosphorylated in mammalian cells in response to lipopolysaccharide and 
changes in osmolarity (Han etal., 1994). This kinase also contains a dual 
phosphorylation motif, in this case in aTGY sequence (Cano and Mahadevan, 1995). 
There is much still to be explained in connection with this, and the other MAPKs, 
especially in the area of how specificity in the parallel cascades is achieved allowing the 
activation of specific pathways in cells (especially if Ras is involved in them all) and also 
the question of substrate selectivity of these kinases.
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GPCRs have also been implicated in the activation of the JAK/STAT pathway (Marrero 
etal, 1995) which is a recently identified tyrosine kinase signalling cascade involved in 
the control of transcription (Edwards, 1995; Malarkey eta l, 1995; Hill and Treisman, 
1995).
1.4.17 Why use a cascade?
One question wliich arises from the identification and study of this cascade is the reason 
for (or more properly the benefit from) its presence and complexity. A much simpler 
mechanism for the activation of MAPK could be envisioned, however one probable 
benefit from this complexity is the increase in the number of targets for positive and 
negative crossregulation by other signalling pathways (for example the stimulation by 
PKC and the various effects of cAMP) as well as for positive and negative feedback 
loops within the cascade. This permits this cascade to respond to numerous signals in a 
cell-specific manner (for example with elevated cAMP levels) and so synchronise the 
response to mitogenic signals with other environmental factors. Also, such a cascade 
allows an increased number of steps at which diversification or branching in the 
mitogenic signal can occur (such as seen with the various Ras effectors), which when 
coupled to the need of many downstream targets for more than one input for functional 
regulation, introduces cross-checks which could ensure that conditions are ideal before a 
commitment to a functional response such as mitogenesis is made.
1.5 Research aims
Although there has been an extensive amount of work detailing the cascade from GPCRs 
to p42/44^P^, as detailed above, there is currently little information on the quantitative 
aspects of this regulation such as the level of GPCR expression or degree of G-protein 
stimulation which is required in order to permit this activation, and how this compares 
with the other effectors of these receptors. Chapter 3 will address these questions with 
the (%2A adrenoceptor expressed in Rati fibroblasts to different densities as well as with a 
mutant form of this receptor which displays a reduced coupling efficiency. Chapter 4
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will determine the ability of the ô opioid receptor to activate p42/44^^^^ when 
expressed at a low and high density and will contrast the quantitative relationship 
between G-protein and p42 /44^P ^  activation in this system to other receptor/effectors 
systems. This work will be continued in Chapter 5 by use of opioid agonists with a 
range of intrinsic activities. In addition, the involvement or influence of various kinases 
and other effector pathways in the regulation of the MAPK cascade by GPCRs will be 
investigated in Chapters 3 and 5.
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Chapter 2: Materials and Methods
Chapter 2: Materials and Methods
2.1 Materials
Materials were obtained from the following suppliers;
2.1.1 General Reagents
Aldrich Chemical Company, Gillingham, Dorset, U.K.
2,2,4-trimethylpentane.
Amersham International pic.. Little Chalfont, Bucks., U.K.
ECU reagents, Biotrak p42/44 MAP kinase enzyme assay system.
Appligene, Chester-le-Street, Co. Durham, U.K.
Water saturated phenol.
Boehringer Mannheim U.K. Ltd., Lewes, East Sussex, U.K.
App(NH)p, creatine phosphokinase, dibutyryl cAMP, hygromycin B, GDP, GTPyS, 
DNAase free RNAase.
Calbiochem-Novabiochem (U.K.) Ltd., Beeston, Nottingham, U.K.
Pansorbin cells, tyrphostin AG1478.
Costar Scientific Corporation U.K., Gordon Road, Bucks., U.K.
Nitrocellulose.
Fisons Scientific Equipment, Loughborough, U.K.
Ammonium fonnate, CaCl2.6H2 0 , DMSO, EDTA, EGTA, ethylacetate, ethylene glycol, 
formic acid, glucose, glycine, HEPES, H2Q2, hydrochloric acid, KCl, KH2PO4, 
K2HPO4, MgCl2.6H2 0 , NaCl, Na2C0 3 , NaHCOg, NaH2P0 4 -
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Gibco BRL Life Technologies Inc, Paisley, U.K.
Agarose, lipofectin, tris, urea, 1 kb DNA ladder.
Koch-Light Lab. Ltd., Colinbrook, Bucks., U.K.
NaK tartrate, MgS0 4 .7 H2 0 .
Lipid Products, South Nutfield, Surrey, U.K.
Phosphatidylbutanol.
May & Baker Ltd., Dagenham, U.K.
CUSO4, sodium tetr aborate.
Merck Ltd., Poole, Dorset, U.K.
Acrylamide, ammonium persulphate, bacto-agar, bacto-tryptone, bacto-yeast extract, 
butan-l-ol, chloroform, DTT, ethanol, Folin and Coicalten's phenol reagent, glacial 
acetic acid, glycerol, imidazole, isoamyl alcohol, isopropanol, methanol, N,N'- 
methylene-bisacrylamide, NaOH, NaHP0 4 , orthophosphoric acid, SDS, sucrose, 
trichloroacetic acid.
Packard Instrument Company, Meriden, CT, U.S.A.
Ultima-Flo AF scintillant.
Pfizer Central research, U.K.
UK14304.
Promega Ltd., Southampton, U.K.
Restriction enzymes.
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Research Biochemicals Inc., Semât Technical (U.K.) Ltd., St. Albans, Herts., U.K. 
Buprenoiphine, diprenorphine, ICI 174864, levorphanol tartrate, morphine, TIPPW.
Sigma Chemical Company, Poole, Dorset, U.K.
Alumina, ampicillin, aprotonin, L-arginine HCl, ascorbic acid, ATP, bromophenol blue, 
BSA, cAMP, charcoal (activated), chelerythrine chloride, cholera toxin, Coomasie blue, 
DADLE, o-dianisidine, Dowex 1, Dowex 50W, EOF, endothelin-1, ethidium bromide, 
forskolin, gelatin, genistein, GTP, idazoxan, Li Cl, LPA, MBP, MOPS, MnCh, NaF, 
naloxone, p-nitrophenol phosphate, NP40, ouabain, PEG8000, pepstatin A, 
phenylmethylsulphonyl fluoride, phosphocreatine, ponceau S, potassium acetate, 
prestained molecular weight standards, RbCD, sodium azide, sodium deoxycholate, 
sodium orthovanadate, TEMED, thimerasol, N-tris(hydroxymethyl)methylgIycine- 
NaOH, Triton-xlOO, trypsin. Tween 20, wortmannin.
Spey wood Ltd., Berkshire, U.K.
Pertussis toxin.
Upstate Biotechnology Inc., Lake Placid, New York, U.S.A.
EGF (human, recombinant).
2.1.2 Radiochemicals
Amersham International pic.. Little Chalfont, Bucks., U.K.
[y-32p]ATP (s.a. 3000 Ci/mmol), [a-32p]ATP (s.a. 400 Ci/mmol), [S-^HjcAMP (s.a. 
24 Ci/mmol), [15, 16(u)-3H]diprenorphine (s.a. 39 Ci/mmol), [ethyl-^H]RS-79948-197 
(s.a. 90 Ci/mmol), [y-^^P]GTP (s.a. > 10 Ci/mmol), myo-[2-^H]inositol (s.a. 16.5 
Ci/mmol), [9,10(n)-3H]palmitic acid (s.a. 51 Ci/mmol).
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Du Pont NEN (U.K.) Ltd., Stevenage, Herts., U.K.
[adenylate-^^P]NAD (s.a. 800 Ci/mmol), [methyl-^H]yohimbine (s.a. 81 Ci/mmol), 
[35s]GTPyS (s.a. 1175 Ci/mmol).
2.1.3 Tissue culture plasticware
Costar Scientific Corporation U.K., Gordon Road, Bucks., U.K.
25 cm^ and 75 cm^ flasks, 10 cm dishes, 6 and 24 well plates.
Bibby Sterilin Ltd., Stone, Staffs., U.K.
Sterile disposable plastic pipettes.
Nunc, Nalge Nunc Inc., Denmark.
Cryovials.
2.1.4 Cell culture Media
Gibco BRL Life Technologies Inc, Paisley, U.K.
lOx DMEM, 200 mM glutamine , inositol free DMEM, 7.5% (w/v) NaHCOg, newborn 
calf serum, 10000 units/ml penicillin /1 0  mg/ml streptomycin.
2.1.5 Standard Buffers: 
Phosphate Buffered Saline (PBS)
2.7 mM KCl
1.5 mM KH2PO4
140 mM NaCl
8 mM Na2HP0 4
pH 7.4
This was made as a lOx solution and stored until required. When required, a Ix solution 
was prepared by dilution giving the above composition and pH was set to 7.4 with 
concentrated HCl.
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Hanks Modified Medium
1.3 mM CaCl2.6H2O
5.4 mM KCl
490 ;^M MgCl2.6H20
410 MgSO4.7H20
137 mM NaCl
4.2 mM NaHCOs
270 ]aM NaH2P0 4
pH 7.2-1 A  at 4°C
This was made as a 2x stock and stored at 4°C until required.
Laemmli Buffer
5 M urea
0.4 M DTT
0.17M SDS
50 mM Tris/HCl (pH 8)
0 .01% (w/v) bromophenol blue
Stored aliquoted at -20''C until required.
2.1.6 Antisera
Anti-p44^^P^ used for immunoblotting was a gift from Dr. Neil Anderson, Dept, of 
Surgery and School of Biological Sciences, University of Manchester, Manchester, U.K. 
A nti-p42^P^ was a gift from Dr. Ailsa Campbell, Division of Biochemistry and 
Moleculai* Biology, Institute of Biomedical and Life Sciences, University of Glasgow, 
Glasgow, U.K.
A nti-p44^P^ used for IP kinase assay was from Dr. Simon Cook, Onyx 
Phannaceuticals, Richmond, California, U.S.A.
HRP-linked donkey anti-rabbit IgG and HRP-linked sheep anti-mouse IgG were 
obtained from the Scottish Antibody Production Unit, Carluke, Lanarkshire, U.K.
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Anti phosphotyrosine antiserum was obtained from Upstate Biotechnology Inc., Lake 
Placid, New York, USA.
2.1.7 cDNAs
pCMV4 expressing haemmaglutinnin tagged wild type and Asn'^  ^porcine U2a  
adrenoceptor was a gift from Dr. Lee Limbird, Dept, of Pharmacology, Vanderbilt 
University Medical Centre, Nashville, Tennessee, U.S.A.
pCMV-msl2 expressing the mouse Ô opioid receptor was a kind gift from Dr. Graeme 
Bell, Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois, 
U.S.A.
2.2 Methods
2.2.1 Cell culture
2.2.1.1 Cell growth
Growth Medium for Rati fibroblasts: 5% DMEM
10% (v/v) Dulbecco's Modified Eagle's Medium 
0.375% (w/v) sodium bicarbonate 
2 mM glutamine
100 units/ml Penicillin
100 /^g/ml Streptomycin
5% (v/v) newborn donor calf serum
Medium for serum starvation was as above without, or with a lower concentration 
(0.05% (v/v)) of, newborn calf serum.
Rati fibroblasts were grown to confluency in 5% DMEM in 75 cm^ tissue culture flasks 
at 37°C and in a humidified atmosphere of 95% air / 5% CO2. At confluency, the 
medium was removed and replaced with 2 ml of a sterile solution of PBS containing 
0.1% (w/v) trypsin, 0.025% (w/v) EDTA and 10 mM glucose. This was incubated at 
37°C until the cells were removed from the surface of the flask. 4.5 vols of 5% DMEM 
were added in order to stop the action of the trypsin and the cell suspension was
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transferred to a 50 ml tube and centrifuged at 800 x g in a MSE centaur centrifuge for 5 
mill. The cell pellet was resuspended and transfeired to other tissue culture flasks or 
plates as required.
2.2.1.2 Cell line maintenance
After trypsinisation and centrifugation, as above, the cell pellet was resuspended in 
newborn calf serum containing 10% (v/v) DMSO and transferred to cryovials. These 
were placed at -80°C for 24 hours and stored in liquid nitrogen.
2.2.1.3 Harvesting cells
Just prior to confluency, cells were scraped off the surface of the flasks into the growth 
medium using a disposable cell scraper (Costar). The suspension was pipetted into 50 ml 
tubes and centrifuged in a Beckman TJ-6 Benchtop centrifuge at 800 x g and 4°C for 5 
min. The cell pellet was washed twice in ice-cold PBS and stored at -80“C.
2.2.1.4 Crude membrane preparation
Membranes were prepared from the frozen cell pellet prepared as above. The cells were 
resuspended in 3 ml of ice-cold TE buffer (10 mM Tris-HCl (pH 7.5), and 0.1 mM 
EDTA) and homogenised with at least 30 strokes of a teflon on glass homogeniser. The 
suspension was then centrifuged at 500 x g in a Ti50 rotor in a Beckman L5-50B 
ultracentrifuge for 10 min. The pellet contained unbroken cells and the nuclear fraction, 
and the supernatant was centrifuged again at 48,000 x g for 10 min. This pellet was 
washed in 5 ml of ice-cold TE buffer and then centrifuged again at 48,000 x g for 10 
min. The pellet containing the cmde membrane fraction was resuspended in TE buffer, 
passed through a fine gauge needle 10 times, then aliquoted and stored at -80°C.
2.2.2 Protein determination
Protein determination was performed using the method of Lowry etal. (1951). Reagent 
solutions were prepared as follows:
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1% (w/v) CUSO4
2% (w/v) NaK tartrate
2% (w/v) Na2C03  in 0.1 niM NaOH
These were mixed in the ratio of 1: 1 : 100 respectively, 20 min prior to assaying. 1 ml 
of the above reagent mix, and then 10 min later 100 pil of 50% (v/v) Folin and 
Ciocalteu's phenol reagent, were added to the protein sample (made up to a constant 
volume with TE buffer). After mixing and incubating at room temperature for at least 20 
min, absorbance at a wavelength of 750 mu was determined with a spectrophotometer 
(Shimadzu). By comparison to a standard curve prepared with various volumes of a 
standard concentration of BSA in TE buffer, the concentration of protein in each sample 
was determined.
2.2.3 Radioligand binding assay
Levels of expression of receptors were determined using radioligand binding assays. 
Borosilicate glass tubes were set up on ice containing:
50 pt\ of membrane suspension diluted from a frozen aliquot (prepared as in 
2.2.1.4) with ice-cold TE buffer to give appropriate protein concentration,
25 pt\ of appropriate concentration of tritiated ligand,
175 of TSM buffer (10 mM Tris/HCl (pH 7.4), 50 mM sucrose and 20 mM 
MgCl2).
Some tubes also contained 25 pi\ of competing non-radioactive ligand (compensated by a 
reduction in volume of TSM buffer added) to define non-specific binding. The reaction 
was incubated at 30°C for 45 min and terminated by filtration through Whatman GF/C 
filters using a Brandel cell harvester. After three (approximately 5 ml) washes with ice- 
cold TSM buffer, the filters were soaked overnight in 5 ml Ultima-Flo AF scintillant prior 
to liquid scintillation counting.
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2.2.4 High affinity GTPase assay
These assays were performed essentially as described in Koski and Klee (1981). Each 
incubation contained the following:
20 }Â of membrane suspension prepared as in 2.2.1.4 and diluted to the required 
concentration with TE buffer,
50 pi\ of p2p]GTP mix which contained: 20 mM phosphocreatine, 100 units/ml 
creatine phosphokinase, 2 mM ATP (pH 7.5), 200 piM App(NH)p, 2 mM Ouabain, 200 
mM NaCl, 10 mM MgCl%, 4 mM DTT, 80 mM Tris/HCl (pH 7.5), 200 ] a M  EDTA (pH 
7.5), 1 piM non-radioactive GTP (pH 7.5), and approximately 50,000 cpm of [y- 
^^P]GTP (specific activity 30 Ci/mmol),
10 jwl of various ligands,
H2O to make volume up to 100 pi\.
Membranes, water and ligands were mixed on ice and the assay was started by the 
addition of the p2p]GTP mix and transfer to a 30°C water bath. Incubation was allowed 
for 30 min, after which the reaction was terminated by the transfer to an ice slurry and 
addition of 900 ^ 1 of ice-cold 5% (w/v) activated charcoal in 10 mM H3PO4. The 
chaicoal was pelleted by centrifugation at 12,000 x g for 20 min in a benchtop microfuge. 
500 pil of the supernatant was transferred to insert scintillation vials and counted by 
Cherenkov counting. 50 pci aliquots of the p^P]GTP mix were also counted directly and 
this allowed calculation of data as pmol of GTP hydrolysed per min per mg of membrane 
protein.
2.2.5 GTPyS binding assay
These assays were perfonned as in Wieland and Jakobs (1994). Borosilicate glass tubes 
were set up on ice containing the following:
25 pel of membranes (diluted from a stock with ice-cold TE to give the required 
concentration),
50 pel of p^S]GTPyS reaction mix which contained: 40 mM HEPES (pH 7.4), 6 
niMMgCl2, 200 mM NaCl, 20 ]aM  GDP, 0.2 mM ascorbic acid (all of these can be
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prepared as a 10 x stock and aliquotted and frozen at -20°C), 50 nCi p^S]GTPyS (stored 
at -80°C diluted in 10 mM N-tiis(hydroxymethyl)methylglycine-NaOH (pH 7.6), 10 mM 
DTT),
25 pel remaining was made up with water, agonists and/or 10 /<1 of 100 piM 
GTPyS (to determine non-specific binding).
The membranes were always added last and then the contents of the tubes were mixed 
well. Incubations were performed at 4°C for 60 min and were tenninated by the addition 
of 3 ml of ice-cold filter wash (20 mM HEPES (pH 7.4) and 3 mM MgCD) to each tube 
and immediate filtration through a Whatman GF/C filter using a Brandel cell hai*vester. 
Each filter was then washed with a further 2 x 5 ml of the filter wash buffer and then 
soaked in 10 ml Ultima-Flo AF scintillant overnight before liquid scintillation counting.
2.2.6 Adeiiylyl cyclase assay
These were performed as in Johnson and Salomon (1991).
This assay measured the production of p^P]cAMP from p^P]ATP. Separation of 
P^PjcAMP from the p^PJATP was achieved using the method of Salomon etal. (1974) 
which made use of Dowex and Alumina columns.
2.2.6 1 Sample preparation
Each incubation tube was prepared on ice to contain the following:
20 pA of membrane suspension (diluted from a frozen stock aliquot with TE 
buffer to give appropriate concentration),
50 pil of p2p] ATP reaction mix containing: 2 ^M GTP (pH 7.5), 2 niM cAMP, 
400 ^ M  ATP (pH 7.5), 2'00 mM Tris/HCl (pH 7.5), 100 mM NaCl, 10 mM MgClg, 40 
mM phosphocreatine, 100 units/ml creatine phosphokinase and 10  ^cpm [a-^^PJATP,
30 pil remaining was made up with water and 10 pil additions of ligands as 
required.
The reaction was initiated by transfer of the tubes to a 30°C water bath, and incubation 
was allowed for 15 min. The reaction was tenninated by removal of tubes to an ice
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slurry and the addition of 100 pd of 2% (w/v) SDS, 45 inM ATP, 1.3 mM cAMP 
(stopper solution). 50 pi\ (10,000 cpm) of a solution of pHjcAMP was added and the 
samples were boiled for 10 min. 750 pi\ of H2O was added and the p^PjcAMP content 
in the sample was determined using the chromatography columns prepared as below.
2.2.6.2 Preparation of the columns
Dowex 50W (50x4-400) (1 g per column) was washed twice with twice its volume of 
water to remove fines. It was then washed with twice its volume of 1 M NaOH and then
1 M HCl. After further washes with water, a 1 ; 1 slurry with water was produced and 2 
ml was added to each glass wool stoppered column. A cold reaction mix (50 pil of 
reaction mix without the p^P] ATP, 100 pil of stopper solution and made up to 1 ml with 
water) was added to each column and allowed to drip to waste. These columns were then 
stored until required at room temperature. On day of use, the columns were washed with
2 X  2 ml of 1 M NaOH, followed by 2 x 2 ml of 1 M HCl and 6 x 2 ml of H2O.
The alumina columns were prepared by adding a 50% (w/v) alumina solution in 0.1 M 
imadazole (pH 7.3) to glass wool stoppered columns (2 ml per column). As with the 
Dowex columns, a cold reaction mix was dripped through each column prior to storage at 
room temperature. On the day of use, the columns were washed with 4 x 2 ml of 0.1 M 
imadazole (pH 7.3).
2 2.6.3 Nucleotide elution profile of columns
This was performed to determine the elution volume of the nucleotides for both the 
Dowex and alumina columns.
A solution containing 50 pil of p^P] ATP reaction mix as used in assay with 50 pil 
(10,000 cpm) of pHJcAMP, 100 pil of stopper solution and the volume made up to 1 ml 
with water was applied to a Dowex column. The eluted solution was collected in vials 
containing 10 ml of Ultima-Flo AF scintillant. Successive washes of the column with 
0.5 ml of water were collected in further vials containing scintillant and counted by liquid
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scintillation on a dual label programme. The elution profiles of both nucleotides were 
then produced and the efficiency of recovery was determined by reference to a direct 
count of the radioactive mixture. An elution profile of the alumina columns could be 
produced in a similai* fashion, using a reaction mix containing only the pHjcAMP and 
0.1 M imidazole (pH 7.3) instead of water as the elution buffer.
2.2.6.4 Determining cAMP production
Once the volume of the samples had been made up to 1 ml by the addition of H2O, as 
described above, the samples were loaded onto prepaied Dowex columns and the ATP 
was eluted with 0.5 ml H2O. 4 x 2 ml washes of H2O were then applied and the eluate 
was allowed to drip onto the prepared alumina columns. The cAMP fraction was then 
eluted from the alumina columns with 4 x 1.5 ml of 0.1 M imidazole (pH 7.3) into 12 ml 
of Ultima-Flo AF scintillant. The samples were counted on a dual label liquid 
scintillation counting programme and so the amount of cAMP produced was calculated 
taking into account the efficiency of recovery from each column determined from the 
recovery of the internal pHjcAMP standard. Results were thus calculated in pmol of 
cAMP produced per min per mg of membrane protein.
2.2.7 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
2.2.7.1 10% Acrylamide resolving gels
10% (w/v) aciylamide/0.25% (w/v) N,N'-methylene-bisacrylamide resolving gels were 
prepared as follows:
8.2 ml H2O
1.6 ml 50% (v/v) glycerol
8 ml 30% (w/v) acrylamide, 0.8% (w/v) N,N'-methylene-
bisaciylamide
6 ml 5 M Tris/HCl (pH 8 .8), 0.4 % (w/v) SDS
90 ]Â 10% (w/v) ammonium persulphate
8/^1 TEMED
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This was mixed and immediately poured into a Hoefer Gel Caster with two 180 x 160 
mm glass plates and 1.5 mm spacers. The gel was layered with 0.1% (w/v) SDS and 
allowed to set at room temperature for 90 min.
14% acrylamide resolving gels were prepared as above with the following alterations:
5 ml of H2O and 11.2 ml of 30% (w/v) acrylamide, 0.8% (w/v) N,N'-methylene- 
bisaciylamide.
2.2.7.2 Stacking gels
After the resolving gel had set, the SDS was washed off and the stacking gel was 
prepared:
9.75 ml H2O
1.5 ml 30% (w/v) acrylamide, 0.8% (w/v) N,N'-methylene-
bisaciylamide
3.75 ml 0.5 M Tris/HCl (pH 6 .8), 0.4 % (w/v) SDS
150 pi\ 10% (w/v) ammonium persulphate
TEMED
This was mixed and layered on top of the resolving gel around a 15 well Teflon comb 
and left to set for another 90 min.
The buffer used in the upper and lower reservoir of the gel electrophoresis tank was 25 
mM Tris base, 0.192 M glycine and 0.1% (w/v) SDS. Once set, the gels were 
assembled into a Hoefer vertical gel electrophoresis kit, loaded using a Hamilton syringe 
and electrophoresis was performed at 60 V overnight.
2.2.7.3 Sample preparation
Samples were sometimes prepared for gel electrophoresis by sodium 
deoxycholate/trichloroacetic acid precipitation:
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To the desired amount of protein, the following was added in the correct order;
750 ]A H2O
10 jWl 2% (w/v) sodium deoxycholate
250 pi\ 24% (w/v) trichloroacetic acid
This was centrifuged in a microfuge for 20 min at 12,000 x g. The supernatant was 
removed and the pellet dissolved in 15 }A of 2 M Tris base. 15 pi\ of Laemmli buffer was 
then added and the sample loaded onto the gel.
2.2.7.4 6M Urea containing polyacrylamide gels
In order to provide adequate separation of proteins as part of the MAPK electrophoretic 
mobility shift assay (see 2.2.9.1), an SDS-PAGE system which contained 6 M urea and 
had a low level of N,N'-methylene-bisacrylamide was used (Kim and Milligan, 1994). 
This was made by preparing three individual solutions on the day of use;
Solution 1: 
Solution 2:
6 M 
6 M 
1.5 M
urea
urea
Tris/HCl (pH 8 .8)
0.4% (w/v) SDS
Solutions: 6 M
30% (w/v)
urea
acrylamide
0.15% (w/v) N,N-methylene-bisacrylamide 
The resolving gel was then prepared from these solutions as follows:
12.2 ml solution 1 
solution 2 
solution 3
10% (w/v) ammonium persulphate 
TEMED
This was mixed and immediately poured into a 20 cm Bio-Rad Protean II gel casting 
apparatus with 1.5 mm spacers. The gel was layered with butan-l-ol and allowed to set 
for 2 hours at room temperature.
9.6 ml 
16.2 ml 
3 0 }4\
6 pil
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The butanol was then thoroughly washed off and stacking gel was prepared as before. 
Electrophoresis was perfonned at 120 V for 18-20 hours.
2.2.8 Western blotting
Subsequent to electrophoresis overnight with any of the above gel types, proteins were 
transferred to a nitrocellulose sheet in an LKM Transphor apparatus filled with 25 mM 
Tris base, 0.192 M glycine and 20% (v/v) methanol at 1.5 mA for 2 hours. The sheet 
was then temporarily stained with 0.1% (w/v) ponceau S, 3% (w/v) trichloroacetic acid 
in order to check transfer efficiency and protein loadings. After washing in transfer buffer 
and distilled water in order to remove the stain, the nitrocellulose sheet was treated in 
different ways depending on the antibody used.
Immunoblotting against p44^^^K  yv^ s with a polyclonal antiserum and the nitrocellulose 
sheet was blocked with 5% (w/v) gelatin in PBS for 2 hours at 37°C. The gelatin was 
washed off with distilled water and the sheet incubated in a 1 : 500 dilution of anti- 
p44MAPK antiserum in 1% (w/v) gelatin, 0,2% (v/v) NP40 in PBS overnight at 37°C. 
The next day, the primary antiserum was washed off with three changes of distilled water 
and at least five changes of 0.2% (v/v) NP-40 in PBS (over a time period of 30 min).
The secondary antibody (horse-radish peroxidase conjugated goat anti-rabbit IgG) was 
then added (in 1% (w/v) gelatin, 0.2% (v/v) NP40 in PBS) and incubation at 37°C was 
allowed for at least 2 hours. The secondary antibody was then removed and the same 
washes were performed as before, with the addition of two washes of PBS at the end. 
The blot was then developed in 50 ml of 0.02% (w/v) o-dianisidine in PBS after the 
addition of 5 pil of H2Q2. Development was terminated by immersion in 1% (w/v) 
sodium azide.
When the monoclonal an ti-p42^^^  or anti-phosphotyrosine antisera were used, the 
nitrocellulose sheet was blocked in 10% (w/v) milk protein, 0.1% (v/v) Tween 20 in 
PBS at 25°C while shaking. The primary and secondary antisera were prepared in 0.5%
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(w/v) milk protein, 0.1% (v/v) Tween 20 in PBS. Horse-radish peroxidase conjugated 
anti-mouse IgG was used as the secondary antiserum. Washes were as above but with 
0.1% (v/v) Tween 20 in PBS and blots were developed using Amersham's ECL kit 
according to the manufacturer's procedure.
Anti-p44^^P^ primary antibodies could be used up to fifteen times, other primary and 
the secondary antibodies were routinely used up to three times. All antibodies were 
stored at 4°C using thimerasol as an anti-bacterial agent.
2.2.8.1 Quantitation of iminunobiots
Immunoblots were quantified by densitometric scanning using a Bio-Rad imaging 
densitometer.
2.2.9 MAPK assays
The activation of the p42/p44^^^^ pathway was determined by three different methods. 
The electrophoretic mobility shift assay was used to demonstrate the phosphorylation of 
p42MAPK or p44MAPK determined by a retardation in mobility in SDS-PAGE. The 
activity of p42/44^^^^ was determined by the immunoprécipitation (IP) kinase assay or 
by the Biotrak p42/44 MAP kinase enzyme assay system (Amersham International), The 
first assay measures the ability of immunoprecipitated p44MAPK catalyse the 
phosphorylation of an exogenously added substrate myelin basic protein (MBP), and the 
kit from Amersham uses a peptide which is highly selective for p 4 2 /4 4 ^ ^ ^  as an 
exogenous substrate in a kinase reaction.
2.2.9.1 Electrophoretic mobility shift assay
This assay was performed as in Leevers and Marshall (1992). Cells were grown in 5% 
DMEM to confluency in 10 cm tissue culture dishes at 37“C and 5% CO2 after which 
they were serum starved in low or zero serum DMEM for 24 to 48 hours. The cells were 
then incubated with the appropriate ligands in serum free DMEM for various lengths of
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time at 37°C and 5% CO2. The incubation was tenninated when the cells were 
transferred to 4°C, the medium was removed and the cells washed in ice-cold PBS. 450 
ja\ of ice-cold lysis buffer was then added to each dish. This lysis buffer contained 25 
inM Tris/HCl (pH 7.5), 25 inM NaCl, 10% (v/v) ethylene glycol, (stored as a stock 
solution at -20°C) and added immediately prior to use 40 niM p-nitrophenol phosphate,
10 piM DTT, 0.2% (v/v) NP40, 1 piglml aprotonin, 1 mM sodium orthovanadate, 3.5 
pig/ml pepstatin A, and 200 piM phenylmethylsulphonyl fluoride. Cells were scraped into 
tubes and passed through a fine gauge needle approximately ten times in order to 
complete cell lysis. The cell suspension was then centrifuged at 4°C in a microfuge at
12,000 X  g for 5 min. 450 //I of the supernatant was then transferred to 115 pi\ Laemmli 
buffer in fresh tubes and boiled at 100°C for 5 min. These samples were then analysed 
directly by SDS-PAGE using 6 M urea containing polyacrylamide gels (as described in 
2.2.7.4). Western blotting of these gels and immunoblotting with anti-p42^P^^ or anti- 
p44MAPK antisera permitted the gel shift, and therefore the phosphoiylation, of these 
MAPKs to be determined. Densitometric scanning allowed quantitation of these blots 
and calculation of the results as the percentage of the total detectable p42^F"K qj- 
p44MAPK which was present in the lower mobility form.
2.2.9.2 IP kinase assay
Cells were grown to confluence in 5% DMEM in 6 well plates and serum starved for 24 
to 48 hours. The cells were treated with the appropriate ligands in semm free DMEM for 
various times. The incubation was terminated as the medium was removed and the cells 
washed in ice-cold PBS. 400 of lysis buffer was then added. This lysis buffer 
contained: 20 mM Tris/HCl (pH 8), 137 mM NaCl, 1 mM EGTA, 1% (v/v) Triton x- 
100, 10% (v/v) glycerol, 1.5 mM MgCl2, stored at 4°C as a 2x stock solution, and added 
just prior to use 0.1 mM sodium orthovanadate, 10 pig/ml aprotonin, 25 mM NaF and 
0.2 mM phenylmethylsulphonyl fluoride. Cells were scraped off the plate and 
transfeiTed to microfuge tubes. These were mixed for 20 min at 4°C and centrifuged at
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4°C in a microfuge at 12,000 x g for 5 min. The cell lysate was then assayed for protein 
concentration.
The volume of cell lysate which contained 300 pig of protein was mixed with 4 pil of anti- 
p 44MAPK antiserum for 2 hours at 4°C. 50 pil of pansorbin cells (washed and 
resuspended in lysis buffer) were added for the last 30 min. After this time, the 
pansorbin cells were pelleted by a pulse centrifugation and the supernatant removed by 
aspiration. The pellet was washed in 3 x 0.5 ml of lysis buffer and once with 0.5 ml of 
kinase buffer (30 mM Tris/HCl (pH 8), 1 mM MnCh, 10 mM MgCh). The kinase 
reaction was initiated by resuspending the washed pansorbin pellet in 30 pi\ of kinase 
buffer containing 1 piM ATP (pH 8), 0.23 mg/ml MBP and 2 piCi of [y-^^PJATP. This 
reaction was incubated at 30°C for 30 min and tenninated when 7.5 pi\ Laemmli buffer 
was added. These samples were boiled for 5 min at 100°C and centrifuged at 12,000 x g 
for 2 min. The supernatant was then analysed by SDS-PAGE using a 14% acrylamide 
gel in a Bio-Rad Mini-Protean II electrophoresis system run at 200 V until the dye front 
was 1 cm from the end of the gel. The stacker and bottom part of the gel (containing the 
dye front and ATP) were discarded, and the gel was stained in 0.1% (w/v) Coomasie 
blue in 40% (v/v) methanol, 10% (v/v) glacial acetic acid for 30 min and destained for a 
further 30 min in 40% (v/v) methanol, 10% (v/v) glacial acetic acid. The gel was washed 
in water and then dried under vacuum in a Bio-Rad gel dryer. These were exposed to a 
phosphor storage plate for about 30 min and analysed using a FUJIX BAS1000 image 
analyser and the radioactivity associated with the MBP band was quantified.
2.2.9 3 Biotrak p42/44 MAP kinase activity assay
Cells were grown to confluence in 5% DMEM in 60 mm plates and serum staiwed for 24 
to 48 hours. The cells were treated with appropriate ligands in serum free DMEM for 
various times and the incubation was terminated and cell lysates were prepared as for the 
IP kinase assay, using 150 pi\ per plate of the same lysis buffer. After protein 
determination, the cell lysates were assayed using the Biotrak p42/44 MAP kinase
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enzyme assay system (Amersham International) according to the manufacturers 
instructions in the presence of 0.2 ]aCH]aI [y-^^PjATP. Samples were counted by liquid 
scintillation and results presented as pmol phosphate transferred per min per mg protein.
2.2.10 Transphosphatidylatioii assay
This was performed as in Cook and Wakelam (1991). This assay was used to monitor 
the activity of PLD by measuring the transphosphatidylation activity of pHJpalmitate- 
labelled cells in the presence of butan-l-ol. This produced pH]phosphatidylbutanol 
which was not metabolised further and could be isolated by phase separation and thin 
layer chromatography. Cells were grown to 70% confluency in 5% DMEM at 37°C and 
5% CO2 in 24 well plates. The medium was replaced with fresh 5% DMEM containing 4 
piCilml pH]palmitate and cells were incubated for another 24 hours. The cells were then 
incubated at 37°C for 20 min in 0.5 ml per well of HBG (Hanks modified medium 
containing 2% (w/v) BSA and 10 mM glucose). This was removed and replaced by 0.5 
ml HBG containing 0.3% (v/v) butan-l-ol (HBGbutanol) for a further 5 min incubation. 
This was removed and the reaction was initiated by adding 0.2 ml HBGbutanol with or 
without the required ligands. After the required incubation time, the medium was 
removed and replaced by ice-cold methanol (0.5 ml per well) to terminate the reaction. 
The cell debris was scraped into glass vials and each well was washed with a further 0.2 
ml methanol. 0.7 ml chloroform was added and the vials were vortexed and allowed to 
stand at room temperature for 15 min. 585 pil of H2O was added and the solutions were 
again mixed. These vials were then stored overnight at -20°C.
Centrifugation at 1,500 x g for 5 min was performed, and 450 pi\ of the lower phase 
(which contained the phospholipids) was transferred to fresh vials and dried down under 
vacuum in a Jouan centrifugal evaporator for 60 min. This was resuspended in 2 x 25 pi\ 
chloroform : methanol mix (19: 1, v/v) and loaded onto Whatman silica gel thin layer 
chromatography plates which had been pre-run and activated at 120°C. In addition, 7.5 
pil of phosphatidylbutanol (Lipid Products) was loaded on top of each sample. Plates
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were developed in the organic phase of a 5: 1 1 :2 : 10 mix of 2,2,4 trimethylpentane, 
ethylacetate, acetic acid and water under non-equilibrated conditions.
Phosphatidylbutanol displayed an Rf value of approximately 0.4, and was detected by 
visualising the exogenously added phosphatidylbutanol by staining with iodine vapour. 
The strip of silica containing this band was then scraped off the plate and subjected to 
liquid scintillation counting. Thus the radioactivity associated with this band, and hence 
the production of pH]-labelled phosphatidylbutanol, was determined.
2,2.11 Total inositol phosphate assay
This was performed as described in MacNulty etal. (1992).
2.2.11.1 Inositol free medium
A stock of inositol free medium was prepared, filter sterilised and stored at 4°C:
6.685 g inositol free DMEM 
1.85 g sodium bicarbonate 
Made up to 500 ml with H2O.
When ready to label, the cells were incubated in this inositol free medium containing 2 
mM glutamine, 2% (v/v) dialysed newborn calf serum, and 1 //Ci/ml pH]inositol.
Newborn calf serum was dialysed prior to use in order to remove endogenous inositol 
and so improve pH]inositol labelling of the cells:
Dialysis tubing was boiled twice in fresh 10 mM EDTA for 10 min and was then stored 
until required in 20% (v/v) ethanol at 4°C.
50 ml newborn calf semm was put into dialysis tubing and the ends were sealed. This 
was placed into 21 of Earles Salts (120 mM NaCl, 1.3 mM KCl, 810 piM MgS0 4 .7H2 0 , 
900 piM NaH2P0 4 , and 5.6 mM Glucose) and left to stir gently at 4°C. The dialysis 
solution was changed every 12 hours for 2 days and then the serum was aliquoted and 
stored at -20°C.
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2.2.11.2 Preparation of Dowex formate
Dowex chloride (Dowex 1x8-200) was converted to Dowex fonnate prior to use in this 
assay. This was carried out in stages due to the strength of the electrostatic interaction 
between the Dowex and chloride ions. 100 g Dowex 1 was washed 3 x 11 of water in 
order to remove fines. This was then transfened to a scintered funnel and washed with 2 
1 of 2 M NaOH and then with 61 of H2O (to remove NaCl and excess NaOH). The 
Dowex was then washed with 500 ml of 1 M formic acid, followed by approximately 20 
1 of H2O until the pH was constant at 5 to 5.5. This was then stored at room temperature 
until required in an approximate 1 : 1 ratio with H2O.
2.2.11.3 Phospholipase C assay
70% confluent cells in 24 well plates were labelled with [^H]inositol by a 24 hour 
incubation at 37°C and 5% CO2 in inositol free medium containing pH]inositol as 
detailed above. The cells were then washed with 0.5 ml per well of HBG, and incubated 
at 37°C for 15 min in HBG containing 10 mM LiCl. Treatment with various ligands was 
then performed in 150 pi\ of HBG containing LiCl for 10 min and tenninated with the 
addition of 0.5 ml of ice-cold methanol. The cells were then scraped into insert vials 
(Sterlin) and each well was washed with a further 200 jA of ice-cold methanol. 310 jû of 
chlorofonn was added to each vial to allow extraction of the lipids for 30 min at room 
temperature. (Sometimes the samples were stored at 4°C overnight at this stage). 500 jA 
of H2O and a further 310 }A of chloroform was then added. The vials were then spun at 
1,500 X g for 5 min to split the phases.
200 jA of the lower phase was removed to a fresh vial and dried down under vacuum in a 
centrifugal evaporator. 4 ml of Ultima-Flo AF scintillant was added and the vials were 
analysed by liquid scintillation counting. 750 jA of the upper phase was removed to fresh 
vials and analysed by batch chromatography: 500 jA of the Dowex formate prepared as 
above was added to each vial. This was allowed to settle and the supernatant was 
removed by aspiration. The Dowex was then washed with 2 x 3 ml of H2O, followed by
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a 3 ml wash with 5 mM sodium tetraborate, 60 mM ammonium formate. After another 3 
ml wash with H2O, 1 ml of 1 M ammonium formate, 0.1 M formic acid was added, the 
Dowex was again allowed to settle and 750 pil of the supernatant was removed and 
subjected to liquid scintillation counting. Knowledge of the radioactivity associated with 
the lower phase permitted correction (for differences in the number and labelling of cells) 
of the values obtained by batch chromatography for the total inositol phosphates released 
from the cells.
2.2.12 Agonist-driven cholera toxin-catalysed p^PjADP ribosylation
This assay was performed as in Milligan etal. (1991).
Each incubation was prepared on ice to contain the following:
20 pil of membrane suspension (diluted with TE buffer from a frozen stock 
aliquot to give appropriate concentration),
5 pil of cholera toxin (activated as a 1 mg/ml solution with equal volume of 100 
mM DTT for at least 60 min at room temperature) or 50 mM DTT as negative control,
5 pil of ligand, or water as control,
20 /fl of p^PJNAD reaction mix containing: 50 mM thymidine, 625 mM 
NaH2P04  (pH 7.0), 625 mM Na2HP04  (pH 7.0), 1.3 mM ATP (pH 7.5), 50 mM 
arginine HCl, and 0.1 piCHpil of p^PjNAD.
The reaction was incubated at 37°C for 2 hours and teiminated by cooling on ice. After 
sodium deoxycholate/trichloroacetic acid precipitation (Section 2.2.7.3), the samples 
were analysed by SDS-PAGE with 10% (w/v) acrylamide / 0.25% (w/v) N,N'- 
methylene-bisacrylamide resolving gels (Section 2.2.7.1). The gels were dried down 
under vacuum, exposed to a phosphor storage plate and analysed using a FUJIX 
BAS 1000 image analyser.
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2.2.13 Data Analysis
Analysis of data curves was perfonned using the Kaleidagraph curve fitting package 
driven by an Apple Macintosh computer. Statistical significance of data was measured by 
Student Ftests.
2.2.14 Molecular Biology
The methods below were derived from Sambrook etal (1989).
2.2.14.1 Solutions for molecular biology 
LB medium
To make 11
10 g bacto-tryptone 
5 g bacto-yeast extract 
10 g NaCl
These were dissolved in 950 ml of H2O, set to pH 7.0 with 5 M NaOH, made up to 1 1 
and sterilised by autoclaving at 126°C for 11 min.
Terrific Broth
To make 11
12 g bacto-tryptone 
24 g bacto-yeast extract 
4 ml glycerol
These were dissolved in 900 ml of H2O and sterilised at 126“C for 11 min. This was 
allowed to cool to at least 60°C and 100 ml of 170 mM KH2PO4 and 720 mM K2HPO4 
(previously sterilised) was then added.
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s o c  medium
To make 11
20 g bacto-tryptone 
5 g bacto-yeast extract
0.5 g NaCl 
10 ml 250 mM KCl
These were dissolved in 950 ml of H2O, the pH was set to 7.0 with 5 M NaOH, the 
volume was made up to 11, and the solution was autoclaved. Just prior to use, 5 ml of a 
sterile solution of 2 M NaCl and 20 ml of 1 M glucose (filter sterilised) was added.
Agar plates
1.5% (w/v) bacto-agar in LB medium was autoclaved and poured into 10 cm petri dishes 
while still warm. Ampicillin was added to some plates prior to pouring to give final 
concentration of 60 ;^g/ml.
TAE buffer
40 mM Tris-acetate
1 mM EDTA
This was prepared as a 50x stock solution by adding 242 g of Tris base, 57.1 ml of 
glacial acetic acid, and 100 ml of EDTA (pH 8) to H2O to give a final volume of 11. On 
day of use, this was diluted with H2O to give Ix stock.
2.2.14.2 Alkaline lysis and purification of plasmid DNA from 
transformed E. coli
2,2.14.2.1 Harvesting and lysis of bacteria
Minipreparations of plasmid DNA were obtained by the alkaline lysis method.
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Solution I: 50 mM glucose
25 mM tris/HCl(pH8)
10 mM EDTA(pH8)
This was autoclaved at 126°C for 11 min and stored at 4°C.
Solution II: 0.2 M NaOH
1% (w/v) SDS 
This was made fresh on the day of use.
Solution III: 3M  potassium acetate
5M  acetic acid
This was autoclaved at 126°C for 11 min and stored at room temperature.
Bacterial cultures of transformed E. coli were grown overnight at 37°C with vigorous 
shaking in LB medium or terrific broth. Various volumes (3 to 6 ml) of these cultures 
were centrifuged in a microfuge at 12,000 x g for 30 seconds at 4°C. The supernatant 
was removed by aspiration and the pellet was resuspended in 200 pi\ of ice-cold solution I 
by vigorous vortexing. 400 ]A of freshly prepared solution II was added and the tubes 
were mixed by inversion. After a 5 min incubation on ice, 300 pi\ of ice-cold solution III 
was added. After a gentle vortex and incubation on ice for another 5 min, the tubes were 
centrifuged at 12,000 x g for 10 min and the supernatant was transfeiTed to a fresh tube.
2.2.14.2.2 RNAase treatment
The supernatant was then incubated with 0.5 mg/ml (DNAase-free) RNAase at 37°C for 
20 min. (DNAase-free) RNAase was prepared as a 10 mg/ml stock in 10 mM Tris/HCl 
(pH 7.5) and 15 mM NaCl, it was heated to 100°C for 15 min, cooled to room 
temperature slowly, and stored aliquoted at -20°C.
2.2.14.2.3 Phenol : chloroform extractions
After RNAase treatment, the DNA solution was phenol : chloroform extracted in order to 
remove protein. 0.5 vols, each of choloroform (96% (v/v) chloroform, 4% (v/v) isoamyl 
alcohol) and water saturated phenol (pH 8) were added to the RNAase-treated supernatant
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and the tube was mixed by vortexing. The phases were separated by cetrifugation at
12,000 X  g in a microfuge for 2 min and the upper, aqueous phase was removed to a 
fresh tube. This phenol : chloroform extraction was repeated, and then it was finally 
repeated with an equal volume of chloroform.
2.2.14.2.4 DNA precipitation
An equal volume of isopropanol was added to the purified DNA solution and this was 
incubated on ice for 15 min. After a 5 min centrifugation at 12,000 x g in a microfuge, 
the DNA pellet was allowed to dry. The pellet was then rinsed with 0.5 ml of 70% (v/v) 
ethanol at 4°C and dried in air for 10 min. The DNA was dissolved in sterile H2O and 
stored at -20°C until required.
2.2.14.2.5 PEG purification
DNA which was required for transfection was further purified by this procedure which 
was performed by preparing a mix composed of DNA solution : 4 M NaCl : autoclaved 
13% (w/v) PEG8000 in a ratio of 4 : 1 :5 . This was thoroughly mixed and incubated on 
ice for 20 min. The DNA was then pelleted by centrifugation at 12,000 x g at 4°C for 15 
min. The supernatant was removed, the pellet was rinsed with 70% (v/v) ethanol, and 
dried as before. It was then redissolved in sterile H2O and stored at -20° C.
2.2.14.2.6 Quantitation of DNA
Spectrophotometric determination of the amount of DNA was performed by measuring 
the absorbance of 5 pd of the stock DNA solution (made up to 1 ml with H2O) at 
wavelengths 260nm and 280nm with a Shimadzu spectrophotometer and quartz cuvettes. 
The absorbance at 260 nm allows the concentration of DNA to be calculated using the 
assumption that a 50 ^g/ml solution of double-stranded DNA gives an absorbance of 1. 
The ratio between the absorbances at 260 and 280 nm provides an estimate of the purity 
of the sample. Pure solutions of DNA are expected to give an Abs26o/Abs280 ratio of 
approximately 1.8 .
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2.2.14.3 Restriction enzyme digests
These were perfonned for a minimum of 1 hour at 37°C in the following solution:
5pil DNA(MO/#g)
2 ]a\ buffer (lOx stock, appropriate for enzyme used)
0.5 ]4l restriction enzyme
12.5 pi\ H2O (sterile)
2.2.14.4 Agarose gel electrophoresis
Electrophoresis through agarose gels was used to sepamte and identify DNA fragments. 
Agarose was melted in a microwave oven in TAE buffer to give a concentration of 1% 
(w/v) (or any other required concentration). This was allowed to cool to approximately 
60°C and ethidium bromide was added to a concentration of 0.5 ^ g/ml (from a stock 
concentmtion of 10 mg/ml). This was then poured into a Horizon electrophoresis kit 
(Gibco-BRL) and allowed to set around a 8 well comb. The comb and kit ends were 
removed and enough TAE buffer was poured into the tank to cover the gel to a depth of 
about 1 mm. The DNA solutions were mixed with 6x gel loading buffer (0.25% (w/v) 
bromophenol blue, 30% (v/v) glycerol) and loaded into the wells of the gel. 
Electrophoresis was performed at 75 V for about 1-2 hours, or until separation of the 
DNA fragments was achieved. Visualisation of the ethidium bromide-stained DNA was 
performed using a UVP ultraviolet transilluminator.
2.2.14.5 Preparation of competent E. coli
Buffer 1: 3 ml 1 M potassium acetate
10 ml lM R bC l2
1 ml IM C aC h
5 ml 1 M MnCl2
18.75 ml 80% (v/v) glycerol
pH was set to 5.8 with 100 mM acetic acid, the volume was made up to 100 ml and the 
solution was filter sterilised and stored at 4°C.
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Buffer 2: 4 ml 100 mM MOPS (pH 6.5)
3 ml 1 M CaCh
0.4 ml IM R bC h
7.5 ml 80% (v/v) glycerol
pH was set to 6.5 with HCl, the volume was made up to 40 ml and the solution was filter 
sterilised and stored at 4°C.
100 ml of LB medium was inoculated with 5 ml of an overnight culture of E, coli 
(DH5ot). This was incubated at 37°C with shaking until the optical density at 550 nm 
was 0.48. The culture was chilled on ice for 5 min, then centrifuged at 3000 rpm in a 
TJ6 Beckman centrifuge for 10 min at 4°C. The medium was poured off and the pellet 
was resuspended in 40 ml of buffer 1. After 5 min on ice, the cells were pelleted as 
before and resuspended in 2 ml of buffer 2. After a 15 min incubation on ice, the 
competent cells were aliquoted and stored at -80°C.
2.2.14.6 Transformation of competent E, coli
1-10 ng (in 1-5 ]A) of DNA was added to 50 pi\ of competent cell suspension and this 
was incubated on ice for 15 min. The mix was then heat shocked at 42°C for 90 seconds 
and returned to ice for 2 min. 450 pi\ of SOC medium was added and the cell suspension 
was shaken at 37°C for 45 min. 200 j a \  of this mix was then plated out on an agar plate 
(containing the appropriate antibiotic) and left to grow at 37°C overnight. Colonies were 
then picked from the plate and grown in LB medium overnight. From these cultures, 
plasmid DNA could be prepared as above.
2.2.14.7 Stable Transfections
Rati fibroblasts were grown on 10 cm dishes until approximately 40-50% confluency 
and then washed twice in serum free DMEM. 5 pig of plasmid DNA (and 0.5 pig of 
additional plasmid DNA used for selection - pBABE hygro) were mixed with sterile 
Hank's modified medium to a final volume of 100 pi\, Lipofectin (100 }A) mixed with 
200 pi\ of sterile Hank's modified medium was then added to the DNA mix. This was
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mixed gently and incubated at room temperature for 15 min. The DNA/lipofectin mixture 
was mixed with 9.6 ml of serum free DMEM and added carefully to the plate of cells. 
After a 16 hour incubation, this medium was removed and the cells were washed twice in 
5% DMEM and incubated for a further 48 hours in fresh 5% DMEM. The medium was 
then replaced by 5% DMEM containing 50 /<g/ml hygromycin B in order to select for 
those cells expressing the antibiotic resistance gene. After approximately 12 days, 
discrete colonies became visible on the plate, and they were picked (by scraping with 
sterile pipette tip) and transferred to 24 well plates. Clones were expanded and stored in 
liquid nitrogen as they were produced. Clones were harvested and analysed for 
expression of the desired protein.
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Chapter 3
The regulation of p44M A P K  b y  the « 2  a  adrenergic 
receptor when expressed in Rati fibroblasts: 
effect of expression levels and the Asn?9 mutation.
Chapter 3: The regulation of p44MAPK by the a2A 
adrenergic receptor when expressed in Rati
fibroblasts:
effect of expression levels and the Asn79 mutation.
3.1 Introduction
The «2A adrenoceptor has been extensively studied at the biochemical and 
pharmacological level. This provided a good model receptor to study the regulation of 
p44MAPK gy gPCRs because a range of phaimacological tools were available, the 
receptor had been cloned and a considerable amount was already known about its 
signalling. The study of endogenously expressed receptors can be difficult because the 
population of the receptors could be mixed with other subtypes and sometimes the 
physiological host cells are more difficult to manage in the laboratory. Much of the 
work described in this introduction, as well as the results which will be presented in this 
thesis, were obtained from heterologously transfected cells which transiently or stably 
expressed the oc2A adrenoceptor.
An «2 adrenoceptor (called « 2-CIO) was cloned from a human genomic DNA libraiy 
with oligonucleotide probes coiresponding to sequences from purified human platelet 
«2  adrenoceptors (Kobilka etaL, 1987) and this was found to correspond to the cc2A 
adrenoceptor subtype by phaimacological analysis. There are possibly four subtypes of 
(X2 adrenoceptors which have been cloned and classified by pharmacological analysis 
(MacKinnon etal.y 1994) and the (%2A adrenoceptor is found in many tissues such as the 
brain, kidney and adipose tissue. Stimulation of the receptor in these tissues resulted in 
the inhibition of adenylyl cyclase and this was also found following heterologous 
expression in Chinese hamster lung fibroblasts and COS-7 cells (Cotecchia etaL, 1990) 
and in Rati fibroblasts (MacNulty etaL, 1992). However in these cells, the (%2-ClO 
adrenoceptor also displayed an ability to couple to multiple signal transduction 
pathways inducing stimulation of phosphoinositide hydrolysis in Chinese hamster lung
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fibroblasts and COS-7 cells and stimulation of PLD-mediated hydrolysis of 
phosphatidylcholine in Rati fibroblasts. In cells of neuronal origin this receptor 
coupled to the inhibition of adenylyl cyclase and L-type Ca^+ channels and the 
activation of K+ channels (Surprenant Qta l,  1992). These effects of the a 2A 
adrenoceptor were all mediated by members of the Gpprotein family as judged by the 
attenuation of the responses with pertussis toxin pretreatment.
Further study of the G-protein coupling of the a 2-C10 adrenoceptor expressed in Rati 
fibroblasts (in a cell line called 1C which expressed the receptor to a high level) 
demonstrated that this receptor had the ability to functionally couple to both Gi2 and 
Gj3 (Milligan etaL, 1991). This was shown by the ability of a selective a 2 adrenergic 
receptor agonist (UK14304) to stimulate cholera toxin-catalysed ADP-ribosylation of 
these proteins in the absence of guanine nucleotides, an assay which defines the 
interaction of these G-proteins with the receptor. This effect was blocked by 
yohimbine, a selective 0 .2  adrenergic antagonist. Although coupling to these two G- 
proteins, Gi2 but not Gq contributed to the inhibition of adenylyl cyclase in these cells 
(McClue etaL, 1992) which is in line with the widely held view of the cellular role of 
Gi2 . However, regulation of other signalling pathways was possible as illustrated by 
Raymond and co-workers who demonstrated that the human ct2A adrenoceptor could 
couple to the inhibition of cAMP accumulation in murine embryonic stem cells which 
lack Gi2a (Raymond etaL, 1994). Heterologous expression of this receptor in some 
cell systems also permitted coupling to Gg leading to the stimulation of adenylyl cyclase 
at high agonist concentrations. This produced biphasic concentration-response curves 
(Eason etaL, 1992). The coupling to Gg can be more clearly seen after pertussis toxin 
pretreatment which attenuates the coupling to the Gf-proteins (Cotecchia etaL, 1990; 
Eason etaL, 1992). Overexpression of Gq^ and G sa also forced the interaction of the 
(%2A adrenoceptor with these G-proteins in HEK 293 cells leading to agonist-mediated 
stimulation of phospholipase C and adenylyl cyclase respectively (Chabre etaL, 1994).
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However, this required a 1000-fold greater concentration of agonist than the 
physiological coupling to Gi which led to the inhibition of adenylyl cyclase.
The «2A adrenoceptor can also couple to the p42/44^^^'^^ cascade, an ability common 
to many Gpcoupled receptors (see Section 1.4.13.3). Many of the original studies on 
Gi-mediated p42/44^'^^^ regulation were performed using the activity of LPA, acting 
on a putative GPCR which can couple to members of both Gi and Gq protein families 
(although only Gf-proteins mediated Ras.MAPK activation (see Moolenaar, 1995)). 
However, this receptor has not been identified at the molecular level and there is a very 
limited pharmacology at this site, therefore many groups have chosen to study the 
signalling of GPCRs heterologously expressed in fibroblast cell lines. A proliferative 
response to agonist stimulation of the (%2 adrenoceptor had been demonstrated 
previously in intestinal crypt cells (Tutton and Barkla, 1987), expression of the oc2-C10 
adrenoceptor in Chinese hamster lung fibroblasts permitted «2 agonists to act as co- 
mitogens (Seuwen etal., 1990) and there was extensive pharmacology and signal 
transduction information available and so this receptor appeared to be potentially useful 
to continue these studies. Agonist stimulation of the a 2A adrenoceptor in the 1C cell 
line (derived from Rati fibroblasts) was shown to stimulate the GTP loading of p2P‘^  
and the phosphorylation of p44^^^^ (Alblas et al, 1993). It was concluded that this 
was not the result of the stimulation of the other known effectors of the «2A 
adrenoceptor but occurred independently of both adenylyl cyclase and phospholipase C 
activity. The work in this chapter continues this research and makes use of the 
endogenous receptors for LPA and EGF as controls for Gj-coupled and tyrosine-kinase 
linked receptor-mediated stimulation of p42/44^'^^^.
Site-directed mutagenesis has permitted the characterisation of some of the specific 
amino acid residues important in various facets of the receptor's function (Wang etal., 
1991). One residue was found to play an important role in receptor-G-protein coupling 
and allosteric regulation by monovalent cations. This work was originally performed
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on the porcine species-variant of the « 2A adrenoceptor (Guyer etal., 1990). This study 
demonstrated a phenomenon which had been seen before, that of allosteric modulation 
by monovalent cations which manifested itself in the accelerated dissociation of an 
antagonist when expressed in COS-M6 cells. This allosteric modulation was dependent 
on the presence of an aspartate residue at position 79 (Asp'^^) shown by the loss of this 
effect, but not the selectivity of adrenergic binding, when this residue lost its side chain 
negative charge through a mutation to an asparagine (Horstman etal., 1990). Similar 
results had been recorded with an aspartate at an analogous position in other GPCRs 
and so possibly this is a general function of this residue in these receptors (see Ceresa 
and Limbird, 1994).
Expression of the Asn'^^ mutant of the human «2A adrenergic receptor in CHO cells 
took this research further as it demonstrated this mutation altered receptor-G-protein 
coupling as shown by both the insensitivity of agonist binding to guanine nucleotides 
and the loss of agonist-mediated inhibition of cAMP accumulation (Wang etal., 1991). 
The suggestion was made that the Asp"^  ^residue was critical for the agonist-induced 
conformational change that catalyses G-protein activation and possibly involves cation 
transfer. However, a significantly different scenario was seen with this mutant receptor 
expressed in mouse pituitary cells (Suiprenant etal., 1992). In this system, a selective 
loss of effector output was shown in that agonist-induced inhibition of adenylyl cyclase 
and voltage dependent Ca^+ currents were preserved but the activation of inwardly 
rectifying K+ currents was lost. Two theories were suggested to explain this; either the 
coupling to the Ca^+ channel and adenylyl cyclase-associated G-proteins, but not the 
K+ channel-associated G-protein(s), was preferentially retained by the Asn'^^ mutant or 
that the reduced receptor-G-protein coupling of Asn^^ is still sufficient to couple to the 
Ca^+ channels and adenylyl cyclase but not to the activation of K+ currents. The latter 
explanation now appears to be more likely due to the work of Chabre and co-workers. 
They demonstrated that although the a 2A adrenoceptor preferentially couples to Gi, it 
could be 'forced' to couple Gg and Gq by overexpression in HEK 293 cells. However,
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the Asn'^^ mutant was only able to couple to Gf and inhibition of adenylyl cyclase, and 
this was with lower potency (Chabre etal., 1994). ’ Therefore the mutation apparently 
reduced the efficiency of coupling of this receptor to all G-proteins thus eliminating the 
signal transduction pathways which were coupled less efficiently to the a 2A 
adrenoceptor. This explanation is, however, too simple to account for the nonreciprocal 
disruption of receptor-G-protein coupling which was detected in mouse pituitary cells 
by Ceresa and Limbird (1994). They demonstrated that loss of the negative charge at 
position 79 (glutamate could substitute for aspartate with limited differences) produced 
loss of allosteric regulation by Na+, as seen before. This was paralleled by an 
attenuation, but not elimination, of anterograde information transfer (receptor to G- 
protein) as seen by a reduction in GTPase stimulation by agonist at the Asn'^^ mutant. 
However, retrograde information transfer (G-protein to receptor) was completely lost as 
demonstrated by the lack of sensitivity of agonist binding to guanine nucleotides.
The experiments using this mutant receptor described in this chapter attempted to 
detennine if this selective, or general loss of G-protein coupling, leads to the loss of 
coupling to the Ras.MAPK cascade. In addition these experiments may also give an 
indication as to the coupling efficiency of the receptor to this pathway in comparison to 
the coupling to the other signalling effectors/G-proteins.
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3.2 Results and Discussion
The level of « 2A adrenoceptor expression in the 1C cell line was regularly monitored as 
expression was not as stable or as great as previously reported (Milligan etal., 1991). 
The mean level of expression was found to be 850 ± 140 fmol/mg membrane protein 
(mean ± SEM, n = 9) as detennined by the specific binding of [^Hjyohimbine at 
saturating concentrations (10'^ M). This level of expression was still sufficient to 
substantially stimulate high affinity GTPase activity on agonist treatment. Maximally 
effective concentrations (10'^ M) of UK14304 increased the high affinity GTPase 
activity by 70 ± 5 pmol/min/mg membrane protein (mean ± SEM of triplicate assays) as 
compared with the level in the absence of this ligand.
As mentioned previously, agonist stimulation of these cells had been reported to 
increase the GTP loading of p2U^ and the level of phosphorylation of p42klAPK^  as 
determined by a mobility shift after SDS-PAGE (Alblas e ta l,  1993). This effect was 
seen to be maximal after 5 min of treatment with 5 x lO'^ M UK14304. It was 
therefore decided to determine if the coupling to the p2 U^^.MAPK cascade could also 
be detected by an increase in the activity of the p44MAPK This was perfonned by 
measuring the ability of immunoprecipitated p44MAPK iq phosphorylate myelin basic 
protein as an exogenously added substrate. The phosphorylation can be measured by a 
phosphorimager because a trace amount of [y-^^PJATP was added to the reaction 
mixture. Figure 3.1 shows that the stimulation of cells of clone 1C with either 10-^ M 
UK14304 or 10’® M EGF (a maximally effective dose) for 5 min significantly activated 
p^MAPK The percentage increase over the basal activity of p44kIAPK stimulation 
with UK14304 from a number of experiments was calculated to be 160 ± 25% and for 
EGF was 240 ± 35% (mean ± SEM, n = 12 in each case).
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Figure 3.1 Stimulation of the activity of p4 4 MAPK cells of clone 1C by EGF and 
UK14304.
Serum starved 1C cells were treated with serum free DMEM containing either no 
agonist (basal), 10^ M U K 14304or 10"  ^M EGF for 5 min and p4 4 MAPK activity was 
determined by the IP kinase method as described in Section 2.2.9.2. Representative 
results o f one o f at least 12 observations are displayed.
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Pretreatment of the cells with 10~3 M dibutyryl cAMP (a cAMP analogue) for 20 min 
significantly attenuated the activation of in response to maximally effective
concentrations of UK14304 and EGF (Figure 3.2A and Table 3.1). This result is 
consistent with the reported effects of elevated cAMP levels on growth factor and 
GPCR-mediated activation of the Ras.MAPK cascade in Rati fibroblasts (Cook and 
McCormick, 1993; Wu etal., 1993; Hordijk etal., 1994). It has been suggested that 
cAMP acts via PKA-mediated phosphorylation of Raf or MEKK (see Section 1.4.10) 
and this would be consistent with the reported lack of effect of elevated cAMP levels on 
the GTP loading of p21^^ by the a 2A adrenoceptor as well as the results here.
Therefore, although the conclusion made by Alblas and co-workers that the activation 
of the p42/44^^^^^ cascade was not secondary to the inhibition of adenylyl cyclase 
(Alblas etal., 1993) is correct, these two signal transduction pathways do not exist 
independently of each other.
Pretreatment with 10”^  M forskolin for 15 min produced a similar attenuation of EGF- 
mediated p44MAPK activation as would be expected because of the ability of forskolin 
to directly stimulate adenylyl cyclase activity in these cells. Forskolin pretreatment 
also consistently reduced the activity of p44^^^^^ on UK14304 treatment but the 
attenuation was not as complete or as significant as with EGF (Figure 3.2B and Table 
3.1). The reason for this is not certain, however UK14304-mediated stimulation of the 
(%2A adrenoceptor can reduce forskolin amplified adenylyl cyclase activity in crude 
membrane preparations (see Figure 3.8) and so the inhibitory effects of the forskolin- 
mediated increase in cAMP may be antagonised by the «2A adrenoceptor. This may 
illustrate the point made earlier as to the fact that the Ras.MAPK cascade initiated by 
the 0C2A adrenoceptor could be influenced by the other effector pathways of the 
receptor.
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Table 3.1 The effect of various pretreatments on UK14304 and EGF-mediated 
p4 4 MAPK activation in 1C cells.
% increase in activity
over basal
Pretreatment Agonist Control Pretreated Significance
Dibutyiyl cAMP UK14304 170 ±30 11 + 5 0.010
EGF 310 + 60 40 ±25 0.007
Forskolin UK14304 170 + 40 110 ± 2 0 0.130
EGF 240 + 30 3 0±6 0.030
Genistein UK14304 190 + 70 340 ±50 0.024
EGF 235 ± 80 340 ±90 0.270
The stimulation of activity by 5 min treatment with 10'^ M UK14304 or 10'^
M EGF was determined by the IP kinase assay as described in Section 2.2.9.2 and in 
the legends to Figure 3.2 and 3.3 after pretreatment with 10'^ M dibutyryl cAMP, 10"  ^
M forskolin or 5 x 10"  ^M genistein. Data is displayed as mean ± SEM (n = 4 for 
dibutyiyl cAMP and n = 3 for forskolin and genistein) and the significance of the effect 
of each of the treatments was calculated using the paired students t-test.
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Figure 3.2 The effect of elevated cAMP levels on p4 4 MAPK activation in cells of 
clone 1C.
A Serum starved 1C ceils in 6 well plates were pretreated for 20 min with serum free 
DMEM with (shaded bars) and without (hatched bars) lO'^ M dibutyryl cAMP and 
were then left untreated or treated with 10'^ M UK14304 or 10^ M EGF for a further 5 
min. The activity of p44^^^^^ was then determined by the IP kinase assay as described 
in Section 2.2.9.2. The data displayed is from one of four similar observations.
B 1C cells were treated as in Figure 3.2A but pretreatment for 15 min was with (shaded 
bars) or without (hatched bars) 10"  ^M forskolin prior to treatment with agonists and 
p44MAPK activity determination. Data is from one of three similar observations.
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Genistein is a selective tyrosine kinase inhibitor that can inhibit the activation of 
p42/44MAPK by niany but not all of the Gi coupled receptors that have been studied (see 
Section 1.4.13.3.3). In cells of clone 1C, however, very different effects were observed. 
A concentration of genistein (5 x 10"  ^M) was used which was found to inhibit LPA 
and thrombin receptor peptide-mediated p2P'^ GTP loading but not that stimulated by 
EGF in Rati fibroblasts (van Corven etal., 1993). Often a reduction in the basal 
activity after pretreatment with 5 x 10"  ^M genistein for 10 min was observed, but this 
was coupled with a consistent enhancement of the UK14304 and EGF-mediated 
stimulation of p44MAPK activity (Figure 3.3). As can be seen in Table 3.1 which was 
calculated from three separate experiments, the increase in activity after genistein 
pretreatment was not found to be significant for the EGF response, but a probability of 
0.024 was calculated for the increased response to UK14304.
Although this would seem to contradict most of the literature as to the effect of this 
agent on Gi-coupled receptor-mediated stimulation of the p42/44^^^^^ cascade, there is 
some similarity to the effect on the activation by muscarinic m2 receptor expressed in 
Rati fibroblasts (Winitz etal., 1993). In this case, genistein (at a concentration of 3 x 
10^ M) did not display any inhibitory effect on the agonist-mediated stimulation of the 
activity of p42/44^^'^^^ or MEK, or on the GTP loading of Ras. However, genistein 
did slightly enhance the agonist-mediated stimulation of Raf. The lack of an inhibitory 
effect of genistein in these experiments could possibly be explained by the presence of 
a genistein-insensitive tyrosine kinase involved in the p42/44^^^^^ pathway but the 
reason for the enhancement of stimulation is puzzling.
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Figure 3.3 The effect on agonist-stimulated p4 4 MAPK activity after pretreatment 
with genistein of cells of clone 1C.
Serum starved 1C cells in 6 well plates were pretreated for 30 min with serum free 
DMEM with (shaded bars) and without (hatched bars) 10'^ M genistein and then left 
untreated (basal) or treated with 10"  ^M U K 14304 or 10-^ M EGF for a further 5 min. 
The activity o f p4 4 MAPK was then determined by the IP kinase assay as described in 
Section 2.2.9.2. The data displayed is from one o f three observations. (Table 3.1 
contains means o f the data from all experiments).
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The next section of work attempted to detennine whether the mutation of Asp^^ to Asn 
would prevent the coupling of the (X2A adrenoceptor to the p42/44^^^^I^ cascade. Rati 
fibroblasts were stably co-transfected with either the wild type or Asn^^ mutant of the 
haemaglutinnin-tagged porcine cx2A adrenoceptor expressed in pcmv4 with the 
hygromycin resistance expression vector pBABE hygro in a 10 : 1 ratio. Clones were 
selected on the basis of resistance to 50 //g/ml hygromycin B and subsequently 
analysed by the radioligand binding assay (with 10“^  M [^HJyohimbine) in order to 
identify and quantify the expression of the ot2A adrenoceptor. Clones expressing the 
wild type and Asn^^ mutant receptor were selected for further analysis (called clones 
TAGWT and ASN79 respectively). There was some degree of variation in the level of 
expression throughout different passages, however, the receptor level was monitored 
frequently and the mean expression level for each clone is shown in Table 3.2. From 
this Table it can be clearly seen that three of the clones (TAGWT 17, ASN79 4 and 9) 
expressed reasonably similar levels of receptor (3-5.6 pmol/mg protein) and that clone 
TAGWT 3 expressed the receptor at considerably lower levels (0.5 pmol/mg protein).
Table 3.2 Receptor expression levels of TAGWT and ASN79 clones.
Specific Binding
Clone (fmol/mg membrane protein)
TAGWT 3 460 + 70
TAGWT 17 5600 + 550
ASN794 3000 ± 430
ASN799 4300 + 580
Specific binding of 10"  ^M [^H]yohimbine to membranes prepared from cells of the 
above clones as determined by the radioligand binding assay described in Section 2.2.3. 
Non-specific binding was determined in the presence of 10"  ^M idazoxan. Data is 
presented as mean ± SEM, from at least 8 observations.
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Scatchard analyses of the two higher expressing clones were performed using [ethyl- 
^H]RS-79948-197 (a high affinity ligand for the U2A adrenoceptor) (see Figure 3.4). 
Calculated values of Bmax for TAGWT 17 and ASN79 9 were 7900 and 6900 fmol/mg 
membrane protein and of were 0,38 and 0.31 nM respectively. The similarity in the 
dissociation constants for the two clones would suggest that the Asn^^ mutation does 
not significantly affect the binding affinity of antagonists to the receptor as described 
previously (Wang etal., 1991). This would justify the use of the radioligand binding 
results to compare the receptor expression levels in each of the clones. Any difference 
between the radioligand binding in TAGWT and ASN79 clones was therefore not due 
to a difference in the affinity for the ligand but in the number of binding sites available.
High affinity GTPase assays were performed to demonstrate and measure the coupling 
of these transfected receptors to their G-proteins (Figure 3.5). As would be expected 
the maximum UK14304-mediated stimulation of GTPase activity over basal in 
membranes prepared from cells of clone TAGWT 17 was much greater (p = 0.001) than 
in the lower expressing clone TAGWT 3 (42 ± 4 and 14 ± 2.5 pmol/min/mg membrane 
protein respectively; mean ± SEM, from at least three independent experiments). The 
maximum possible stimulation by UK14304 of GTPase activity in membranes prepared 
from cells of both of the ASN79 clones was also significantly (p < 0.0015) lower than 
that seen with TAGWT 17 (6.9 ±1.3 and 8.5 ± 1.5 pmol/min/mg membrane protein for 
clones ASN79 4 and ASN79 9 respectively; mean ± SEM, from at least three 
independent experiments). In addition, the wild type receptor expressed in drastically 
lower levels in TAGWT 3 stimulated a significantly greater level of GTPase activity 
than the much higher level of expression of the mutant receptor in ASN79 4 (p = 
0.027). Therefore the Asn^^ receptor expressed in Rati fibroblasts displayed a much 
reduced, but still measurable ability to couple to the G-protein machinery compared to 
the wild type receptor. A similar situation occurred when these receptors were 
expressed in mouse anterior pituitary cells (Ceresa and Limbird, 1994), when the Asn^^ 
mutation attenuated but did not eliminate the G-protein coupling.
9 2
Figure 3.4 Scatchard analysis of clones TAGWT 17 and ASN79 9.
A Saturation specific binding curves of [e th y lH]RS-79948-197 to membranes 
prepared from cells of clones TAGWT 17 and ASN79 9 were produced using the 
radioligand binding assay as described in Section 2.2.3. Results are presented as 
concentration of pH]RS-79948-197 added (as determined by measuring the 
radioactivity of samples of each dilution added to each tube) against specific binding to 
the membranes. Specific binding was determined as the difference between the total 
binding and the binding in the presence of 10^ M idazoxan. This data was then 
subjected to Scatchard analysis (Scatchard, 1949) and displayed in panel B.
For both graphs, the open circles and broken line represent clone TAGWT 17, and the 
filled squares and full line represent clone ASN79 9.
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Figure 3.5 Stimulation of high affinity GTPase activity in membranes of clones 
TAGWT and ASN79 by UK14304.
High affinity GTPase activity was determined in membranes o f cells o f clones TAGWT 
3 and 17 and of clones ASN79 4  and 9 according to Section 2.2.4. Hatched bars 
represent basal activity and the shaded bars represent GTPase activity on treatment with 
10’  ^M U K 14304. Activity is presented as mean ± SEM of triplicate assays from a 
representative experiment of at least three independent experiments.
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Concentration-response cuises to UK14304 for high affinity GTPase activity in each of 
the four clones are shown in Figure 3.6. As would be expected, the EC50 value was 10 
fold lower for the clone expressing the wild type receptor at the higher level (EC50 
value for TAGWT 17 was 3.7 x 10'^ M and for TAGWT 3 was 3.0 x 10-8 M). This 
was also reflected in the EC50 values for the mutant receptors (EC 50 for ASN79 9 was 
5.8 X  10'^ M and for ASN79 4 was 5.0 x  10"8 M). Hill slopes of the concentration- 
response curves ranged from 0.6 to 0.9. It was noticeable that the differences in the 
EC50 values were less pronounced compared to the differences seen in the maximum 
stimulation of GTPase and that there was no significant difference in the concentration 
of UK14304 required to produce half-maximal stimulation of GTPase activity between 
the two higher receptor level expressing clones (TAGWT 17 and ASN79 9).
Under normal circumstances, cholera toxin catalyses the ADP-ribosylation of G 
proteins belonging to the Gg family. However, in the absence of guanine nucleotides, 
cholera toxin can catalyse the ADP-ribosylation of Gplike proteins if they are coupled 
to an agonist-activated receptor. A similar experimental approach has been used 
previously to establish the coupling of the a^-ClO adrenoceptor expressed in Rati 
fibroblasts to two Gpproteins (Milligan etal., 1991). Maximally effective 
concentrations of UK14304 stimulated a large increase in the level of p^PJADP- 
ribosylation of Gi-like proteins by cholera toxin in membranes of clone TAGWT 17 
(Figure 3.7). Results are displayed as the relative stimulation over the level of Gg 
labelling which was unaffected by the presence of UK14304. Veiy little increase in 
labelling of Gi-like proteins occuired on treatment of membranes of clone TAGWT 3 
with UK14304 and there was little or no detectable increase in the cholera toxin- 
catalysed [^^P]ADP-ribosylation of Gplike proteins in the ASN79 mutant cell lines. 
This is consistent with the lower level of expression of the wild type a%A adrenoceptor 
in TAGWT 3 peimitting coupling to fewer Gi-proteins and the lower ability of the 
Asn'^  ^mutant to couple to the G-protein machinery. These results therefore concur 
with those conclusions which were based on the high affinity GTPase assays.
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Figure 3.6 Concentration-response curves for UK14304 stimulated high affinity 
GTPase activity in TAGWT and ASN79 clones.
A High affinity GTPase activity was measured (as in Section 2.2.4) in response to 
various concentrations of UK14304 in membranes from cells of clones TAGWT 3 
(filled circles, full line), TAGWT 17 (open circles, broken line).
B High affinity GTPase activity was measured in response to various concentrations of 
UK14304 in membranes from cells of clones ASN79 4 (open squares, broken line) and 
ASN79 9 (filled squares, full line).
As the amount of stimulation of GTPase activity was different for each clone (see 
Figure 3.5), data is presented as % of the maximum level achieved by the agonist in 
each of the clones, mean ± SEM of triplicate assays.
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Figure 3.7 UK14304 -driven cholera toxin-catalysed [^^P]ADP-ribosylation of the 
a  subunit of Gi-like proteins in TAGWT and ASN79 clones.
Membranes o f cells o f the clones noted were subjected to cholera toxin-catalysed 
p2p]ADP-ribosylation performed in the absence (hatched bars) or presence of 10"^  M 
U K 14304 (shaded bars). Quantitation of the phosphorimage is shown in the graph and 
the data has been displayed as the relative labelling o f Gi-like proteins as compared 
with that o f Gg-like proteins (whose labelling does not significantly alter on agonist 
treatment) for each of the samples analysed.
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The inhibition of forskolin-aniplified adenylyl cyclase activity by UK14304 was 
determined in order to demonstrate the functional output of the receptors beyond the 
level of the G-protein. Figure 3.8 demonstrates that the largest level of inhibition by 
UK14304 was achieved in clone TAGWT 17. The % inhibition of forskolin-amplified 
adenylyl cyclase activity by UK14304 was calculated to be 54 + 9% (mean ± SEM, n = 
3). The level of agonist-mediated inhibition possible in clone TAGWT 3 was smaller 
than this (38 ± 2%, mean ± SEM, n = 3). It is of interest to note however that the 
difference in the maximal inhibition of adenylyl cyclase between these two clones was 
not as pronounced as the difference at the GTPase level (Figure 3.5). This lesser 
response at the level of adenylyl cyclase to higher receptor expression has been reported 
previously (Ashkenazi etaL, 1987) and tends to implicate the adenylyl cyclase catalytic 
element, rather than the receptor, as the limiting component in this pathway in these 
cells.
The two mutant clonal cell lines also displayed a significant degree of agonist-mediated 
inhibition of forskolin-amplified adenylyl cyclase activity (Figure 3.8; mean ± range of 
two individual experiments for ASN79 4 was 24+11%  and for ASN79 9 was 25 +
7%). Therefore the mutant receptor has a reduced ability to produce a functional 
output, however this is not as pronounced as at the GTPase level. It was reported that 
the Asn^^ mutant receptor was able to couple to the inhibition of adenylyl cyclase and 
Ca2+ currents in mouse anterior pituitary cells, although the activation of K+ currents 
was lost (Surprenant etaL, 1992) and when expressed in HEK 293 cells, the mutant 
receptor could also still couple to the inhibition of adenylyl cyclase but with reduced 
potency (Chabre etaL, 1994). In contrast, agonist stimulation of this mutant receptor 
failed to produce any effect on cAMP production in CHO cells (Wang etaL, 1991). 
Therefore the Asn'^  ^receptor in Rati fibroblasts displayed a similar coupling ability to 
when it was expressed in pituitaiy and HEK 293 cells in that coupling to at least one of 
its effectors was still detectable.
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Figure 3.8 Inhibition of forskolin-amplified adenylyl cyclase activity by UK14304 
in membranes of clones TAGWT and ASN79.
Adenylyl cyclase activity was determined as in Materials and Methods in membranes 
prepared from cells o f the clones TAGWT and ASN79 as indicated. The basal activity 
was determined in the absence o f any agonist and the stimulation over this activity on 
treatment with 10'^ M forskolin is represented by the hatched bars. The shaded bars 
represent the activity on treatment with both forskolin and lO'^ M UK 14304 and thus 
the difference between these two values represent the inhibition o f forskolin-amplified 
adenylyl cyclase activity by the agonist-stimulated a%A adrenoceptor. Results shown 
are presented as mean ± SEM of triplicate assays from one o f two or three independent 
experiments performed.
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The extent of the similarity of signalling between the receptor expressed in Rati 
fibroblasts and pituitaiy cellular systems was then tested by attempting to determine 
whether the Asn'^^ receptor could still couple to the Ras.MAPK cascade. From the 
literature, coupling to the Ras.MAPK cascade can be mediated by the Py complex (see 
Section 1.4.14.3.1) and the K+ channel in pituitary cells may be regulated by Gi~protein 
coupled receptors via Gpy as well. It was of interest to determine if there was any 
selective loss of signalling pathways regulated by this mutant receptor in Rati 
fibroblasts and also to deteiinine whether the efficiency of coupling of the receptor to 
the Ras.MAPK cascade was significantly less than to other effectors.
Figure 3.9 shows that treatment of serum staiwed cells of TAGWT and ASN79 clones 
with 10’^  M UK14304 for 5 min phosphorylated a significant proportion of the 
p44MAPK jjj the cells. The basal levels of phosphorylation in the absence of any ligand 
were somewhat variable ranging from 0% for TAGWT 3 to 40% for ASN79 9. The 
actual level of basal phosphorylation was not consistent over a number of passages but 
the significance of this observation is not clear. There was only a limited pattern to this 
level of 'basal' phosphorylation in that the cells expressing higher receptor levels 
invariably produced a larger basal level of phosphorylation (seen especially with 
TAGWT clones). Therefore some level of empty-receptor activation of the p44MAPK 
cascade might possibly have been observed (see chapter 4 for more on this).
It is obvious, however, that both of the TAGWT clones produced a strong 
phosphorylation of p44MAPK after treatment with UK14304. This would suggest that, 
in a similar fashion to what was observed at the level of adenylyl cyclase, there is no 
requirement to produce the maximum level of G-protein activation possible in these 
cells in order to produce a strong signal at the level of p44MAPK poj- many years it was 
suggested that the heterologously expressed Gf-coupled receptors could couple to the 
Ras.MAPK pathway because of the overexpression of such receptors in the experiments 
perfonned (see Malarkey etaL, 1995). However, this data would suggest that this is
1(X)
not necessarily the case as the much lower expression level in TAGWT 3 was able to 
produce a substantial phosphorylation of p44MAPK
The UK14304-mediated phosphorylations of p44MAPK observed with both of the 
ASN79 clones (stronger in ASN79 9) are also in agreement with such a conclusion. 
These results also demonstrated that the Asn^^ mutation did not produce a selective loss 
of coupling to the Ras.MAPK cascade but a reduction in coupling efficiency. Therefore 
the coupling efficiency to the Ras.MAPK pathway appears not to be substantially lower 
than that to adenylyl cyclase as both effects are reduced, but not eliminated by this 
mutation. When this mutant receptor was expressed in HEK 293 cells, the coupling to 
Gq and Gg-coupled effectors was selectively lost while the signalling through Gi- 
proteins was reduced (Chabre etaL, 1994). This was interpreted as a reduction in 
general G-protein coupling efficiency due to the mutation of the receptor with the 
selective elimination of those G-protein systems less efficiently coupled. Ceresa and 
co-workers suggested that the apparently selective effects of the mutation (such as in 
Surprenant etaL, 1992) may be explained by the difference in the stoichiometry: of 
receptor-G-protein coupling required for each effect. They suggested that perhaps the 
activation of the K+ channel was mediated by Py subunits and that this would explain 
the requirement for the greater stoichiometiy. However, the results presented here 
would not really support this view because the coupling to the Ras.MAPK cascade (also 
mediated by Gpy ) was apparently not affected to a significantly greater extent than the 
inhibition of adenylyl cyclase (mediated selectively by Gi2a, McClue etaL, 1992).
As would be expected with cells from the same parental Rati fibroblasts, EGF and LPA 
stimulated very similar levels of p44 MAPK phosphorylation in all of the clones (Figure 
3.9), demonstrating that the differences in the response to UK14304 was due to the 
expressed «2A adrenoceptors.
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Figure 3.9 Effect of UK14304, EGF and LPA on p4 4 MAPK phosphorylation in 
cells of clones TAGWT and ASN79.
A Serum starved cells of clones TAGWT 3 and 17 and ASN79 4 and 9 were treated for 
5 min with serum free DMEM containing no agonist, 10"^  M UK14304, 10"^  M EGF or 
10*^  M LPA. The cells were lysed according to the electrophoretic mobility shift assay 
(see 2.2.9.1) and fractions were resolved by SDS-PAGE in 6 M urea-containing 
polyacrylamide gels and immunoblotted for p44^^^^. The shift from the higher 
mobility to the lower mobility form is representative of the phosphorylation of 
p44MAPK
B The percentage of the total detectable p44^^^^ which was present in the lower 
mobility form was then be calculated by densitometric scanning and this represented 
the percentage phosphorylation of p4 4 MAPK m these cells. The quantitation of the 
above immunoblot is shown where hatched bars represent no agonist, darkly shaded 
bars 10^ M UK14304, striped bars with 10"® M EGF and lightly shaded bars 10'  ^M 
LPA.
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The time courses of phosphorylation of p44MAPK yy UK14304 were very similar in 
both the wild type and mutant 02A adrenoceptor clones, as shown in Figure 3.10. It is 
obvious from Figure 3.10A that in both TAGWT clones, nearly all of the detectable 
p44MAPK ^as phosphorylated after 5 min of UK14304 treatment and this was sustained 
for at least 5 min. Thereafter the phosphorylation decreased, so that by 20 min, 
approximately 40% remained phosphorylated in clone TAGWT 17 and 20% in clone 
TAGWT 3. Therefore the only slight difference in the time courses between these two 
clones appears to be that the phosphorylation of p44MAPK was slightly more sustained 
in the higher receptor expressing clone. This would be consistent with the reported 
effects on the time course of p42/44^^^^^ activation by insulin or EGF in PC 12 cells 
which overexpress either receptor and could be important for the determination of the 
functional response to the activation of the Ras.MAPK cascade by the «2A 
adrenoceptor (see Section 1.4.15.1 and Chapter 4 discussion).
In the ASN79 clones, the highest detected level of phosphorylation was on average 
approximately 50% (Figure 3. lOB). These clones followed a similar time course to the 
wild type clones, although some differences were detected. The maximum level of 
phosphorylation was achieved by 10 min, while typically only 50-70% of this 
maximum was seen after 5 min (the point at which the maximal level was achieved in 
the TAGWT clones). Only very limited detectable phosphorylation of p44MAPK 
persisted beyond 20 min. These differences between the time courses can perhaps be 
more clearly seen when the data is presented as a percentage of the maximum level of 
phosphorylation over the basal level achieved in each experiment for each clone 
(displayed in Figure 3. IOC). Therefore the maximum effect and time course of 
phosphorylation of p44MAPK ^an be conelated to some extent to the level of G-protein 
coupling (as measured by the GTPase assay) in each of the clones. This will be 
discussed further in Chapters 4 and 5.
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Figure 3.10 Time courses of the phosphorylation of p4 4 V^lAPK yy 1 0  5 m  UK14304 
in cells of clones TAGWT and ASN79.
Ceils of TAGWT and ASN79 clones were treated with 10~^  M UK14304 for various 
times and the levels of phosphorylation of p44MAPK jn these samples were determined 
as in Section 2.2.9.1.
A Percentage of the total detectable p44MAPK which was present after various times of 
treatment with 10"  ^M UK14304 for clones TAGWT 3 (filled circles, full line) and for 
TAGWT 17 (open circles and broken line). Data is presented as mean ± SEM (n = 3).
B Percentage of the total detectable p44MAPK which was present after various times of 
treatment with 10'^ M UK14304 for clones ASN79 4 (open squares, broken line) and 
for ASN79 9 (filled squares and full line). Data is presented as mean ± SEM (n = 3).
C Results used to produce Figures 3.10A and B were converted to the percentage of the 
maximal phosphorylation of p44MAPK achieved over the basal level in each of the 
clones for each experiment, and the data was averaged. The clones are represented by 
the same symbols but SEM are not displayed in this graph for clarity of presentation.
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The assumption made above was that the observed differences between the time 
courses of the clones was solely due to the transfected adrenoceptors and their level of 
expression. This would seem reasonable because they were produced from the same 
parental cell line. The similarity in the time course of LPA-mediated p44MAPK 
phosphorylation (acting on endogenous receptors) in TAGWT 17 and ASN79 9 (Figure 
3.11) clearly demonstrated that indeed there were no intrinsic differences in the time 
courses of phosphorylation of p44MAPK jjj these two clones.
Concentration-response curves to UK14304 in clones TAGWT 3 and 17 (Figure 3.12) 
clearly demonstrated that significantly (p -  0.008) higher concentrations of UK14304 
were required to give half maximal agonist-mediated phosphorylation of p44^ ^ K  jn 
the lower expressing cell line (EC50 for TAGWT 17 = 1.3 ± 0.6 x 10"9 M (mean ± 
SEM, n = 4) and for TAGWT 3 = 1.7 ± 0.5 x 10'^ M (mean ± range, n = 2)). These 
values are similar to the EC 50 values determined for the stimulation of high affinity 
GTPase activity in the same clones (3.7 x 10"  ^M for TAGWT 17 and 3,0 x 10'^ M for 
TAGWT 3) and so can be explained in the context of a higher concentration of agonist 
being required in the lower expressing cells to provide the required level of G-protein 
stimulation to achieve stimulation of the MAPK cascade.
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Figure 3.11 Time coui*ses of the phosphorylation of p4 4 MAPK by 10"^  M LPA in 
cells of clones TAGWT 17 and ASN79 9.
Cells of clones TAGWT 17 (open circles, broken line) and ASN79 9 (filled squares, 
full line) which had been serum starved for 24 hours were treated with 10‘'^  M LPA for 
various times and the levels of phosphorylation of p 4 4 ^ P ^  in these samples were 
determined as in Section 2.2.9.1.
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Figure 3.12 Concentration-response curves to UK14304 for p4 4 MAPK 
phosphorylation in cells of clone TAGWT 3 and TAGWT 17.
Serum starved cells of clones TAGWT 3 and TAGWT 17 were treated with various 
concentrations of UK14304 for 5 min and samples were analysed by SDS-PAGE and 
immunoblotted to determine the percentage of the total detectable p443VIAPK which was 
in its phosphorylated state as described in Section 2.2.9.1. Results were converted into 
percentages of the maximal level of phosphorylation achieved over the basal level in 
each experiment and are presented as the mean ± SEM (n = 4) for TAGWT 17 (open 
circles, broken line) and mean ± range (n = 2) for TAGWT 3 (filled circles, full line).
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However there is some inconsistency with this data. Maximal phosphoiylation of 
p44MAPK after 5 min UK14304 treatment was achieved in both TAGWT 3 and 17 
clones. However, the level of G-protein activation which produced this maximal 
phosphorylation of p44MAPK TAGWT 3 cells occuixed in TAGWT 17 cells at a 
concentration of agonist which stimulated less than 50% of total p44MAPK 
phosphorylation. In other words, maximum phosphorylation of p44MAPK j-equired 
nearly maximum G-protein activation in both clones. However, this maximum level of 
G-protein activation was very different in each of the clones and so different levels of 
G-protein activation in each clone were required to stimulate the activation p44MAPK 
A possible contribution to this inconsistency may be a variation of the receptor 
expression levels between the various passages. In addition the averaging of data from 
a number of experiments could magnify this inconsistency. A comparison between 
assays using membrane preparations and those in whole cells may be expected to 
produce inconsistencies like this, however no such problems were seen in similar 
experiments presented in Chapter 4.
It is of interest to note that the Hill coefficient for p 4 4 ^ '^ ^  phosphorylation for clone 
TAGWT 17 was on average 1.2 ± 0.3 (n = 4), and for TAGWT 3 was 0.6 ± 0.06 (n = 
2). These values are also similar to those achieved for GTPase activity (0.8 and 0.7 
respectively). Therefore no co-operative nature was seen in the concentration-response 
curves for these receptors. The significance of these observations will be discussed in 
more detail in Chapter 4.
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3.3 Conclusions
The work presented in this chapter attempted to further the knowledge of the control of 
the p42/44^^^'^^ cascade by the «2A adrenoceptor when expressed in Rati fibroblasts. 
The first part of this chapter measured the aetivation of p44MAPK by the agonist- 
stimulated human aa-ClO adrenoceptor expressed in the 1C cell line and studied the 
effects of cAMP-elevating agents and a tyrosine kinase inhibitor in these cells.
Although it is clear that the adrenoceptor's activation of the Ras.MAPK cascade is 
not mediated by an inhibition of adenylyl cyclase, the attenuation of UK14304 
-mediated activation of p44MAPK by dibutyryl cAMP or forskolin pretreatment 
demonstrated that these pathways do not act independently of each other. The data may 
also suggest that the inhibitory effect of the «2A adrenoceptor on adenylyl cyclase 
could enhance the effect of the coupling to the p42/44 '^*^bVPK cascade. The enhanced 
effect of UK14304 and EGF on pqqMAPK activation after genistein pretreatment is in 
contrast with most of the reported effects of this agent and would appear to be 
unexplainable at this stage.
The second part of the chapter was concerned with determining the relative efficiency 
of the coupling of the adrenoceptor to the Ras.MAPK cascade and the effect of site 
directed mutagenesis of this receptor at residue Asp^^. Clones of Rati fibroblasts 
transfected with the wild type U2A adrenoceptor displayed greater ability to couple to 
the G-protein machinery than clones expressing the Asn^^ mutant receptor as measured 
by the agonist-mediated stimulation of GTPase activity and cholera toxin-catalysed 
ADP-ribosylation of Gf-like proteins. A similar effect was seen at the level of adenylyl 
cyclase, but the magnitude of the differences were less, possibly because the limiting 
factor in this system is the catalytic element of adenylyl cyclase. The effects seen in the 
two wild type clones could also be correlated to their relative receptor expression 
levels.
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Both the wild type and Asn^^ mutant receptors coupled to the phosphorylation of 
p44MAPK in nil four clones studied. The time course of activation was studied for all 
clones as was the concentration-response relationships for both wild type clones. From 
the data produced it was concluded that significant phosphoiylation of p 4 4 ^ ^ ^  
occurred with much less than full G-protein stimulation, indicating that the coupling 
efficiency of the receptor to the Ras.MAPK cascade is not exceptionally less than to 
adenylyl cyclase. Thus a large overexpression is not required in order for significant 
stimulation of the cascade to occur, although increased expression led to a more 
sustained time course and so perhaps a greater functional response. These results 
would indicate that the rate of phosphorylation and dephosphorylation is related to the 
level of G-protein activation achieved on agonist stimulation.
No selective loss of signalling ability to the Ras.MAPK cascade was determined for the 
Asn'^  ^mutation but rather it appeared that a general reduction in coupling efficiency 
could explain the results presented. This manifested itself as a reduction in the 
maximum level of stimulation of p44MAPK phosphorylation achieved, coupled with a 
time course which displayed a delay in reaching the maximum level and a reduction in 
the length of time this level was sustained.
The concentration-response curves were difficult to interpret as they appeared not to be 
consistent with previous results. However, they did appear to correlate the level of G- 
protein stimulation with the level of phosphorylation of p44MAPK ^nd showed that 
there was no co-operativity in this response The relation of G-protein activation to 
p44MAPK phosphorylation will be discussed further in the next chapter.
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Chapter 4
Agonist-mediated regulation of p4 2 MAPK and 
p44M ÂPK following expression of the mouse ô 
opioid receptor in Rati fibroblasts: 
effects of receptor expression levels and 
comparison with G-protein activation and coupling
to other effectors.
Chapter 4: Agonist-mediated regulation of p42MAPK 
and p44M APK following expression of the mouse ô 
opioid receptor in Rati Rbroblasts: 
effects of receptor expression levels and comparison 
with G-protein activation and coupling to other
effectors.
4.1 Introduction
The results presented in Chapter 3 provided information concerning the quantitative 
aspects of GPCR-regulation of the p42/44^'^^^ cascade. However, there were some 
inconsistencies within this data which were difficult to reconcile. Another system was 
therefore chosen to attempt to reconcile some of these inconsistencies and to determine 
how general these observations were for Gi-coupled receptors expressed in fibroblasts. 
Previous work in the laboratory provided clones which expressed the mouse ô opioid 
receptor in Rati fibroblasts at two markedly different levels, and there is considerable 
pharmacology and signalling information available for this receptor. Therefore this 
seemed to be a potentially useful system.
The opioid receptors have been extensively studied because opioid drugs are the 
principal agents used for treating chronic severe pain. There are numerous ligands for 
these receptors (see Knapp etaL, 1995) displaying a range of effects and specificities 
and some of these will be used in Chapter 5. Pharaiacological studies suggested the 
presence of three opioid receptor types (ô, \i and k) and these have now been cloned 
and sequenced and shown to belong to the seven transmembrane-spanning GPCR 
family (Knapp etaL, 1995; Zaki etaL, 1996). These three types aie very similar and 
display an overall homology of approximately 70%. Recent reports have suggested the 
presence of additional subtypes (Zaki etaL, 1996). Primary cellular responses of 
opioid receptors culminate in the inhibition of neuronal activity via inhibition of
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adenylyl cyclase, increase in K+ current, or inhibition of Ca^+ channel activity which 
are all mediated by pertussis toxin-sensitive G-proteins.
In a similar observation to that for the (%2A adrenoceptor, the ô opioid receptor which is 
expressed endogenously in mouse neuroblastoma x rat glioma hybrid (NG108-15) cells 
was shown to specifically couple to Gi2 to inhibit adenylyl cyclase activity (McKenzie 
and Milligan, 1990). However, also in common with the tx2A adrenoceptor, functional 
coupling to multiple G^ subunits and other effectors has been demonstrated. Coupling 
of the Ô opioid receptor to multiple members of the Gi-protein family was demonstrated 
in stably transfected CHO cells, and there was no requirement for overexpression of the 
receptor to force these interactions (Pmther etaL, 1994). Coexpression studies in HEK 
293 cells demonstrated the ability of the ô opioid receptor to couple to G% (a member of 
the Gi-protein family which lacks the required Cys residue for pertussis toxin 
modification) and this coupling permitted opioid agonist-mediated inhibition of cAMP 
accumulation in a pertussis toxin-insensitive manner (Tsu etaL, 1995). Coupling of 
opioid receptors ([.i and/or ô) to the stimulation of basal adenylyl cyclase activity, 
mediated apparently by Gg, has also been demonstrated (Cruciani etaL, 1993).
Other effectors of the ô opioid receptor have been described. These include a 
stimulatory effect on intracellular Ca^+ in differentiated NG108-15 cells which was 
observed at a lower agonist concentration than that required for the inhibitory effect 
(Jin etaL, 1992). A ô opioid receptor-mediated stimulation of type I phosphodiesterase 
activity in a pertussis toxin-insensitive manner was demonstrated in NG108-15 cells 
(Law and Loh, 1993). This was shown not to be due to an increase in intracellular 
Ca^+ levels. In addition, stimulation of PI-PLC activity has been observed as a 
consequence of agonist stimulation of the ô opioid receptor (Tsu et al., 1995). In this 
case, the stimulation was sensitive to inhibition by pertussis toxin.
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Previous studies on the ô opioid receptor in our laboratory have included an 
investigation of the spontaneous activity of the receptor to couple to Gi-like proteins in 
the absence of agonist treatment when expressed in Rati fibroblasts (Mullaney etaL, 
1996). Agonist treatment ([D-Ala^, D-Leu^] enkephalin or DADLE) enhanced this 
activity and ICI 174864 acting as an inverse agonist attenuated this activity. These 
studies used a clonal cell line named clone D2 which expressed a considerable level 
(some 6 pmol/mg membrane protein) of the mouse ô opioid receptor cloned from a 
mouse brain cDNA library (Yasuda etaL, 1993) and measured the functional output at 
the level of the G-protein.
The Ô opioid receptor displays many signalling properties similar (but not identical) to 
those described for the a2A adrenoceptor (see Chapter 3) and so it was expected that 
this receptor would also display an ability to couple to the p42/44^^^^^ cascade. This 
was indeed shown, and the availability of another clone which expressed the receptor in 
considembly lower levels (170 fmol/mg membrane protein, called clone DOE) 
provided data to support some of the conclusions made in chapter 3 such as the relation 
of expression levels to the time course of activation of p42/44^''^^^. Further study of 
this signalling ability uncovered some surprising conclusions in regard to the receptor 
and activated G-protein reserve and to the co-operativity which was present in these 
clones for the activation of p42/44^'^^^.
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4.2 Results and Discussion
Rati fibroblasts (which do not endogenously express an opioid receptor) were 
cotransfected in a 10 : 1 ratio with pCMV-msl2 encoding the mouse ô opioid receptor 
(Yasuda etaL, 1993) and pBABE hygro, which permits the expression of resistance to 
hygromycin B. Clones which demonstrated resistance to 200 /^g/ml hygromycin B 
were selected and expanded and the expression of the heterogenous receptor was 
determined by reverse transcriptase-polymerase chain reaction (RT-PCR) (results not 
shown but see Mullaney etaL, 1996) and expression of high-affinity binding sites for 
the opioid ligand pHJdiprenorphine. Two clones of interest were chosen because of 
their considerably different levels of receptor expression. Clone D2 was found to 
express 6400 ±100 fmol/mg membrane protein of the ô opioid receptor while clone 
DOE expressed considerably lower levels of 170 ± 30 fmol/mg membrane protein 
(mean ± SEM, n = 3 in each case).
The Ô opioid receptor expressed in these clonal cell lines was effectively coupled to the 
cellular G-protein signal transduction machinery as evidenced by the ability of the ô 
opioid agonist DADLE to stimulate high affinity GTPase activity in both these clones 
(Figure 4.1). The stimulation of activity by a maximally effective concentration of 
DADLE (10"-^  M) was found to be significantly (p = 0.0001) greater in membranes of 
clone D2 (20,9 ±1.0 pmol/min/mg protein, mean ± SEM, n = 4) compared to clone 
DOE (6.9 ±1.2 pmol/min/mg protein, mean ± SEM, n = 4). This is consistent with the 
higher receptor expression level in D2 cells which would be anticipated to permit 
greater coupling to the G-protein machinery. This coupling was predominantly, if not 
exclusively, to G-proteins which are members of the Gi-subfamily as pretreatment of 
these cells with pertussis toxin drastically attenuated the DADLE-mediated stimulation 
of GTPase activity.
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Figure 4.1 The effect of pertussis toxin on DADLE-mediated stimulation of high 
affinity GTPase activity in membranes of clones D2 and DOE.
Membrane preparations from cells o f clone D2 and clone DOE which were either 
untreated or treated with 25 ng/ml pertussis toxin for 16 hours prior to harvesting, were 
assayed for basal and lO'^ M DADLE-stimulated high affinity GTPase activity as 
described in Section 2.2.4. Basal activity is represented by the hatched bars, DADLE- 
stimulated activity by the shaded bars, both in membranes from untreated cells.
GTPase activities o f membranes from pertussis toxin treated cells are represented by 
striped bars (basal) and speckled bars (lO'^ M DADLE stimulated). Results represent 
mean ± SEM, o f triplicate assays.
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The coupling of the ô opioid receptor to the G-protein population in both clones was 
further demonstrated by the stimulation by DADLE of [%]GTPyS binding to 
membranes from these cells (Figure 4.2). It was obvious again that the stimulation of 
P^SJGTPyS binding after DADLE treatment was greater in membranes of the higher 
expressing clone D2 compared to DOE (200 ± 8 compared to 17 ± 2 fmol/mg protein). 
In contrast, the stimulation of [35s]GTPyS binding by lO"-^  M LPA, acting at 
endogenous GPCRs (Figure 4.2), was veiy similar in both of the clones (32 ± 2 and 27 
± 2 fmol/mg protein for clone D2 and clone DOE respectively). This would indicate 
that the observed differences on stimulation with DADLE was indeed due to the level 
of expression of the ô opioid receptor and not some intrinsic property of the clonal cell 
line such as variation in G-protein level.
The functional interaction of these heterogenously expressed receptors and the Gi-like 
population of the cellular G-proteins was further shown by the ability of DADLE to 
stimulate cholera toxin-catalysed [^2p]A£)p_bbosylation of Gi-like proteins in 
membranes from both elone D2 and DOE (Figure 4.3). The greater coupling to the G- 
protein machinery in D2 cells was again obvious from the considerably greater 
stimulation of cholera toxin-catalysed [^^PJADP-ribosylation by maximally effective 
concentrations of DADLE in membranes of clone D2 as compared with membranes 
from clone DOE. Therefore three separate strategies demonstrated the ability of the ô 
opioid receptor expressed in Rati fibroblasts to functionally couple to Gi-like G- 
proteins and the considerably greater possible activation of the cellular Gi-like 
population in the higher expressing clone D2.
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Figure 4.2 The effect of DADLE and LPA treatment on [^^SjGTPyS binding to 
membranes of clones D2 and DOE.
P^S]GTPyS binding to membrane preparations of clones D2 and DOE was assessed 
with and without treatment with 10’  ^M DADLE or 10'^ M LPA according to Section 
2.2.5. Basal binding is represented by hatched bars, binding stimulated by 10'^ M 
DADLE is represented by the shaded bars and 10'^ M LPA by speckled bars. Results 
are presented as mean ± SEM, o f triplicate assays.
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Figure 4.3 DADLE-mediated stimulation of cholera toxin-catalysed [^^PJADP- 
ribosylation in membranes of clones D2 and DOE.
Cholera toxin-catalysed p^P]ADP-hbosylation was performed as in Section 2.2.12 on 
membranes (20 p t g )  o f either clone DOE (lanes 1-2) or clone D2 (lanes 3-4) in the 
absence (lanes 1 and 3) and presence (lanes 2 and 4) o f 10'^ M DADLE. One 
representative autoradiograph is shown from four produced.
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The greater level of expression of the receptor also altered the concentration of agonist 
which was required to produce stimulation of G-protein activation. This was illustrated 
by the concentration-response curves for DADLE-mediated stimulation of high affinity 
GTPase activity as shown in Figure 4.4. As the maximum output in the two clones was 
markedly different (see Figure 4.1), the results are presented as a percentage of the 
maximum acliievable stimulation over the basal level in each of the clones. A 
significantly (p = 0.03) higher concentration of DADLE was required to produce half - 
maximal GTPase activity in cells of clone DOE (EC50 = 4.2 ± 0.6 x 10"  ^M, mean ± 
range, n = 2) compared to the higher expressing D2 cells (EC50 = 5.7 ± 2.2 x lO’^  M, 
mean ± range, n = 2). The Hill coefficients for both clones ranged from 1.2 to 0.7 for 
the experiments performed. The significance of this observation will become clearer 
later.
These previous two conclusions that a greater activation of the Gi-like proteins was 
possible in the higher expressing clone D2 and that the concentrations of agonist 
required to produce a half-maximal response was less in the higher expressing clone 
were similar to those made for the ot2A adrenoceptor (Chapter 3). However, these 
results are distinctly different from observations made with the ô opioid receptor 
expressed in CHO cells where although the maximal G-protein response was greater 
with higher expression levels, the EC50 values did not show any change (Prather etal., 
1994).
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Figure 4.4 Concentration-response curves for DADLE-mediated stimulation of 
high affinity GTPase activity in membranes of clones D2 and DOE.
High affinity GTPase activity in response to various concentrations of DADLE was 
determined in membranes from cells of clone D2 (open circles and full line) and DOE 
(filled circles and broken line) as described in Section 2.2.4. The maximum DADLE- 
mediated stimulation of GTPase activity in the two clones were markedly different 
(between 27.1 and 29.1 pmol/min/mg protein for clone D2, and between 6.9 and 7.3 
pmol/min/mg protein for clone DOE) and so the results are presented as a percentage of 
the maximum achievable stimulation over the basal level in each of the clones. Results 
are presented as mean ± SEM of triplicate assays, from one of two experiments 
performed.
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As previously illustrated for both endogenously and heterologously expressed ô opioid 
receptors (e.g Knapp etal., 1995; McKenzie and Milligan, 1990), agonist stimulation 
of the Ô opioid receptor expressed in Rati fibroblasts inhibited forskolin-amplified 
adenylyl cyclase activity (Figure 4.5). This was mediated by Gi-like proteins as shown 
by the attenuation of this response after pretreatment of the cells with pertussis toxin. 
The percentage inhibition of forskolin-amplified adenylyl cyclase activity on treatment 
with a maximally effective concentration of DADLE was higher in clone D2 (37.7 ± 
7.5%, mean ± SEM, n = 4) than in clone DOE (24.6 ± 5.2%, mean ± SEM, n = 5). This 
was as expected because of their respective receptor expression levels and a similar 
obseiwation has been made before for this receptor (Tsu etal., 1995). However, the 
difference in maximum output due to the receptor level was not as pronounced as that 
demonstrated at the level of G-protein activation (Figures 4.1 to 4.3). This supports the 
similar observation with the adrenoceptor expressed in these fibroblasts (Figure 
3.8) which was interpreted to indicate that the catalytic element of adenylyl cyclase was 
the limiting factor in this system.
It is of interest to note that the basal level of adenylyl cyclase activity was consistently 
higher in membranes from cells of clone DOE in comparison with cells of clone D2 
(Figure 4.5). This is consistent with the suggestion that a higher level of spontaneous 
activity would be produced when the receptor was expressed to higher levels (Mullaney 
etal., 1996). This conclusion was also supported by the p^SJGTPyS binding and 
agonist driven, cholera toxin-catalysed [^^P]ADP-ribosylation experiments. However, 
for some unknown reason, such an increased basal G-protein activation was not 
detected with the high affinity GTPase assays.
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Figure 4.5 Inhibition of forskolin-amplified adenylyl cyclase activity by DADLE 
in membranes of clones D2 and DOE.
Adenylyl cyclase activity was assayed in membranes from cells o f clone D2 and clone 
DOE, with and without pertussis toxin pretreatment (25 ng/ml for 16 hours) as 
described in Section 2.2.6. Basal activity is represented by the hatched bars, the 
activity on treatment with 10'^ M forskolin is represented by the speckled bars and the 
activity after treatment with both 10’  ^M forskolin and 10'^ M DADLE is represented 
by the shaded bars. Results are presented as mean ± SEM of triplicate assays.
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When the «2A adrenoceptor was expressed in Rati fibroblasts, agonist treatment 
stimulated PLD-mediated hydrolysis of phosphatidylcholine in addition to adenylyl 
cyclase inhibition and both effects were mediated by Gi-like proteins (MacNulty et aL, 
1992). In addition, opioid peptide mediated-stimulation of PLD activity has been 
reported (Mangoura and Dawson, 1993). It was subsequently discovered that the ô 
opioid receptor displayed a similar signalling ability when expressed in Rati fibroblasts 
as evidenced by the stimulation of transphosphatidylation in [^H]palmitate labelled 
cells. Figure 4.6 shows that in cells of both clones D2 and DOE, 10’^  M DADLE 
stimulated the transphosphatidylation activity as determined by the radioactivity 
present in the phosphatidylbutanol-containing band after thin layer chromatography.
As was expected, maximally effective concentrations of ET-1 (acting on endogenously 
expressed Gq/n-coupled receptors) and LPA also stimulated PLD activity. ET-1 
consistently demonstrated the strongest stimulation of PLD activity in both clones 
which was also expected due to its known signalling properties. However it is obvious 
that the tyrosine kinase linked receptor agonist, EGF, did not significantly stimulate 
this activity.
Direct comparison of the absolute levels of transphosphatidylation activity between the 
clones was not possible as correction for variation in the numbers of cells assayed or 
the labelling efficiency in each clone was not performed. Each experiment therefore 
depended on plating down similar numbers of cells in each well when the plates were 
seeded. However, DADLE-mediated transphosphatidylation activity was consistently 
stronger in cells of D2 as compared with DOE. This can be clearly demonstrated if the 
DADLE-mediated stimulation is calculated as a percentage of the stimulation obtained 
with ET-1 (34 ± 1.5% of the ET-1 response in D2 cells, and 16 ± 1.6% in DOE cells, 
mean ± SEM, n = 3). Therefore, once again the greater expression of the ô opioid 
receptor in clone D2 permitted coupling of the receptor to the effector (in this case 
PLD) to a greater extent than in clone DOE.
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Figure 4.6 Transphosphatidylation activity in response to various ligands in 
[^Hjpalmitate-Iabeiled cells of clones D2 and DOE.
The transphosphatidylation activity was determined in cells o f clone 0 2  (hatched bars) 
and clone DOE (shaded bars) which had been labelled with 4  ;<Ci/ml pHJpalmitate for 
24 hours. Stimulation by 10’  ^M DADLE, 10 M ET-1, IQ-  ^M EOF and 1 0 M LPA 
was performed in HBGbutanol as described in Section 2.2.10 for 15 min prior to 
stopping the reaction with ice-cold methanol. Phase separation was performed and the 
aqueous layers were subjected to thin layer chromatography and bands containing 
phosphatidyl butanol (as detected by an internal standard after iodine staining) were 
counted by liquid scintillation. Results (mean ± SEM, of triplicate assays) are 
presented as the percentage activation achieved by each of the agonists over the basal 
activity in each o f the clones.
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The coupling of the ô opioid receptor to PLD was indeed mediated by Gi-like proteins 
as shown by the complete attenuation of this response after pertussis toxin pretreatment 
(Figure 4.7). As stated before, ET-1 acts on Gq/n-coupled receptors and so its response 
was, not surprisingly, unaffected by pertussis toxin.
The time course of DADLE-mediated activation of PLD was quite distinct from that 
induced by ET-1 (Figure 4.8). Production of phosphatidylbutanol was complete within 
2 min of stimulation with 10"  ^M DADLE, and levels were maintained thereafter. In 
contrast, the rate of production of phosphatidylbutanol was greater with ET-1 and 
continued beyond 2 min although the rate of production began to decrease after 5 min. 
These differences may be produced because the ô opioid receptor activated PLD 
through Gi-proteins but the endothelin receptor used Gq/n-proteins. However, the 
stimulation of PLD activity was apparently rapidly desensitised for both receptors and 
so the difference in time courses may reflect variation in rates of receptor 
desensitisation. This result is similar to the obseived time course of activation of PLD 
by agonist-stimulated thrombin and ml muscarinic receptors in hamster lung 
fibroblast-derived cell lines (McKenzie etal., 1992).
1 2 5
01
■S*îcieuQ
15000
12500-
10000 -
7500-
5000-
2500-
Basal ET-1 DADLE
Figure 4.7 The effect of pertussis toxin pretreatment on ET-1 and DADLE- 
mediated stimulation of transphosphatidylation activity in cells of clone D2.
The transphosphatidylation activity in pHJpalmitate (4 /<Ci/ml) labelled D2 cells was 
determined as in Section 2.2.10 with (shaded bars) and without (hatched bars) pertussis 
toxin pretreatment (25 ng/ml for 16 hours). Stimulation by no agonist (basal), lO '^  M 
ET-1 and 10'^ M DADLE was performed for 15 min. Results are presented as mean ± 
SEM, of triplicate assays from one experiment o f two performed.
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Figure 4.8 Time course of ET-1 and DADLE-mediated stimulation of 
transphosphatidylation activity in [^Hjpalmitate labelled cells of clone D2.
pHJpalmitate labelled (4 //Ci/ml) cells of clone D2 were treated with 10"  ^M DADLE 
(open circles, full line) or 10"  ^M ET-1 (open squares, broken line) in the presence of 
butan-l-ol for various times and transphosphatidylation activity was assayed as 
described in Section 2.2.10. Results are presented as mean ± SEM (of triplicate assays) 
for ET-1, and mean ± SEM (of three independent experiments) for DADLE, of 
measured DPM in the phosphatidylbutanol-containing band of the thin layer 
chromatography plate.
1 2 7
It can be seen from Figure 4.8 that 15 min treatment of agonist produced a response 
that was maximal for both ET-1 and DADLE. This result therefore justifies the use of 
a 15 min time point for treatments in the experiments presented in Figures 4.6 and 4.7. 
In subsequent concentration-response curves, treatments with various concentrations of 
DADLE in cells of clone D2 and DOE were also performed for 15 min (Figure 4.9). 
There was only a very limited response to DADLE in cells of clone DOE and so the 
concentration-response curves were difficult to produce and the shape of the curve was 
quite different from clone D2. Therefore, although the calculated EC50 value (2.3 x 
10’^  M) is apparently lower than that for D2 cells, it can be seen that this is not because 
the stimulation of PLD activity is detectable at a lower concentration of DADLE, but 
rather that the maximal stimulation is achieved very abruptly. The average EC50 value 
calculated from the concentration-response curves to DADLE in clone D2 was 2.5 ± 
0.6 X  10'^ M (mean ± SEM of three independent experiments) and the Hill coefficient 
was 1.0 ± 0.3. These values were very similar to those for the GTPase activity and so 
would conelate the level of transphosphatidylation activity with the level of G-protein 
activation.
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Figure 4.9 Concentration-response curves of DADLE-mediated stimulation of 
transphosphatidylation activity in cells of clones D2 and DOE.
pHJpalmitate labelled (4 /<Ci/ml) cells of clone D2 (open circles, full line) and DOE 
(filled circles, broken line) were treated with various concentrations of DADLE for 15 
min in the presence of butan-l-ol and the transphosphatidylation activity was assayed 
as described in Section 2.2.10. Results are presented as mean ± SEM of triplicate 
assays from one representative experiment of three performed.
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The activation of PLC by the a2A adrenoceptor in Rati fibroblasts was reported as 
negligible (MacNulty etal., 1992), however an activation of PLC activity was reported 
for the Ô opioid receptor expressed in Ltk' fibroblasts (Tsu etal., 1995), This was also 
detected in cells of clone D2 on treatment with 10"  ^M DADLE (Figure 4.10). The 
response was rather variable over the experiments which were performed with between 
480% and 100% increase of activity over basal levels on treatment with DADLE. 
Pretreatment of the cells with pertussis toxin attenuated the response to DADLE, and so 
would indicate that this response was mediated by Gi-like proteins, however some 
DADLE-mediated activation was still detectable over the basal level (which also was 
often increased on pertussis toxin pretreatment). The response to ET-1 was of a similar 
magnitude, and as expected for a Gq/n-protein coupled agonist, was largely unaltered 
after pretreatment with pertussis toxin. However, some reduction in ET-1-mediated 
activation was sometimes seen after pertussis toxin treatment, but may be partly 
explained by the previously mentioned altered basal levels. The significance of the 
slightly unusual aspects of these results is not known.
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Figure 4.10 The effect of pertussis toxin pretreatment on the stimulation of 
production of total inositol phosphates by DADLE and ET-1 in cells of clone D2.
Cells o f clone D2 were labelled with inositol (1.5 ;<Ci/ml, 24  hours) in inositol free 
medium with (shaded bars) and without (hatched bars) pertussis toxin pretreatment (25 
ng/ml for 24 hours) and stimulated with 10'^ M DADLE or 10-^ M ET-1 in the 
presence o f Li+ for 10 min as described in Section 2.2.11. The radioactivity associated 
with the total inositol phosphates was determined by batch elution from Dowex 
formate. Results are presented as percentage stimulation of activity over the basal 
level, mean ± SEM of triplicate assays, and is a representative experiment o f three 
performed.
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The above results demonstrated the coupling of the ô opioid receptor via Gi-like 
proteins to adenylyl cyclase, PLD and PLC. As mentioned previously, the signalling of 
this receptor in Rati fibroblasts was very similar to that described for the «2A 
adrenoceptor (Chapter 3) and so it was no surprise that the agonist-stimulated ô opioid 
receptor was able to activate p42/44^'^(^^. Treatment of serum starved cells of clone 
D2 and clone DOE with maximally effective concentrations of DADLE for 5 min 
stimulated the phosphorylation of virtually the entire population of as
detected by immunoblotting with a specific anti-p44^^^^ antibody (Figure 4.11). This 
phosphorylation was seen as a gel shift from the higher mobility unphosphorylated 
fonn to the lower mobility, phosphorylated form and the data is presented as the 
percentage of the total detected p44MAPK which was in the phosphorylated fonn. 
DADLE failed to have any effect on the phosphorylation of p44MAPK serum starved 
parental Rati fibroblasts but in all three cell lines, 5 min treatment with maximally 
effective concentrations of EGF phosphorylated the entire population of p44MAPK 
(Figure 4.11). For cells of clone D2 the average percentage phosphorylations of 
p44MAPK were 22 ± 6% (basal), 92 ± 3% (lO’^  M DADLE) and 99 ± 1% (lO * M EGF) 
and for cells of clone DOE were 12 ± 5% (basal), 94 ± 2% (IQ--^  M DADLE) and 99 ± 
1% (10’^  M EGF), mean ± SEM from at least 6 independent experiments. Stimulation 
of the phosphoiylation on tyrosine residues of proteins apparently corresponding to 
p42MAPK and p44^'f^PK. yy DADLE and EGF in cells of clone D2 was also 
demonstrated by means of immunoblotting with a phosphotyrosine specific antiserum 
(data not shown).
Therefore in contrast to the other effects measured, apparently maximum output could 
be achieved in the lower receptor expressing clone DOE. In these clones (in a similar 
manner to what was seen with clone TAGWT 3 in Chapter 3), maximum G-protein 
activation was not required in order to stimulate maximal phosphorylation of p44^^I"^ 
as measured after 5 min agonist treatment.
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Figure 4.11 Effect of DADLE and EGF on the phosphorylation of p4 4 MAPK 
cells of clones D2 and DOE and in parental Rati fibroblasts.
Serum starved cells o f clone D2, DOE or parental Rati fibroblasts were treated for 5 
min with serum free DMEM containing no agonist (hatched bars), lO'^ M DADLE  
(shaded bars) or 10’^  M EGF (speckled bars). The phosphorylation of p4 4 MAPK was 
then measured by the electrophoretic mobility shift assay as described in Section 
2.2.9.1. This assay involved subjecting the cell lysates to SDS-PAGE (in the presence 
of 6 M urea) and immunoblotting with an anti serum specific for p4 4 MAPK 
proportion o f the total detectable p 4 4 ^ ^ ^  which was present in the lower mobility, 
phosphorylated form was then calculated by densitometric scanning. Results for clones 
D2 and DOE are representative o f at least six experiments performed.
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As expected, the phosphorylation of p4 4MAPK was associated with an increase in the 
activity of p42/44^^*^^ (Figure 4.12). These results were obtained with the Biotrak 
p42/44 MAP kinase activity assay (Amersham) which measured the labelling of a 
peptide specific for p42MAPK and p44^ P K  with P^P] which was determined by liquid 
scintillation counting (Section 2.2.9.3). With this assay, the measured activity 
stimulated by maximally effective concentrations of DADLE in cells of clone DOE was 
often lower than that seen in cells of clone D2. This was also commonly seen for 
treatment with EGF, but the maximum response of DADLE was of a similar magnitude 
to the maximum EGF response. This was interpreted to imply that a similar maximum 
level of activation was achieved in each clone on DADLE treatment and that the 
differences in actual levels of activity was somehow related to clonal differences. The 
actual measured activity did vaiy quite substantially between different experiments, 
however the same basic effects of the ligands were noted each time. DADLE and EGF- 
mediated stimulation of p44MAPK activity was also demonstrated using the IP kinase 
method (Section 2.2.9.2) where the activity of immunoprecipitated p44^^b^l^ was 
determined by its ability to p^P]-Iabel exogenously added myelin basic protein (data 
not shown).
The phosphorylation of p44MAPK stimulated by DADLE in clones DOE and D2 was 
attenuated by pretreating the cells with pertussis toxin (Figure 4.13 and data not 
shown). Pertussis toxin displayed a similar effect on the LPA-mediated 
phosphoiylation of p44^^^b l^ ,^ but had no effect on the phosphorylation stimulated by 
EGF. This is consistent with both LPA and DADLE signalling via Gi-like proteins and 
EGF acting on a tyrosine kinase-linked receptor. Pertussis toxin pretreatment also 
sometimes reduced the basal level of phosphorylation of p44^^^^, however, this was 
not always observed.
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Figure 4.12 Stimulation of p42/44^^*^ activity in cells of clones D2 and DOE by 
EGF and DADLE.
Serum starved cells of clone D2 or clone DOE were treated for 7.5 min with serum free 
DMEM containing no agonist (hatched bars), lO'  ^M DADLE (shaded bars) or IQ-* M 
EGF (speckled bars). The activity of p42/p44^^*^ in cellular lysates was then 
measured by the Biotrak p42/44 MAP kinase activity assay (Amersham) as described in 
Section 2.2.9.S. The activity of the p42/44^^^^ was calculated as pmol phosphate 
transferred/min/mg protein. Results are presented as mean ± range of duplicate assays 
from a representative experiment of two (D2) or three (DOE) performed.
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Figure 4.13 Effect of pertussis toxin on p 4 4 ^ ^ ^  phosphorylation stimulated by 
DADLE, LPA and EGF in cells of clone DOE.
Serum starved cells of clone DOE, some of which had been pretreated for 16 hours 
with 25 ng/ml pertussis toxin, were stimulated for 5 min with serum free DMEM 
containing no agonist (lanes 1 and 5), 10"  ^M DADLE (lanes 2 and 6), 10“^  M EGF 
(lanes 3 and 7) or 10"  ^M LPA (lanes 4 and 8). The cells were lysed according to 
Section 2.2.9.1, fractions resolved by SDS-PAGE (in the presence of 6 M urea) and 
immunoblotted with a specific antiserum raised against p44MAPK A representative 
immunoblot is shown. Lanes 5-8 were pretreated with pertussis toxin, lanes 1-4 were 
not.
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In order to prove that DADLE-mediated phosphorylation of p44MAPK indeed 
mediated by the transfected ô opioid receptor, the ability of naloxone (a general opioid 
receptor antagonist (Knapp et aL, 1995)) to prevent the effect of DADLE was 
investigated in DOE and D2 cells (Figure 4.14 and data not shown). In cells of clone 
DOE, the presence of 10'^ M naloxone significantly reduced and totally prevented the 
phosphorylation of p44^^^^ stimulated by lO'^ M and 10"  ^M DADLE, respectively. 
In D2 cells, an inhibitory effect could only be seen on 10'^ M DADLE-mediated 
phosphorylation. Therefore, it would appear that higher concentrations of the agonist 
can compensate for the actions of the antagonist as anticipated for a competetive 
interaction. However, the ability of this antagonist to have any inhibitory effect would 
support the conclusion that the phosphorylation of p44MAPK yy DADLE is indeed 
mediated by the opioid receptor. As expected naloxone had no effect on EGF-mediated 
phosphoiylation of p44MAPK either clone.
It was noted in several experiments that p44MAPK was not always totally 
unphosphorylated after 5 min of treatment with serum free DMEM without any agonist. 
There seemed to be some pattern to this in that the basal levels of phosphorylation in 
the DOE cells and in the parental Rati fibroblasts were commonly lower than that seen 
in cells of clone D2 (for an example see Figure 4.11). It was suggested that this could 
be a manifestation of spontaneous activity (mentioned above). In order to investigate 
this, the phosphorylation of p 4 4 ^ ^ ^  in serum starved cells of clone D2, clone DOE 
and parental Rati fibroblasts was monitored after various times of incubation with 
serum free DMEM (Figure 4.15). In cells of clone D2, a peak of p44^ ''^^  
phosphorylation which was stimulated only by the change of medium was commonly 
seen, but the magnitude of this peak was highly variable and sometimes it was not 
detected at all. A much more limited agonist-independent phosphoiylation was 
obseived in cells of clone DOE, and no effect was seen in the parental Rati fibroblasts. 
p42/44MAPK activity in these 'basal’ conditions as measured with the Biotrak activity 
assay, followed a similar pattern as the phosphorylation of p 4 4 ^ ^ ^  (data not shown).
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Figure 4.14 The antagonistic effects of naloxone on DADLE-mediated 
phosphorylation of p4 4 MAPK cells of clone DOE.
Cells of clone DOE were serum starved for 24 hours and treated with no agonist, 10^ 
or 10'  ^M DADLE or 10^ M EGF in the presence (shaded bars) or absence (hatched 
bars) of 10'  ^M naloxone. The phosphorylation status of p4 4 MAPK was determined 
using the electrophoretic mobility shift assay as described in Section 2.2.9.1.
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Figure 4.15 Time counse of phosphorylation of p44^^*^ on treatment with 
control' serum free DMEM in cells of clones D2 and DOE and parental Rati 
fibroblasts.
Cells of clone D2 (open circles, full line), clone DOE (filled circles, broken line) or 
parental Rati fibroblasts (open squares, full line) were serum starved for 24 hours and 
then treated with fresh serum free DMEM for various times as noted. The 
phosphorylation level of p44MAPK was determined by the electrophoretic mobility shift 
assay (as described in Section 2.2.9.1) and the percentage of the total detectable 
p44MAPK which was present in the lower mobility, phosphorylated form was 
calculated.
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The variation according to the receptor level would suggest that this observation may 
indeed be due to an ’empty' receptor-activation of the Gi-mediated-p42/4 4 ^ ^ ^  
cascade. These results could also be consistent with the presence of low levels of an 
opioid agonist in DMEM (which could be studied further by determining the effect of 
naloxone on the 'basal' peak of activity). Some agonist-independent phosphorylation of 
p44MAPK was still detected after pertussis toxin pretreatment in control time courses 
(data not shown) which would suggest a different, but at this stage unknown, 
mechanism. The significance which should be attached to these observations is not 
obvious and they might just be an artefact of the method used in these experiments, 
however, they do present the possibility that the ô opioid receptor has some sort of 
agonist-independent activity on this cascade which becomes observable when the 
receptors are expressed to a high level.
By pretreating the cells with serum free DMEM for 30 min after the semm starvation 
but prior to the agonist treatment, the 'control' peak had decayed to negligible levels 
and the stimulation induced solely by the added ligand could be observed. Time 
courses and concentration-response curves (see later) were not significantly altered 
depending on whether the cells were pretreated as above or whether the percentages of 
the maximum response achieved over the various basal levels were calculated. 
Therefore this slightly odd observation is not thought to have any bearing on the 
conclusions drawn from any of the experiments performed.
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The time course of phosphorylation of stimulated by maximally effective
concentrations of DADLE was more prolonged in cells of clone D2 as compared with 
clone DOE (Figure 4.16). In both clones the phosphoiylation was rapid and was easily 
detected within 1 min, and maximal by 5 min of agonist treatment. This maximum 
level of phosphorylation of p44MAPK cells of clone DOE was not maintained so that 
levels had returned close to basal by 15 min. In cells of clone D2, however, the 
elevated level of phosphoiylation was still detectable at 30 min after the agonist had 
been added. The time course of phosphorylation of p42MAPK iQ-5 ^  DADLE was 
found to be very similar to that obseiwed for p44MAPK (Figure 4.17). The same 
increased duration of the phosphorylation of p 4 2 ^ ^ ^  was seen in clone D2 as 
compared to clone DOE.
Veiy similar time courses were displayed at the level of the activity of p42/44^^^^^ as 
measured by the Biotrak p42/44 MAP kinase activity assay (Figure 4.18). The slight 
delay on the activation of p 4 2 /4 4 ^^^  in cells of clone D2 was observed to be the only 
consequence of the 30 min pretreatment with semm free DMEM (after the 24 hour 
serum starvation) prior to treatment with IQ-  ^M DADLE. The reduced duration of the 
activation in these cells as compared with the phosphoiylation data is not thought to be 
significant and can be explained in terms of variation over the different passages of 
cells involved.
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Figure 4.16 Time course of DADLE-mediated phosphorylation of p4 4 MAPK in 
cells of clones D2 and DOE.
A and B Serum starved cells of clone D2 (A) and clone DOE (B) were treated with 10"  ^
M DADLE for various times. The phosphorylation of p44fdAPK \yas then assessed by 
the electrophoretic mobility shift assay as described in Section 2.2.9.1. Representative 
immunoblots from such experiments are shown in A (clone D2) and B (clone DOE).
C Scanning by densitometry was used to quantify immunoblots such as in A and B 
from a number of experiments and the data was calculated as the percentage of the 
maximal level of phosphorylation achieved over the basal level. Results are 
represented by open circles and full line for D2 and filled cireles and broken line for 
DOE. Data is presented as mean ± SEM, from three (clone DOE) and six (clone D2) 
independent observations.
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Figure 4.17 Time course of DADLE-mediated phosphorylation of p4 2 MAPK 
cells of clones D2 and DOE.
A and B In similar experiments to Figure 4,16, serum starved cells of clone D2 (A) and 
clone DOE (B) were treated with 10"  ^M DADLE for various times. Samples were 
processed as described in Section 2.2.9.1 by the electrophoretic mobility shift assay and 
after SDS-PAGE, immunoblotting was performed with a specific anti-p42^''^^ 
anti serum and the immunoblots are displayed.
C Scanning by densitometry was used to quantify the immunoblots in A and B and the 
data was calculated as the percentage of the maximal level of phosphorylation of 
p42MAPK achieved over the basal level. Results are represented by open circles and 
full line for D2 and filled circles and broken line for DOE.
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Figure 4.18 Time course of stimulation of p42/44^^^^^ activity by DADLE in cells 
of clones D2 and DOE.
Serum starved cells of clone D2 and clone DOE were pretreated for 30 min in serum 
free DMEM and then treated with a final concentration of 10“-^  M DADLE for various 
times. Cellular lysates were prepared as described in Section 2.2.9.S and the activity of 
p42/44MAPK in these samples was assessed by the Biotrak p42/44 MAP kinase activity 
assay from Amersham. Results are presented as % of maximum activity over basal, 
mean ± range of duplicate assays from one of two experiments performed. Data is 
represented by open circles and full line for clone D2 and filled circles and broken line 
for clone DOE.
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These three separate pieces of evidence therefore support the idea suggested in Chapter 
3 that a greater level of GPCR expression can produce a more sustained stimulation of 
p42/44MAPK importance of this observation lies in the fact that the final effect on 
the cell of the stimulation of the Ras.MAPK cascade is believed to be dependent on the 
length of time the activation is sustained as this determines if significant nuclear 
translocation of activated p42/44^^^^ can occur (see Section 1.4.15.1). Therefore, 
although the clone expressing lower levels of the receptor can stimulate the 
phosphorylation of essentially all the detectable p42/44^'^^^ in these cells, this 
activation is more transient and so the effect of DADLE on these cells may be very 
different from the effect on clone D2. Similar effects on the time course of activation 
of p42/44^P ^ have been demonstrated for the overexpression of tyrosine kinase 
linked receptors, including receptors for EGF and insulin in PC 12 cells (Marshall,
1995; Schlessinger and Bar-Sagi, 1994).
The time courses of phosphorylation of upon treatment with 1 0 M LPA
were not noticeably different between clone D2 and clone DOE (Figure 4.19).
Maximal phosphorylation was achieved 5 min after LPA treatment and this decayed to 
greatly reduced levels by 30-60 min. LPA acts on GPCRs which are endogenous to the 
parental Rati fibroblasts and so should be present in similar levels in each of the 
clones. The observed differences between the clonal cell lines for DADLE-mediated 
activation of p42/44^^^^ are clearly due to the levels of expression of the ô opioid 
receptor and not because of some variation in the individual clonal cell lines.
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Figure 4.19 Time course of the phosphorylation of p^^MAPK ceHs of clones D2 
and DOE on treatment with LPA.
Cells of clone D2 and clone DOE were serum starved for 24 hours and then subjected 
to 10'^ M LPA for various times. The phosphorylation level of p44MAPK ^^s then 
assessed by the electrophoretic mobility shift assay (Section 2.2.9.1). p44^^^^ 
immunoblots were scanned by densitometry and the data was calculated as the 
percentage of the maximal phosphorylation of p44MAPK over the basal which was 
present at each of the time points. Results are presented as mean ± range from two 
independent experiments. Data is represented by open circles and full line for clone D2 
and filled circles and broken line for clone DOE.
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Two proposals could possibly explain the sustained kinetics in clone D2: possibly the 
receptor level in clone D2 but not clone DOE was high enough such that full 
desensitisation could not occur therby the receptor could continue to stimulate the 
phosphorylation of p42/44^^^^^; or the higher receptor expression was able to 
stimulate a greater level of G-protein activation which stimulated the Ras.MAPK 
cascade to a greater extent which could not be overcome as rapidly by the cellular turn 
off mechanisms (presumably MAPK phosphatases). In order to test these ideas further 
the time courses of phosphorylation of p44MAPK mediated by different concentrations 
of DADLE were determined in cells of clone D2 (Figure 4.20). The time courses of 
10-6 lyf and 10"  ^M DADLE were very similar. Maximal phosphorylation was 
achieved after 5 min of agonist treatment and this was maintained for a further 10 min. 
However, the dephosphoiylation was slightly more rapid in cells which had been 
treated with 10"  ^M DADLE as near basal levels were seen after 20 min while 50% of 
p44MAPK was still phosphorylated at this time in 10-6 ^  DADLE-treated cells. 10-^6 
M DADLE stimulated nearly complete phosphorylation of the p44^^^^ population but 
10 min was required for this to be reached, and the dephosphorylation was more rapid.
These results can be very approximately correlated with the level of high affinity 
GTPase stimulation which can be achieved by each of these concentrations of ligand in 
clones D2 and DOE. 10'^ M DADLE (and 10“6 M DADLE) produced greater GTPase 
activity than could be achieved by maximally effective concentrations in clone DOE 
and so produced a more sustained time course of phosphorylation of p44MAPK 
M DADLE produced a stimulation of GTPase activity which was less than the maximal 
level in clone DOE and so the time course of phosphorylation of p44MAPK for this 
concentration of DADLE was more delayed and possibly more transient than for clone 
DOE cells. These results therefore support the model in which the magnitude and 
duration of the phosphorylation of p42 /44^P ^  is dependent on the level of G-protein 
stimulation achieved and indicate that an inability to desensitise the receptors was not 
the reason for the more sustained kinetics in clone D2.
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Figure 4.20 Time course of p4 4 MAPK phosphorylation stimulated by treatment 
with various concentrations of DADLE in cells of clone D2.
Serum starved cells of clone D2 were treated with DADLE at 10'^ M (open circles, full 
line), 10'® M (filled circles, broken line) and M (open squares, dotted lines) for 
various times. The phosphorylation status of p44^^^^ in each sample was assessed by 
the electrophoretic mobility shift assay as described in Section 2.2.9.1. Results are 
presented as mean ± SEM from three independent experiments.
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Concentration-response curves of DADLE-mediated pM^IAPK phosphorylation 
demonstrated that a significantly (p = 0.04) larger concentration of DADLE was 
required to produce half-maximal phosphoiylation of p 4 4 ^ P ^  in cells of clone DOE 
compared with clone D2 (Figure 4.21). This was similar to what was expected on the 
basis of the GTPase results in these cells and the p44MAPK phosphorylation results in 
Chapter 3. The average EC50 for phosphorylation of p 4 4 ^ ^ ^  by 5 min treatment of 
DADLE in clone DOE was 3.1 + 0.9 x 10"  ^M which was some 40 fold higher than for 
clone D2 which displayed an EC50 value of 7.3 ± 2.4 x lO ^l M (mean ± SEM, n = 3 
for clone D2, n = 4 for clone DOE). It is of note that these concentration-response 
curves were co-operative in nature as shown by the Hill coefficients of 2.3 ± 0.4 for 
clone D2 and 1.9 ± 0.2 for clone DOE.
The concentration-response cuiwes of DADLE-mediated stimulation of p42/44^^^^^ 
activity in clones D2 and DOE were veiy similar to those for phosphorylation (Figure
4.22). The EC 50 values displayed for each clone were similar to the phosphorylation 
data, with a significantly (p = 0.005) larger concentration required to produce a half - 
maximal effect in cells of clone DOE as compared to clone D2 (EC50 value for clone 
D2 was 1.4 ± 0.3 x lO"!® M and for DOE was 2.8 ± 0.2 x 10“^  M, mean ± range, n = 2 
for each clone). Hill coefficients were typically calculated at approximately 2.5, 
showing co-operativity in these concentration-response curves.
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Figure 4.21 Concentration-response curves of DADLE-mediated phosphorylation 
of p4 4 MAPK in cells of clone D2 and clone DOE.
A and B Serum starved cells of clones D2 and DOE were treated with various 
concentrations of DADLE for 5 min. Samples were prepared as described in Section 
2.2,9.1 for the electrophoretic mobility shift assay and resolved by SDS-PAGE and 
immunoblotted with an anti-p44^'^^^ antiserum. Representative immunoblots are 
shown for clone D2 (A) and DOE (B).
C Immunoblots such as in A and B were scanned by densitometry and the percentage 
of the maximal phosphorylation of which was produced with each
concentration was calculated. Results are presented as mean ± SEM, n = 3 for clone 
D2 (open circles, full line) and n = 4 for clone DOE (filled circles, broken line).
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Figure 4.22 Concentration-response curves of DADLE-mediated stimulation of the 
activity of p42/44^^^^ in cells of clone D2 and clone DOE.
The activity of p42/44^^^^^ in serum starved cells of clone D2 and DOE was 
determined by the Biotrak activity assay (as described in Section 2.2.93) in response to 
7.5 min treatment of various concentrations of DADLE after a 30 min pretreatment 
with serum free DMEM. Results ai*e presented as mean ± range of duplicate assays of 
the percentage of the maximal response achieved over the basal level in cells of clone 
D2 (open circles, full line) and clone DOE (filled circles, broken line). Data is shown 
from one of two experiments peifonned.
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In contrast, the concentration-response cui*ves to LPA-mediated phosphorylation of 
p44MAPK were not significantly (p = 0.11) different between the two clones (Figure
4.23). The EC50 for clone D2 was 1.2 ± 0.3 x lO-'^  M and for clone DOE was 1.1 ± 0.5 
X  10’^  M, mean ± SEM, n = 3 in each case. Therefore the above marked differences in 
the concentration-response curves for DADLE were clearly due to the difference in the 
expression levels of the ô opioid receptor in the clones. The LPA-mediated 
concentration-response curves surprisingly did not show any co-operativity. The 
values of the Hill coefficients were calculated as 1.1 ± 0.2 for clone D2 and 0.8 ± 0.2 
for clone DOE and were significantly (p = 0.04 for clone D2 and p = 0.007 for clone 
DOE) different to that calculated for the DADLE-mediated p44^'"^^^ phosphoiylation.
As displayed in Figure 4.4 the concentration-response curves of DADLE-mediated high 
affinity GTPase activity also displayed a requirement for a higher concentration of 
DADLE to produce a half-maximal effect in clone DOE compared to clone D2. 
However, this was not as pronounced as for the p44^^^L phosphorylation. Direct 
comparison of the concentration-response curves to DADLE-mediated p44MAPK 
phosphorylation and high affinity GTPase activity demonstrated that in cells of clone 
D2, only a very small proportion of the cellular Gi-protein population was required to 
be activated to cause maximal phosphorylation of p44^PI'^ (Figure 4.24A). Therefore 
only a small fraction of the ô opioid receptor population was required to be occupied to 
produce this maximal effect and a large receptor and activated Gi-protein reserve exists 
in these cells. This is consistent with the maximum p44MAPK phosphorylation 
response to DADLE (5 min treatment) in clone DOE where the maximal agonist- 
stimulated GTPase response is much lower than in clone D2. However, the receptor 
and activated G-protein reserve was also obvious in cells of clone DOE (Figure 4.24B), 
although the magnitude of this was significantly (p = 0.03) smaller: a 94 ± 23 fold 
higher concentration of DADLE was required to produce the half-maximal GTPase 
activation compared with p44MAPK phosphorylation in clone D2, whereas this was 
only 27 ± 14 fold higher in clone DOE (mean ± SEM, n = 3 (D2) or 4 (DOE)).
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Figure 4.23 Concentration-response curves of LPA-mediated phosphorylation of 
p4 4 MAPK in cells of clone D2 and clone DOE.
The level of phosphorylation of p44^^^^ was determined by the electrophoretic 
mobility shift assay (Section 2,2.9.1) in serum staiwed cells of clones D2 and DOE in 
response to 5 min treatment of various concentrations of LPA. The results from 
densitometric scans of the immunoblots were calculated as the percentage of the 
maximal response achieved over the basal level for each of the clones and the data is 
presented as mean ± SEM from three independent experiments. The results for clone 
D2 are represented by open circles and full line and for clone DOE by filled circles and 
broken line.
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Figure 4.24 Comparison of the concentration-response curves of the stimulation of 
high affinity GTPase activity and phosphorylation of p4 4 MAPK by DADLE in cells 
of clone D2 and DOE,
Data from concentration-response curves to DADLE for high affinity GTPase (as in 
Figure 4.4) and for phosphorylation of p44^^^^ (as in Figure 4.21) for cells of clone 
D2 (A) and clone DOE (B) are presented as the percentage of the maximal effect 
produced by DADLE. Experimental details are as in the legends to the figures 
mentioned.
A For cells of clone D2, the phosphorylation of p44^^^^ is represented by open circles 
and full line, and high affinity GTPase activity by open squares and dotted line.
B For cells of clone DOE, the phosphorylation of p44MAPK jg represented by filled 
circles and broken line, and high affinity GTPase activity by filled squares and dotted 
line.
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The suggestion was made that these differences in concentration-responses might occur 
because the comparison is between the response to a treatment with DADLE on whole 
cells (p44MAPK phosphorylation) and treatment on membrane preparations (GTPase 
activity). In order to exclude this explanation, the concentration-response curve for 
clone D2 of p44MAPK phosphoiylation was compared with that for 
transphosphatidylation activity (from Figure 4.9) as both involve whole cell treatments. 
Again the curves displayed a similarly significant (p -  0.02) difference in the EC50 
values (Figure 4.25) indicating that the large receptor and activated Gi-protein reserve 
in the response of ô opioid receptor-mediated activation of p44MAPK was not general 
for all effectors of this receptor and was not just a consequence of the experimental 
method.
As noted previously, the Hill coefficients for the concentration-response curves for 
DADLE-mediated phosphorylation of p44^^^^ displayed marked co-operativity. In 
contrast the Hill coefficients for the transphosphatidylation assay in clone D2 and the 
GTPase assays in both clones were significantly (p = 0.04) smaller, with values less 
than or equal to 1. Thus there was no co-operativity at the level of the G-protein or 
PLD activation. This might suggest that the receptor feeds into the Ras.MAPK 
pathway at more than one distinct point which would create the co-operativity as well 
as the observed highly potent effect.
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Figure 4.25 Comparison of the concentration-response curves for DADLE- 
mediated stimulation of transphosphatidylation activity and phosphorylation of 
p44MAPK in cells ef clone D2.
Data from concentration-response curves to DADLE for transphosphatidylation activity 
(as in Figure 4.9) and for phosphorylation of p 4 4 ^ ^ ^  (as in Figure 4.21) for cells of 
clone D2 are presented as the percentage of the maximal effect produced by DADLE. 
The phosphorylation of p 4 4 ^ ^ ^  is represented by open circles and a full line, and 
transphosphatidylation activity by open squares and a dotted line. The experimental 
details are as reported in the legends to the figures mentioned.
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That these obseivations were not just artefacts of the experimental methods used was 
further demonstrated by the fact that they were not common to other Gi-protein coupled 
receptors expressed in these cells. The activation of endogenous receptors with LPA, 
led to the phosphorylation of in a manner which did not display any co-
operativity but displayed a similar EC50 value to that calculated for GTPase activation 
in parental Rati fibroblasts (Carr etal., 1994). In addition, the results presented in 
Chapter 3 with the a2A adrenoceptor expressed in Rati fibroblasts did not show any 
co-operativity and were inconsistent as to the presence of a receptor or activated G- 
protein reserve. Therefore, although there were many similarities between the 
signalling of the « 2A adrenoceptor and the ô opioid receptor when expressed in these 
cells, they display quantitatively different features in their ability to couple to the 
p42/44MAPK cascade. Since the ô opioid receptor in these experiments demonstrated a 
peculiarly efficient coupling ability to the activation of p 4 2 /4 4 ^ ^ ^  it would be 
interesting to determine if there is any variation in the pathways used by these three 
GPCRs to activate the cascade which might explain these results.
The reason for this difference between the signalling of these receptors is puzzling and 
at this stage is a matter of pure speculation. The coupling to the Ras.MAPK cascade by 
Gi-protein coupled receptors has been suggested to be mediated by py subunits released 
from pertussis toxin sensitive G-proteins (see Section 1.4.13.3.1). These results may 
suggest that the ô opioid receptor may couple to the Ras.MAPK cascade not only by 
this pathway, in common with the other Gi-protein coupled receptors, but also through 
another as yet undefined point in the pathway which is exclusively available to the ô 
opioid receptor. Other speculations to explain this property may include an ability of 
the Ô opioid receptor to selectively couple to G-proteins containing py subunits with 
greater (and selective) potency to couple to the Ras.MAPK cascade. It would be 
interesting to detennine if these observations are specific for the ô opioid receptor or if 
other receptors could reproduce these results creating a subset of Gj-protein coupled 
receptors which would display these properties.
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Previous studies which recorded the various concentration-response relationships for 
p42/44^^ dAPK ^nd other effectors have failed to demonstrate any markedly greater 
efficiency of coupling to the MAPK cascade in contrast with other effectors. Such 
examples include the activation of p 4 2 /4 4 ^ ^ ^  by agents which use pertussis toxin 
insensitive pathways such as prostaglandin p2a (Watanabe etal., 1995), pertussis toxin 
sensitive pathways such as thrombin (Chen etal., 1994) and pathways which are 
partially sensitive to pertussis toxin such as platelet activating factor (Honda etal., 
1994). Therefore, although the stoichiometry of the GPCR-mediated activation of 
p42/44^P ^ had not previously been studied to any great extent, the available data 
does suggest that the observations described for the ô opioid receptor expressed in the 
Rati fibroblasts cannot be applied in general to all GPCRs.
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4.3 Conclusions
For the first time, the activation of by the ô opioid receptor has been
described and so the range of GPCRs which can activate this cascade has been 
extended. However, this result is perhaps not surprising considering the opioid 
receptor's previously described ability to signal via the G-proteins of the Gi family and 
the knowledge of a mechanism of Gi-protein-mediated activation of the Ras.MAPK 
pathway by Gpy. Much more surprising and novel conclusions, however, were made 
regarding the quantitation of this coupling and the relationship between the receptor 
expression level and the response to agonist stimulation.
The Ô opioid receptor expressed in Rati fibroblasts at a high and low density could 
functionally couple to the G-protein machineiy as shown with three different assays: 
agonist stimulation of high affinity GTPase activity, p^S]GTP/S binding and cholera 
toxin catalysed p^PJADP ribosyiation of Gi-like proteins. The maximal agonist- 
mediated stimulation was dependent on the receptor level in the two clones and the 
concentration of agonist which produced a half-maximal GTPase stimulation was lower 
in the higher receptor expressing clone. A greater inhibition of forskolin-stimulated 
adenylyl cyclase activity was also possible in the higher receptor expressing clone. In 
keeping with previously described multiple signalling ability, the receptor could also 
stimulate transphosphatidylation activity in a dose and receptor level-dependent 
manner. In addition, a somewhat variable ô opioid agonist-stimulated PLC activity was 
demonstrated. All these responses were mediated by pertussis toxin-sensitive, Gi-like, 
G-proteins.
Maximally effective concentrations of DADLE stimulated the phosphorylation of all 
the detectable p 4 2 ^ ^ ^  and p44MAPK both of these clones at a 5 min time point. 
This was sensitive to inhibition by both naloxone and pertussis toxin and therefore 
indicated that it was indeed mediated by the ô opioid receptor signalling through Gf- 
like proteins. An increase in activity of p42/44^^^^ accompanied their
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phosphorylation in both clones. The time courses of activation and phosphoiylation 
demonstrated distinct differences between the two clones which supported the idea 
proposed in chapter 3 that a greater expression of the GPCR would produce a more 
sustained time course due to the activation of a greater proportion of the G-protein 
population. This was further supported by the time course of p44MAPK 
phosphorylation in response to different concentrations of DADLE which appeared to 
allow some correlation between the possible GTPase activation and the activation of 
p42/44MAPK The more sustained activation of p42 /44^P ^  in clone D2 may make a 
great difference to the functional outcome of DADLE-treatment in these cells. It has 
been shown that DADLE-treatment of D2 cells is mitogenic as determined by its ability 
to stimulate DNA synthesis (Wilson e ta l ,  submitted), however, it remains to be seen if 
this occurs with DADLE-treatment of cells of clone DOE. It is unlikely that 
p42/44MAPK activation is sufficient for this effect as p70®^  ^activity appears to be 
required.
Perhaps the most novel and suiprising conclusions arose from the concentration- 
response curves for DADLE-mediated phosphorylation and activation of p42/44^^^I^. 
These results displayed a very large receptor and activated G-protein reserve in both 
clones, although the magnitude was greater in the higher expressing clone D2. This 
would indicate that the coupling between the receptor and this cascade is highly 
efficient. The inconsistencies which could not be reconciled in Chapter 3 do not arise 
from the data presented in this chapter. Another interesting observation was that the 
concentration-response curves for DADLE-mediated phosphorylation of p44klAPK 
displayed marked co-operativity (Hill coefficients were approximately 2.5). This was 
not observed, however, for the DADLE-mediated stimulation of GTPase activity and 
PLD activity nor for the phosphorylation of p44MAPK ppA nor by the Q2a 
adrenoceptor. Therefore this indicates that the ô opioid receptor, when expressed in the 
Rati fibroblasts, has some novel signalling ability with regards to the p42 /4 4 ^^^  
cascade which may involve an additional input site into this pathway.
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Chapter 5
Further studies on the regulation of the 
phosphorylation of p42/44M A PK  by the ô opioid
receptor:
partial agonists, inhibitors and cross-talk.
Chapter 5: Further studies on the regulation of the 
phosphorylation of p42/44M APK by the ô opioid 
receptor: 
partial agonists, inhibitors and cross-talk.
5.1 Introduction
The previous chapter quantitatively described the regulation of p42/44^*'^^'^ activity by 
the Ô opioid receptor following expression in Rati fibroblasts. This chapter initially 
will continue this work and provide evidence in support of the conclusions of the 
coupling efficiency to this cascade by a study on the ability of opioid agonists with a 
range of intrinsic activities at this receptor to stimulate the phosphorylation of 
p42/44MAPK The influence that other signalling pathways have on the p42/44^*'^^ 
activation by the ô opioid receptor will be examined by means of second messenger 
analogues and selective enzyme inhibitors in the second part of this chapter.
The different expression levels of the ô opioid receptor in clone D2 and clone DOE 
were used in Chapter 4 to study the relationship between the level of Gi-protein 
activation and stimulation of the p42/44^^^^ cascade. In this chapter, the regulation 
will be studied using ligands which have different levels of intrinsic activity and so 
would be expected to stimulate the G-protein machinery and the p 4 2 /4 4 ^ ^ ^  cascade 
to different extents. These ligands have been described as full agonists, partial agonists 
(which display lower intrinsic activity as measured by their inability to produce a 
maximal response, even at maximal receptor occupancy), neutral antagonists (which 
have no intrinsic activity), and one ligand has been described as an inverse agonist 
because it reduced the spontaneous activity of the receptor (Mullaney etaL, 1996). The 
relative efficacy of the ligands used in these experiments was detennined in NG108-15 
cells (Klee etal,, 1984). A ligand can display a range of intrinsic activities and 
potencies at a given receptor depending on a combination of different factors including 
the receptor expression level, receptor reserve and the level at which the output is
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measured (Hoyer and Boddeke, 1993) and, to some extent, these factors will be 
illustrated in this system.
The activation of by GPCRs does not occur in isolation of the other signal
transduction pathways in a cell but rather the cross-talk between pathways provides a 
further level of complexity and control. This could be of benefit to the cell because the 
functional output of the p42/44^^^^^ cascade (for example mitogenesis or 
differentiation) is synchronised with various environmental and cellular conditions. An 
example of this is the inhibitory effect of elevated cAMP levels on the G-protein 
coupled receptor-mediated activation of p42/44^^^^^ as described in Section 1.4.10 
and illustrated for the a%A adrenoceptor in Chapter 3. This chapter will extend this 
obseiwation to include the ô opioid receptor and will further examine cAMP's inhibitory 
effect on the time course of activation.
Phospholipases have been implicated in the control of mitogenesis by a number of 
GPCRs. The activation of p42 /4 4 ^^^  by many but not all Gq-protein coupled 
receptors has been shown to be dependent on PKC activation following the activation 
of PLC (for examples see Section 1.4.13.2). The activation of p42/44 d^APK yy many 
Gi-protein coupled receptors has been shown to be independent of PKC activity, 
however, it was thought that because the ô opioid receptor stimulated a measurable 
PLC activity, it would be worthwhile to determine whether a PKC-selective inhibitor 
(chelerythrine) affected the ô opioid-induced activation of p42 /44^P ^ . A slightly less 
well defined relationship is the role of PLD activity in the mitogenic response to both 
tyrosine kinase and G-protein-linked receptors (discussed in Boarder, 1994). PLD- 
derived phosphatidic acid has been implicated in the mitogenic response to ET-1 and 
angiotensin II in vascular smooth muscle cells (Wilkes etal,, 1993; Wilkie etal,,
1996). This was demonstrated by the selective inhibition mediated by butan-l-ol which 
diverted the PLD-formed phosphatidic acid to phosphatidyl butanol. However, there is 
no evidence to link the activities of p 4 2 /4 4 ^^^  and PLD and, for example, the
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vasopressin-mediated activation of p42/44^'^^^ and PLD in rat vascular smooth 
muscle cells were shown to be concurrent, but independent of each other (Jones et al., 
1994). The relationship between the stimulation of PLD and p42/44^^^^^ activity was 
examined in these cells as agonist stimulation of the Ô opioid receptor expressed in cells 
of clone D2 led to a strong stimulation of PLD activity (see Chapter 4).
As discussed in Chapter 1, the EGFR tyrosine kinase, PI3-kinase and a genistein- 
sensitive tyrosine kinase have been implicated in Gi-protein-mediated activation of 
p42/44MAPK The final part of this chapter will attempt to detennine if these kinases 
are involved in the pathway initiated by the ô opioid receptor by use of tyrphostin 
AG1478, wortmannin and genistein. In addition, the effect of the level of receptor 
expression on the potency of the inhibitors will be examined.
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5.2 Results and Discussion
Maximally effective concentrations of opioid ligands, which displayed a range of 
intrinsic activities at the level of adenylyl cyclase inhibition and GTPase activation in 
the NG108-15 cell line (Klee etal., 1984), produced a range of stimulations of high 
affinity GTPase activity in membranes from cells of clone D2 and clone DOE (Figure 
5.1). DADLE stimulated the greatest GTPase activity in both of the clones, although 
the maximal effect was larger in membranes of clone D2 compared with clone DOE as 
obseiYed earlier (Figure 4.1). In membranes of clone D2, the other ligands, except 
TIPPW, produced a range of stimulations of GTPase activity which were greater than 
the stimulation with DADLE in clone DOE. However, these ligands struggled to 
produce a measurable stimulation of GTPase activity in membranes from clone DOE 
and DADLE and possibly levorphanol were the only ligands which produced a 
stimulation over the basal level. TIPPW was previously described as a neutral 
antagonist and no efficacy of this ligand was detected at this level in either clone. The 
relative order of intrinsic activity of the ligands for GTPase activity in clone D2 was 
similar to that previously observed (Klee etal., 1984);
DADLE > Levoiphanol > Diprenorphine > Morphine > Buprenorphine > TIPPV 
This order of intrinsic activity in cells of clone D2 was also observed using other assays 
of G-protein coupling namely [^^8]GTPyS binding and cholera toxin-catalysed 
[32p]ADP-ribosylation experiments (data not shown). Therefore DADLE could be 
described as a full agonist, TIPPW as a neutral antagonist and the other four ligands as 
partial agonists.
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Figure 5.1 Effect of various opioid ligands on the high affinity GTPase activity in 
membranes from cells of clone D2 and clone DOE.
High affinity GTPase activity was measured as described in Section 2.2.4 on treatment 
of membranes derived from cells of clone D2 (hatched bars) and clone DOE (shaded 
bars) with various ligands (all at 10"^  M). Results are presented as mean ± SEM of 
triplicate assays of the activity in pmol/min/mg membrane protein and were calculated 
from one representative experiment from two (DOE) and three (D2) independent 
experiments performed.
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Treatment of cells of clone D2 and DOE with maximally effective concentrations of 
these ligands for 5 min stimulated the phosphoiylation of p4 4 MAPK an extent which 
was generally consistent with the observed stimulation of GTPase activity (Figure 5.2). 
As was expected from the previous chapter, DADLE stimulated the phosphorylation of 
the entire detectable population of p44MAPK both clones. In cells of clone D2, every 
other opioid ligand produced a near maximal phosphorylation of p44MAPK while only 
levorphanol produced a measurable effect in cells of clone DOE. The effect of the 
partial agonists in clone D2 is not surprising as the level of stimulation of GTPase 
activity by these ligands in these cells was greater than that achieved by DADLE in 
clone DOE. TIPPW, however, was not expected to produce this maximal (or any) 
effect as it is classed as a neutral antagonist. This ligand may stimulate the Gf-protein 
machinery to a slight degree which cannot be measured at the level of GTPase activity 
(there is no data to support this), but which is sufficient to induce the phosphorylation 
of p44^APK This explanation, however, is inadequate as the level of GTPase 
activation by TIPPW in clone D2 is lower than that produced by levorphanol in DOE 
cells, which can stimulate only a partial phosphorylation of p44 ^^ b^VPK The other 
unexpected result was that ICI 174864 consistently stimulated the phosphorylation of 
p44MAPK over the basal levels in clone D2. This ligand has been reported to be an 
inverse agonist in these cells (Mullaney etal., 1996) and so stimulation of 
phosphorylation of p44MAPK was totally unexpected. Although difficult to explain, the 
stimulation by TIPPW and ICI 174864 does appear to have been mediated by the Ô 
opioid receptor and not through some other effect on the cells as neither ligand 
displayed any detectable effect on the lower receptor expressing clone DOE. The lack 
of effect of the partial agonists in cells of clone DOE can perhaps be understood in 
tenns of the low or undetectable level of Gi-protein stimulation as measured by the 
GTPase assay.
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These results are similar in some ways to the effect of ligands with a range of intrinsic 
activities on the p2-^drenoceptor-mediated activation of adenylyl cyclase in two clones 
with differing levels of receptor expression (MacEwan et al., 1995). These ligands 
displayed higher intrinsic activities in the higher receptor expressing clone and the 
ligands with a relatively lower intrinsic activity were more sensitive to a reduction in 
receptor expression level Therefore, the elimination of a greater fraction of the 
receptor population was required to reduce the effect of a full agonist compared to that 
of a partial agonist. As presented in Figure 5.2, DADLE produced essentially maximal 
phosphorylation of p44^^^^ (at this time point) in both clone D2 and in clone DOE, 
whereas the agonists with lower intrinsic activity could produce a maximal response 
only in the clone expressing the higher level of receptors, and struggled to produce any 
effect in the lower expressing cell line. Therefore a similar differential sensitivity to 
the level of receptor expression was seen with partial agonists in this system.
EOF stimulated maximal phosphorylation of in both cell lines, again
indicating that both clones were sensitive in this assay. Treatment with ET-1 was 
included in this experiment because there were conflicting reports of the effect of this 
agonist in Rati fibroblasts (discussed in Section 1.4.13.2). In cells of clone D2 and 
DOE, the effect of 5 min treatment with ET-1 was somewhat inconsistent, however, 
usually a strong (but not maximal) stimulation of p44MAPK phosphoiylation was 
detected. ET-1 stimulated PLD and PLC activity more strongly than DADLE in clone 
D2 (see Figure 4.6 and 4.10) and the DADLE-mediated stimulation of PLD activity in 
clone DOE was very limited. This data indicates that it is highly unlikely that DADLE- 
mediated activation of PLD or PLC was responsible for the activation of p42/44^^^^, 
but would not mle out the involvement of PLD or PLC activity in this pathway (see 
below).
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Figure 5.2 Phosphorylation of p4 4 MAPK after 5 min treatment with maximally 
effective concentrations of various agonists in cells of clones D2 and DOE.
Serum starved cells o f clone D2 (hatched bars) and clone DOE (shaded bars) were 
treated with various agonists for 5 min at a concentration of 10-^ M apart from EOF 
(10'8 M) and ET-1 (10 M). The percentage o f p 4 4 ^ ^ ^  which was present in its 
phosphorylated form in each sample was measured by the electrophoretic mobility shift 
assay as described in Section 2.2.9.1. The result is representative o f two (DOE) or 
three (D2) experiments performed.
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Although the opioid partial agonists could maximally phosphorylate p#MAPK clone 
D2, differences were seen in the duration of this response (Figure 5.3A).
Buprenorphine and morphine were chosen to be compared with DADLE as they were 
two of the less efficacious partial agonists and so it was assumed that any differences 
would be greater and more easily observed for these ligands. Although the average 
maximum phosphorylation reached was perhaps slightly less than 100%, essentially the 
only difference between the time courses was that the duration of phosphorylation was 
consistently less for buprenorphine and morphine compared to that for DADLE (Figure 
5.3A). By 15 min of buprenoiphine or morphine treatment, phosphorylation levels of 
p44MAPK tiad fallen to approximately 45%, whereas on average 90% was still 
phosphorylated after treatment with DADLE. This is consistent with the differences in 
the DADLE-mediated time courses between clones D2 and DOE (see Figure 4.16) and 
time courses produced by different concentrations of DADLE in clone D2 (Figure 4.20) 
and supports the conclusion that a greater level of G-protein stimulation induces a more 
sustained activation of p42/44^"^^. The phosphoiylation of p44MAPK treating 
clone D2 with TIPPW or ICI 174864 was rather inconsistent and 100% phosphorylation 
was not usually detected. However, the time course of phosphorylation stimulated by 
these ligands, as shown in Figure 5.3B, followed similar patterns to that seen for the 
other partial agonists with perhaps a more transient peak of activity which would be 
consistent with a lesser degree of G-protein stimulation.
The time courses of two of the more efficacious opioid partial agonists in cells of clone 
DOE are displayed in Figure 5.4. The phosphorylation by diprenorphine and 
levoiphanol was also rather variable from experiment to experiment (perhaps because 
they are more sensitive to variations in receptor expression levels over different 
passages) but it was noted that the phosphorylation was more delayed than that 
obseiwed with DADLE in these cells (seen in Figure 4.16). These results are consistent 
with a lower level of G-protein stimulation (detected by the GTPase assay) producing a 
delayed, weaker and more transient stimulation of the phosphorylation of p4 4MAPK
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Figure 5.3 Time course of phosphorylation of p4 4 MAPK yy various opioid ligands 
in cells of clone D2.
Serum starved cells of clone D2 were treated for various times with different opioid 
ligands (all at M) and the phosphorylation status of p44MAPK each of the 
samples was measured by the electrophoretic mobility shift assay (according to Section 
2.2.9.1). Results are presented as the percentage of the total detectable p44^*'^^^ which 
was present in its phosphorylated form.
A Time courses for DADLE (open circles, full line), buprenorphine (closed circles, 
broken line) and morphine (open squares, dotted line). Results presented are mean ± 
SEM from at least three independent experiments.
B Time courses for TIPPW (open triangles, broken line) and ICI 174864 (closed 
triangles, dotted line). Results presented are from one of two experiments performed.
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Figure 5.4 Time coui*se of phosphorylation of p4 4 MAPK by diprenorphine and 
levorphanol in cells of clone DOE.
Serum starved cells of clone DOE were treated with 10"  ^M diprenorphine (open 
squares, full line) or 10“^  M levorphanol (closed squares, broken line) for various times. 
The percentage of phosphorylation of p 4 4 ^ ^ ^  present in each of the samples was 
measured by the electrophoretic mobility shift assay as described in Section 2.2.9.1 and 
results presented are from one of two experiments performed,
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Therefore the results produced with these opioid ligands confirm the conclusions 
presented in Chapter 4 concerning the relationship of the extent of G-protein 
stimulation by the receptor and the magnitude and time course of activation of
p 4 2 /4 4 M A P K .
It has already been stated that the ET-1-mediated phosphorylation of p 4 4 ^ ^ ^  in cells 
of clone DOE and D2 indicated that PLD activity was not responsible for the DADLE- 
mediated phosphoiylation of p 4 2 /44^^^ . The involvement of PLD activity in the 
regulation of p44MAPK was investigated further by pretreating the cells with 0.3% (v/v) 
butan-l-ol which trapped the PLD-derived phosphatidic acid as phosphatidyl butanol 
and prevented its action (Wilkes etal., 1993). This treatment produced no effect on the 
stimulation of p44MAPK phosphorylation in clone D2 by maximally effective 
concentrations of DADLE or EOF, however, there was some inhibition of the ET-1 
response (Figure 5.5A), (a reduction in basal phosphorylation of p44MAPK was also 
sometimes detected). The results were insufficient to conclusively prove that butanol 
had a significant effect on ET-1, and although work described later in this chapter 
would suggest that inhibitor studies using only cells which express high levels of 
receptor should be interpreted with caution, the data presented here would support the 
conclusion that PLD activity is not involved in the ô opioid receptor-mediated 
activation of p44MAPK The stimulation of PLD activity may still play a role in the 
mitogenic response to agonist-activation of the ô opioid receptor as demonstrated for 
angiotensin II-mediated mitogenesis in vascular smooth muscle cells (Wilkie etal., 
1996). Activation of p42/44^^^^ was necessary, but not sufficient, for the mitogenic 
response to angiotensin II, and the inhibitory effect of butan-l-ol on this response 
suggested that PLD activity was one of the other required signalling components.
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Cheleiythrine similarly displayed no consistent, inhibitory, effect on DADLE-mediated 
phosphoiylation of p 4 4 ^ ^ ^ in  clone D2 (Figure 5.5B). This compound is a protein 
kinase inhibitor which displays selectivity for PKC (Herbert etal., 1990) and so this 
data would tend to mle out an involvement of PKC in the ô opioid receptor-mediated 
activation of p 4 4 ^ ^ ^  (consistent with previous results for Gi-coupled receptors as 
discussed in Section 1.4.13.3). However, these results should be treated with caution as 
although chelerythrine did inhibit the phosphorylation induced by ET-1, this was not a 
complete effect and so the lack of effect on the response to DADLE could conceivably 
be due to the strong stimulation of the MAPK cascade being able to overcome a weak 
inhibition (see later for a similar observation with tyiphostin AG1478). Therefore, 
although not proved conclusively, the data would tend to exclude the involvement of 
PLD or PKC activity in the ô opioid mediated phosphorylation of p44MAPK but would 
indicate that these activities contribute to the ET-1-induced phosphorylation of 
p44.MAPKas was observed in vascular smooth muscle cells (Wilkes etal., 1993).
The involvement of the adenylyl cyclase pathway in the MAPK cascade was 
investigated by elevating cAMP levels with either dibutyryl cAMP or forskolin. 
Pretreatment of cells of clone D2 and DOE with 10"^  M dibutyiyl cAMP significantly 
(p < 0.05) attenuated the phosphorylation of p44MAPK stimulated by 5 min treatment 
with maximally effective concentrations of DADLE and EGF (Figure 5.6 and data not 
shown). 10"-^  M forskolin pretreatment of cells of clone D2, however, only attenuated 
the phosphorylation in response to EGF and not to DADLE. A similar observation was 
made with the «2A adrenoceptor (see Table 3.1) and is possibly because of Ôopioid 
receptor-mediated inhibition of forskolin-amplified adenylyl cyclase activity (see 
Figure 4.5). Therefore, the ô opioid receptor-mediated phosphorylation of p4 4^APK 
Rati fibroblasts was also attenuated by elevated cAMP levels as observed for 
numerous other GPCRs (see Section 1.4.10).
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Figure 5.5 The effect of pretreatment of butanol and chelerythrine on the 
phosphorylation of p4 4 MAPK jjy DADLE, EGF and ET-1 in cells of clone D2.
A Serum starved cells of clone D2 were pretreated for 10 min with serum free DMEM 
containing 0.3% (v/v) butan-l-ol (shaded bars) or with no additions (control - hatched 
bars). The cells were then treated for a further 5 min by the addition to final 
concentrations of 10"  ^M EGF, 10"  ^M DADLE, 10"  ^M ET-1 or no addition (basal). 
The percentage phosphorylation of was then assessed by the electrophoretic
mobility shift assay as described in Section 2.2.9.1.
B Serum starved cells of clone D2 were pretreated for 30 min with serum free DMEM 
containing 10"  ^M chelerythrine (shaded bars) or with 0.1% (v/v) DMSO (control - 
hatched bars). The cells were then treated and p44MAPK phosphorylation was assessed 
as in part A.
Results for both parts are from one of two experiments performed.
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Figure 5.6 The effect of pretreatment of cells of clone D2 with dibutyryl cAMP or 
forskolin on DADLE and EGF-mediated phosphorylation of p4 4 MAPK
Serum starved cells of clone D2 were pretreated with serum free DMEM containing no 
addition (hatched bars), 10’^  M dibutyryl cAMP (shaded bars), or M forskolin 
(speckled bars) for 20 min prior to 5 min treatment with lO'  ^M DADLE, IQ-^  M EGF 
or no ligand (basal). The percentage phosphorylation of p44^P^ was assessed in 
each of the samples by the electrophoretic mobility shift assay (Section 2.2.9.1) and the 
data is presented as mean ± SEM, from three independent experiments.
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The attenuation by dibutyryl cAMP of the phosphorylation of p 4 4 ^ ^ ^  in response to 
5 min treatment with DADLE in clone D2 was not usually complete (on average 20% 
phosphorylation remained). It was subsequently discovered that pretreatment of these 
cells with 10'^ M dibutyryl cAMP did not eliminate the DADLE-mediated 
phosphorylation of p44MAPK rather produced a time course which was delayed, 
more transient and had a reduced maximum (Figure 5.7A). It typically took a further 5 
min after the maximum was achieved in the control cells for the maximal 
phosphorylation to be reached in the dibutyiyl cAMP-treated cells and this maximum 
was only 70% phosphorylation. This level was not sustained, in contrast with the 
elevated phosphorylation in the control cells which was still detected after 30 min. A 
similar but greater effect was observed in cells of clone DOE (Figure 5.7B). The delay 
of phosphorylation was perhaps even more obvious and the greater magnitude of 
inhibition of phosphorylation was sometimes such that a complete elimination of 
DADLE-mediated phosphorylation was observed. This perhaps was because the 
stimulation of this cascade by the lower expression level of ô opioid receptors in clone 
DOE was sometimes unable to overcome the inhibitory effect of the dibutyryl cAMP. 
Alterations in the time course of activation can have profound effects on the functional 
outcome of the stimulation of the MAPK cascade (as discussed in Section 1.4.15.1) and 
so these results illustrate how the functional effect on a cell of the stimulation of the 
MAPK cascade could be modified by other signal transduction pathways.
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Figure 5.7 Effect of dibutyryl cAMP pretreatment on the time course of DADLE- 
mediated phosphorylation of p44 '^*^*  ^in cells of clone D2 and DOE.
Serum starved cells of clone D2 (A) or clone DOE (B) were pretreated for 20 min with 
serum free DMEM containing 10"  ^M dibutyryl cAMP (closed circles, broken lines) or 
left untreated (open circles, full lines). The cells were then treated with the addition of 
DADLE to a final concentration of 10"  ^M and incubated for various times. The 
phosphorylation of p44MAPK was assessed in each of the samples by the 
electrophoretic mobility shift assay (Section 2.2.9.1) and the results are presented as 
percentage of the total detectable p44^^^^ which was phosphorylated. Data in part A 
represents mean ± SEM from three independent experiments, data in part B is from one 
of two experiments performed.
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The effect of elevated levels of cAMP is thought to be mediated by a PKA-directed 
phosphorylation of Raf or other MEKK (see Section 1.4.10). These results would 
therefore suggest that this inhibition can be overcome by a greater stimulatoiy signal on 
these MEKKs or that the greater expression of the ô opioid receptor in clone D2 
permits the activation of a cascade which does not involve a PKA-sensitive component. 
They might also suggest that the second input into the MAPK cascade suggested from 
the co-operativity observed in the concentration-response curves of DADLE-mediated 
activation of p 4 2 /4 4 ^ ^ ^  (see Figure 4.21-4.23) could possibly be provided by a 
reduction in cAMP (by an inhibition of adenylyl cyclase or stimulation of a 
phosphodiesterase). Although this idea is cuiTently purely speculative a similai' dual 
input to the p42/44^ ‘^' ^ ^  cascade has been proposed for the p-adrenoceptor in COS-7 
cells (Crespo etal., 1995). In this case the simultaneous signals are opposing with the 
balance between the stimulatory signal (mediated by Ggjjy) and the inhibitory signal (by 
Gsa-mediated elevation of cAMP and PKA activation) determining the outcome. 
However, in the case of the ô opioid receptor, the two signals appear to be stimulatory 
which could possibly produce the obseived co-operativity.
Pretreatment with 10"  ^M dibutyryl cAMP also reduced the transphosphatidylation 
activity in response to DADLE in cells of clone D2 (Figure 5.8A). However the results 
are not conclusive because the basal activity was reduced by the pretreatment so that 
although the actual activity in the presence of DADLE was reduced, there was still a 
substantial stimulation over basal in the presence of dibutyryl cAMP. The pretreatment 
had no consistent effect on the response to ET-1. There was no obvious change in the 
time course of DADLE-mediated activation of PLD other than a slight decrease in the 
maximal activation (Figure 5.8B). Elevated cAMP levels in these cells, therefore, did 
not have the same effect on the PLD activity as it does on the MAPK cascade which 
would indicate that the inhibitory effect of this compound did not occur at the level of 
the receptor.
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Figure 5.8 The effect of pretreatment with lO"^  M dibutyryl cAMP on the ET-1 
and DADLE-mediated activation of transphosphatidylation activity in cells of 
clone D2.
A Cells of clone D2 were labelled with [^H]palmitate (4 ;<Ci/ml) for 24 hours and then 
pretreated with HBGbutanol for 20 min with (shaded bars) or without (hatched bars) 
10"^  M dibutyryl cAMP (after the usual washes of HBG and HBGbutanol). The cells 
were treated for 15 min by the addition of agonists to final concentrations of 10"  ^M 
DADLE or 10-  ^M ET-1 or there was no addition (basal activity). The 
transphosphatidylation activity was then measured as described in Section 2.2.10 and 
the activity in each sample is presented as the radioactivity measured in 
phosphatidylbutanol in DPM. Results displayed are mean ± SEM of triplicate assays 
from one of three experiments performed.
B Cells were treated, in an identical fashion to part A, with a final concentration of 10”^  
M DADLE for various periods of time. Transphosphatidylation activity was then 
assayed as before. Results are mean ± SEM of triplicate assays from one of two 
experiments performed. Control cells are represented by the open circles and full line, 
cells which were pretreated with 10'^ M dibutyryl cAMP are represented by filled 
squares and broken line.
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Tyrphostin AG1478, at the lowest concentration used (2.5 x 10'^ M), attenuated the 
phosphorylation of p44MAPK jjj response to 5 min DADLE to almost half of the control 
level in cells of clone DOE (Figure 5.9B). Slightly more inhibition was produced by 
higher concentrations of this inhibitor, but it was never complete. This was in contrast 
to the lack of effect of tyrphostin A G1478 (at up to 2.5 x 10“*^ M) on the stimulation of 
phosphoiylation of p44MAPK ^y 5 min of DADLE treatment in cells of clone D2 
(Figure 5.9A). The attenuation of ô opioid receptor-mediated phosphorylation of 
p44MAPK by tyrphostin AG1478 is consistent with its previously reported inhibitory 
effects on GPCR-mediated activation of p 4 2 /4 4 ^^^  in Rati fibroblasts (Daub etal., 
1996). However, the attenuation was never complete in clone DOE and was not 
detected in clone D2. This, presumably, reflects the greater receptor expression level in 
clone D2 and would suggest that the tyrphostin AG1478-mediated inhibition can be 
overcome by a greater stimulation of the MAPK cascade. A loss of sensitivity of 
insulin-mediated phosphoiylation of p44MAPK to pertussis toxin and pARKct was 
reported following overexpression of the insulin receptor in Rati fibroblasts (Luttrell et 
aL, 1995b). The suggestion was made that this indicated that the insulin receptor at 
high density could utilise a Gpy-independent pathway or that Gpy was only required at 
low receptor expression when efficient signalling was essential. Another interpretation 
of the response for the ô opioid receptor-mediated effect could be that the tyrphostin 
AG1478-sensitive step can similarly be by-passed, but only in clone D2 can this 
alternative pathway be sufficiently stimulated to produce maximal phosphorylation of 
p44M A P K
In both clones, tyiphostin A G1478 inhibited EGF-mediated phosphorylation of 
p44MAPK jn a dose-dependent manner (Figure 5.9). It was reported that the G-protein 
coupled activation of p44^^^^K was more sensitive to inhibition by tyrphostin A G1478 
than was the stimulation by EGF (Daub etal., 1996). The results presented here 
demonstrated that this conclusion depends on the GPCR expression level. These 
results therefore implicate the EGFR kinase in the p44MAPK cascade activated by the ô
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opioid receptor. However, this conclusion depends on the specificity of tyrphostin 
AG1478 for the EGFR kinase which may not be as exclusive as previously reported as 
shown by an inhibition of the PDGF-mediated p44 MAPK activation at similar levels to 
that required for the inhibition of the EGF-mediated response (Wilson, Milligan and 
Anderson, unpublished observations).
Some tyrphostins have been reported to display inhibitoiy effects on GTPase activities. 
However, tyrphostin AG1478 did not display any ability to interfere with the ô opioid 
receptor-mediated activation of G-proteins in clone D2 or DOE as demonstrated by the 
lack of effect of this compound on DADLE-mediated stimulation of high affinity 
GTPase activity in membranes prepared from either clone (data not shown). Therefore 
tyrphostin AG1478 must act at a point downstream of the G-protein machinery in order 
to inhibit the activation of the p42/44^'^^^^ cascade.
Pretreatment of cells of clone DOE with 2.5 x lO'^ M tyrphostin AG1478 did not 
significantly alter the time course of DADLE-mediated phosphorylation of p44MAPK 
(Figure 5.10). Although the magnitude of the inhibition was not always identical, 
consistently a reduction in the maximal phosphorylation was detected without any 
drastic alteration to the time course. Therefore the effect of tyrphostin AG1478 in 
clone DOE was a true inhibition and not just a delay of the time course of 
phosphoiylation.
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Figure 5.9 The effect of various concentrations of tyrphostin AG1478 on DADLE 
and EGF-mediated phosphorylation of p4 4 MAPK ju cells of clone D2 and DOE.
Serum starved cells of clone D2 (A) and clone DOE (B) were pretreated for 10 min 
with serum free DMEM containing 10"^% (v/v) DMSO (control - hatched bars) or 
tyrphostin AO1478 at the following concentrations: 2.5 x 10"^  M (shaded bars), 1.25 x 
1 0 M (striped bars) or 2.5 x 10"'^  M (speckled bars). Cells were then treated for a 
further 5 min with no agonist (basal), 10“^  M EGF or 10-  ^M DADLE and the 
phosphorylation status of p44MAPK was assessed by the electrophoretic mobility shift 
assay (Section 2.2.9.1). Data is presented as the percentage of the total detectable 
p 4 4 M A PK  which was present in its phosphorylated form, mean ± range, from two 
independent experiments for each clone.
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Figure 5.10 The effect of tyrphostin AG1478 on the time coui-se of 
phosphorylation of p44^ ^^ ^^  ^by DADLE in cells of clone DOE.
Serum starved cells of clone DOE were pretreated for 10 min with serum free DMEM 
containing IQ'4% (v/v) DMSG (control - open circles, full line) or 2.5 x ICr  ^M 
tyiphostin A G1478 (filled circles, broken line). Cells were then treated with 10"  ^M 
DADLE for various times and the phosphorylation status of p44MAPK ^as assessed by 
the electrophoretic mobility shift assay (Section 2.2.9.1). Data is presented as the 
percentage of the total detectable p44MAPK which was present in its phosphorylated 
form, and is from one of three experiments performed.
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The concentration-response curve of DADLE-mediated phosphoiylation of p44MAPK 
in cells of clone D2 was basically unaffected by pretreatment with 2.5 x 10’^  M 
tyrphostin AG1478 (Figure 5.1 lA). There was, however, a consistent, slight increase 
in the required concentration of DADLE for half-maximal effect in these cells and so 
there may have been some inhibition which could be easily overcome. This shift to the 
right in the concentration-response curves of DADLE-mediated phosphoiylation of 
p44MAPK was also demonstrated in cells of clone DOE, although this was not as 
striking as the reduction in the maximum effect (Figure 5.1 IB). The magnitude of the 
inhibition was rather variable over different experiments, however, in each experiment 
with clone DOE, an obvious reduction in the maximum phosphorylation of p44^^^*^  ^
and an increase in the EC50 value was obseiwed after pretreatment with tyiphostin 
AG1478.
Pretreatment with 2.5 x 10'^ M tyrphostin AG1478 also produced a rightward shift in 
the concentration response curves of EGF-mediated phosphorylation of 
both clone D2 and clone DOE (Figure 5.12). The EC50 values were increased between
1.5 and 4.5 fold. Therefore, although this concentration of inhibitor was unable to 
prevent 100% phosphoiylation of p4 4 MAPK^  the concentiation of EGF which was 
required in order to produce this effect was consistently increased. It is of interest that 
these concentration-response curves also displayed a large Hill coefficient as was 
calculated for the DADLE-mediated phosphorylation of p44MAPK (gee Chapter 4). 
Tyrphostin A G1478, therefore, appears to have a similar effect on the phosphorylation 
of p44^^l'^ mediated by the ô opioid receptor and by the EGFR which may imply the 
involvement of a common kinase in the cascades induced by either receptor.
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Figure 5.11 Effect of tyrphostin AG1478 on the concentration-response curves for 
DADLE-mediated phosphorylation of p4 4 MAPK [j, Qf clone D2 and DOE.
Serum starved cells of clone D2 (A) or clone DOE (B) were pretreated for 10 min with 
serum free DMEM containing 10-4% (y/v) DMSG (control - open circles, full line) or
2.5 X 10-  ^M tyrphostin AG1478 (filled circles, broken line). Cells were then treated 
for 5 min with various concentrations of DADLE and the phosphorylation status of 
p44MAPK was assessed as described in Section 2.2.9.1 by the electrophoretic mobility 
shift assay. Data is presented as the percentage of the total detectable p44MAPK which 
was present in its phosphorylated form, and is from one of two (D2) and three (DOE) 
experiments performed.
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Figure 5.12 Effect of tyrphostin AG1478 on the concentration-response curves for 
EGF-mediated phosphorylation of in cells of clone D2 and DOE.
Serum starved cells of clone D2 (A) or clone DOE (B) were pretreated for 10 min with 
serum free DMEM containing 1 0 " ^  (v/v) DMSG (control - open circles, full line) or
2.5 X 10'^ M tyrphostin AG1478 (filled circles, broken line). Cells were then treated 
for 5 min with various concentrations of EGF and the phosphorylation status of 
j>44MAPK was assessed as described in Section 2,2.9.1 by the electrophoretic mobility 
shift assay. Data is presented as the percentage of the total detectable p44MAPK which 
was present in its phosphorylated form, and is from one of two experiments performed.
1 8 6
Figure 5.12
A 120
1 0 0
a 8 0 “
t
a  6  0 “%
5  2 0  “Q*
- 2 0
1 o " 1 0'^ ®
[EGF] (M)
B
1
oÆg-O
aIeu
120
100
8 0
6 0
4 0  -
2 0
- 20 -H-
10
I I
-12 j  Q-11 j  Q-10
[EGF] (M)
1 0 1 0 1 0-7
Genistein (a tyrosine kinase specific inhibitor) has been reported to attenuate the 
activation of p 4 2 /4 4 ^ ^ ^  by some, but not all, Gi-coupled receptors (see Section 
1.4.13.3.3). As discussed in Chapter 3, genistein failed to display any inhibitory effect 
on the (%2A adrenoceptor-mediated activation of p44MAPK Figure 3.3). Similarly, 
in cells of both clone D2 and clone DOE, 5 x 10"  ^M genistein pretreatment failed to 
affect the stimulation of phosphorylation of p4 4MAPK by a 5 min treatment with 10'^ M 
DADLE (Figure 5.13). This was observed even although, in these experiments, the 
DADLE-mediated phosphorylation of in clone DOE was much less than
maximal. This concentration of genistein did consistently reduce the phosphorylation 
of p44MAPK by EGF to a small extent in cells of clone D2, but not (for some unknown 
reason) in cells of clone DOE. The data, however, would demonstrate that the ô opioid 
receptor-mediated phosphorylation of p 4 4 ^ ^ ^  is insensitive to genistein.
Pretreatment of cells with 10"'^  M wortmannin significantly (p < 0.05) attenuated the 
phosphorylation of p44MAPK response to 5 min treatment of maximally effective 
concentrations of DADLE in cells of clone DOE (Figure 5.14B). In a similar 
obseiwation to the effect of tyrphostin AG1478, only a limited attenuation of the 
DADLE-mediated phosphorylation of p4 4MAPK ^vas observed in clone D2 (Figure 
5.14A). The phosphorylation in response to 5 min treatment of EGF in either clone 
was unaffected. This would implicate a wortmannin-sensitive PI3-kinase activity in the 
cascade leading to phosphorylation of p44^^^^I^ by the ô opioid receptor in these cells 
as has been reported for other GPCRs (see Section 1.4.14.1). A different explanation 
could be that wortmannin acted at a different target which is involved in this MAPK 
cascade. Wortmannin-sensitivity has been reported for the activation of p70®^  ^by the ô 
opioid receptor (Wilson etal., submitted) and the cc^ A adrenoceptor (Wilson etal.,
1996) expressed in Rati fibroblasts and so there is a possibility that wortmannin acts at 
a step which is common to the Gf-protein coupled receptor-mediated activation of 
p42/44l^^APK and p7Qs6k.
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Figure 5.13 Effect of pretreatment with genistein on the phosphorylation of 
p4 4 MAPK by DADLE and EGF in cells of clone D2 and DOE.
Serum starved cells of clone D2 (A) and clone DOE (B) were pretreated with serum 
free DMEM containing 1% (v/v) DMSG (control - hatched bars) or 5 x 10-^ M 
genistein (shaded bars) for 10 min. Cells were then stimulated with no agonist (basal), 
10-8 jyi EGF or 10'^ M DADLE for a further 5 min and the phosphorylation level of 
p44MAPK was assessed by the electrophoretic mobility shift assay (Section 2.2.9.1). 
The percentage of the total detectable p4#lAPK which was in its phosphorylated form 
is represented as mean ± range from two independent experiments performed for each 
clone.
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Figure 5.14 The effect of wortmannin on the p4 4 MAPK phosphorylation stimulated 
by DADLE and EGF in cells of clone D2 and clone DOE.
Serum starved cells of clone D2 (A) and clone DOE (B) were pretreated in serum free 
DMEM containing 10-8% (y/v) DMSO (control - hatched bars) or 10'^ M wortmannin 
(shaded bars) for 5 min. Cells were treated for a further 5 min in the presence of no 
agonist (basal), 10*8 M EGF or 10'^ M DADLE and the electrophoretic mobility shift 
assay was performed to determine the phosphorylation status of p44MAPK each of 
the samples according to Section 2.2.9,1. Results are presented as the percentage of the 
total detectable p44MAPK which is present in its phosphorylated form, mean ± SEM 
from three (D2) or four (DOE) observations.
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5.3 Conclusions
The work described in this chapter continued the study of the regulation of 
p42/44MAPK yy the Ô opioid receptor following its expression into Rati fibroblasts as 
described in Chapter 4. Specifically, the first section of this chapter provided evidence 
in support of the conclusions made regarding the quantitative relationship between the 
activation of p42/44^''^^^ and the stimulation of G-proteins. Opioid ligands with 
various intrinsic activities at this receptor demonstrated a much greater ability to 
stimulate p44 b^U^ K phosphorylation in cells of clone D2 than in cells of clone DOE. 
Ligands which displayed partial agonism at the level of G-protein activation displayed 
activities at the level of p44 l^APK phosphoiylation which could permit their description 
as full agonists in that they induced maximal phosphorylation by 5 min treatment in D2 
cells. However, in cells of clone DOE, these ligands struggled to stimulate 
phosphorylation over the basal level. This can be explained in the light of the large 
receptor and activated G-protein reserve present for the activation of p44MAPK jn clone 
D2 (described in Chapter 4), which would enable a ligand which can stimulate only a 
limited G-protein coupling to significantly activate the p 4 2 /4 4 ^^^  cascade. A 
surprising and unexplainable observation, however, was the stimulation of 
phosphorylation in cells of clone D2 produced by previously described neutial 
antagonists and inverse agonists.
This work also supported the conclusion that the time course of activation was closely 
regulated by the extent to which the G-protein machinery was stimulated. Therefore, in 
clone D2, the opioid ligands which had a lower efficacy produced a delayed and more 
transient activation of p4 4MAPK^  the difference seen with the time courses 
corresponding to the differences measured at the level of G-protein stimulation. In 
clone DOE, although the efficacies of the ligands were insufficient to maximally 
phosphorylate p44MAPK^  two of the partial agonists were able to stimulate a limited 
phosphoiylation of p44MAPK which displayed a more delayed and transient time course 
in compaiison to that produced by DADLE.
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The second section of work considered the involvement of other signalling pathways 
and kinases in the ô opioid receptor-mediated phosphorylation of p44MAPK g^ta was 
presented which indicated that PLD and PKC activity was not sufficient for, and 
probably not involved in, the regulation of p44MAPK hy this receptor. In contrast, 
elevated cAMP displayed a definite inhibitory effect on the stimulation of p44 MAPK 
phosphorylation which was consistent with the results with the o.2A adrenoceptor 
(Chapter 3). Elevated levels of cAMP did not completely eliminate the ô opioid 
receptor-mediated phosphorylation of p44MAPK cells of clone D2 and DOE, but 
rather produced a delayed and more tiansient time course coupled with the reduction in 
maximal output. These effects were more substantial in the lower receptor expressing 
cell line and so raised the possibility of an alternative PKA-insensitive pathway which 
could be stimulated to a greater extent by a greater receptor density. This data also 
proposed a reduction in cAMP levels as a possible secondary input by the opioid 
receptor into the MAPK cascade. Elevated levels of cAMP also displayed very limited 
ability to attenuate the DADLE-mediated activation of PLD in clone D2 which was 
considered as evidence to indicate that the effect of elevated cAMP on the activation of 
p42/44MAPK not occur at the level of the receptor.
The final part of this chapter made use of inhibitors which had been previously reported 
as having inhibitory effects on selective kinases. The data in general supported the 
conclusion that the ô opioid receptor-mediated phosphorylation of p44^ 1^ K was 
achieved through a genistein-insensitive, but wortmannin and tyiphostin AG 1478- 
sensitive pathway. This implicates both a PI3-kinase and an EGFR kinase in the 
cascade leading to the activation of p44MAPK was also clear that the overexpression 
of the receptor in clone D2 allowed DADLE to activate the MAPK cascade even in the 
presence of these inhibitors. This would either suggest that the inhibitory effects can be 
overcome or that alternative pathways are possible.
191
Chapter 6: Final Discussion
Chapter 6: Final Discussion
Understanding of GPCR-mediated stimulation of the p42/44^^PI^ cascade has 
progressed rapidly in the last few years. However, there was only a limited amount of 
quantitative infoiination available on this regulation and it was this deficit that my thesis 
initially aimed to meet. It had been proposed that Gpprotein coupled p 4 2 /4 4 ^ ^ ^  
activation occurred as a result of receptor overexpression which forced unphysiological, 
or at least inefficient, coupling to the pathway to give a detectable response (e.g.
Malarkey et a/., 1995). This was conclusively shown to be incorrect as low level 
expression of the (%2A adrenoceptor or the ô opioid receptor in Rati fibroblasts permitted 
significant (maximal at 5 min time point) activation of p42 /44^^^ . The coupling of 
these receptors to the MAPK cascade would thus appear to be highly efficient, because 
the coupling to other effectors and to G-protein activation was severely limited in these 
lower receptor expressing cells. This conclusion was reinforced by the ability of opioid 
ligands witli little intrinsic activity in GTPase activity measurements to significantly 
phosphoi-ylate p 4 4 ^ P ^  in clone D2.
The presence of a large receptor and activated G-protein reserve for the stimulation of 
p42/44MAPK hy the ô opioid receptor was further demonstrated by comparison of the 
concentration-response curves for DADLE-mediated phosphoiylation/activation of 
p42/44MAPK and high affinity GTPase activity (Figure 4.24). EC50 values for the 
activation of GTPase activity in clones D2 and DOE were 5.7 x 10'^ M and 4.2 x 10"^  M, 
respectively, which are in a similar range as the Kdfor DADLE binding to the ô opioid 
receptor (approximately 2 to 5 x 10"  ^M). This would possibly indicate the absence of a 
receptor reserve for the coupling to the G-protein population in these cells. However, the 
difference in EC50 values between clone D2 and DOE would perhaps suggest that in 
clone D2, such a receptor reserve does exist because in a situation of no receptor reserve, 
it might be expected to only see a reduction in the maximal output with no change to EC50 
value when comparing a high and low receptor expressing cell line. This could be
1 9 2
investigated further by means of increasing concentrations of an in’eversible antagonist 
which would increasingly ‘knock out’ proportions of the receptor population. 
Deteimination of the ability of these vai ious functional receptor populations to stimulate 
high affinity GTPase activity (or another measure of G-protein activation) would 
determine whether a receptor reserve is present in clone D2. A receptor reserve would be 
seen as a shift in the concentration-response cuiwes to the right with no reduction in the 
maximum output with increasing concentrations of irreversible antagonist, until the 
receptor reserve was abolished (Figure 6 .1). Further increases in ineversible antagonist 
concentrations would reduce the maximum output without further affecting the EC50, as 
might be anticipated to be observed if clone D2 contained no receptor reserve for G- 
protein activation. It is of interest to notice that earlier work (MacNulty e/a/., 1992) with 
Rati fibroblast clonal cell lines expressing the adrenoceptor to various levels, 
demonstrated the absence of a receptor reserve for the activation of high affinity GTPase 
activity by the high correlation between receptor expression level and maximal agonist- 
stimulated high affinity GTPase activity, although the receptor expression levels observed 
in clone D2 were never produced in those experiments.
Although it is difficult to interpret the results from the concentration-response curves to 
DADLE for the stimulation of transphosphatidylation (PLD) activity for DOE cells, it 
would appear that there is no receptor reseiwe for this effector in the D2 cell line. This 
was concluded because the EC50 value for DADLE in clone DOE was not greater than for 
clone D2 but mther there was a significant reduction in the maximum output (Figure 4.9). 
Once again the the EC50 value for clone D2 was very similar to the Kd for this receptor 
(Figure 4.9).
Even if some degree of receptor reserve for the activation of the G-protein population in 
clone D2 does exist, it is dramatically smaller than that which exists for the activation of 
p42/44MAPK these cells. This was clearly demonstrated by the significantly smaller 
EC50 value (7.3 x M), and so for this effect there exists a large receptor and
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Figure 6.1 Illustration of receptor reserve
Hypothetical results from an experiment proposed in the main text to investigate the effect 
of treatment with increasing concentrations of an irreversible antagonist prior to 
concentration-response determinations for an agonist in a situation where a large receptor 
reserve exists in the control state.
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activated G-protein reserve (Figure 4.21 and 4.22). In clone DOE, such a reserve was 
also obvious, although it was significantly smaller as is consistent with the lower level of 
receptor expression in this clone. Thus, there would appear to be a very low receptor 
expression requirement in order for the ô opioid receptor to maximally activate (at 5 min) 
the p 4 2 /44^P ^  cascade. The use of an ineversible antagonist acting on the ô opioid 
receptor in clone DOE which would further reduce the level of functional receptors in the 
cells, or an inducible receptor expression system to control the level of receptor 
expresssion would facilitate further study of the receptor reserve and may allow a 
detennination of the minimum receptor expression level which is required to maximally 
activate p42/44^^^^. It would then be of interest to compare this required level of 
receptor expression with other GPCRs expressed in Rati fibroblasts and various other 
cellular backgrounds, to investigate the generality of these obseiwations and the 
possibility of receptor/cell specificity in the coupling efficiency to the p42/44^PI'^ 
cascade. As the coupling to the p42/44^'^P^ cascade is assumed to be mediated by the 
Gj3y subunits, the large activated G-protein reserve for p4 2 /44^P ^  activation in both 
clone D2 and DOE would appear to contradict the previous ideas that effectors which use 
such a coupling mechanism display a requirement for greater stoichiometry of G-protein 
and effector activation (higher receptor occupancy) than do Ga-coupled responses.
The situation is not as clear for the ct2A adrenoceptor expressed in Rati fibroblasts. A 
receptor reserve for the agonist-stimulated, high affinity GTPase response (Figure 3.6) 
could possibly exist based on the same reasons noted above for the ô opioid receptor.
The ability of the lower expressing clone TAGWT 3 to maximally stimulate p42/44^^P^ 
on treatment with UK14304, and the ability of the ASN79 clones to stimulate the 
phosphorylation of p 4 4 ^ P ^  (Figure 3.10), when they displayed a much reduced 
signalling capacity to G-proteins and effectors (Figures 3.5, 3.7 and 3.8), would suggest 
that a receptor and activated G-protein reserve did exist for this effect. However, the 
concentration-response curves appealed to contadict such a conclusion. Unfortunately 
this inconsistency was not resolved in these experiments and so further work is still
1 9 5
required to determine if highly efficient coupling to the p42/44^^^^ cascade is a selective 
property of the ô opioid receptor.
Another difference between the GPCRs studied in this thesis was that the ô opioid 
receptor-mediated p42/44^^^^ activation/phosphorylation was co-operative in nature 
(Figure 4.21), whereas this was not observed for the oc2A adrenoceptor (Figure 3.12) or 
LPA receptor (Figure 4.23). This suggests that there may be additional input sites into 
the MAPK pathway for the ô opioid receptor which are not available for the other 
GPCRs. The ability of the ô opioid receptor to inhibit adenylyl cyclase activity (Figure 
4.5) and the inhibitory effect of elevated cAMP levels on p 4 2 /4 4 ^P ^  activation in these 
cells (Figure 5.6) could suggest that a secondary input into the MAPK pathway may 
occur at this level. However, this suggestion is unable to explain the selective nature of 
this regulation because co-operativity has only been recorded for the ô opioid receptor, 
whereas the other GPCRs studied also displayed agonist-mediated inhibition of adenylyl 
cyclase (Figure 3.8). It would be of interest to know to what extent the co-operativity 
can be observed for other receptor/cell systems. This might help explain the exclusive 
ability of the ô opioid receptor as well as suggest what signalling component is 
responsible for the proposed secondary input into the MAPK cascade. In addition, the 
level in the cascade at which co-operativity can still be observed could also focus the 
investigation into possible secondary input points.
The time course of activation of p 4 2 /4 4 ^ ^ ^  appeared to be closely regulated by the 
level of G-protein activation produced by the receptor. Therefore, a greater G-protein 
coupling produced a more rapid and sustained stimulation. The time course varied 
greatly with the GPCR expression levels, the coupling efficiency of the receptor (wild 
type versus Asn'^  ^mutant), and the concentration and intrinsic activity of ligands used 
(see Figures 3.10, 4.16, 4.20, 5.3 and 5.4). As discussed previously (Section 
1.4.15,1), the functional outcome of the MAPK cascade is closely dependent on the 
duration of activation and so in this way the outcome of the GPCR-mediated
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p42/44^^Pï^ activation in each cell could possibly be modified and controlled by all of 
the above factors as well as by cross-talk from other signalling pathways (such as the 
cAMP pathway).
Understanding the involvement of vaiious kinases and other signalling pathways in the 
regulation of p42/44^^^^ by GPCRs was the final objective of this thesis. Agents with 
reported inhibitory activity at selective kinases were used to address some of these issues 
and the conclusions from such experiments necessarily depend heavily upon the 
selectivity of these agents. The influence of the cAMP signalling pathway on the GPCR- 
mediated p42/44^^P^ cascade has been discussed above. It would appear, however, 
that PLD or PKC activity does not influence the MAPK pathway initiated by the ô opioid 
receptor (Figure 5.5) as expected for Gi-protein coupled receptors (see Section 
1.4.13.3), although the results presented in Chapter 5 do not exclude the possibility of 
the Ô opioid receptor using a PKC activity to provide an additional or alternative 
mechanism for stimulating the p 4 2 /4 4 ^ ^ ^  pathway. The data does support the view 
that Ô opioid-mediated stimulation of PLD activity was not sufficient for the observed 
level of activation of p42/44^^^^ but further study would be required in order to 
conclude that these pathways are completely independent.
The sensitivity to wortmannin may imply the involvement of a PI3-kinase y-like (G- 
protein activated) PI3-kinase isotype (Stoyanov etal, 1995) in the regulation of ô opioid- 
induced p42 /44^P ^  activation (Figure 5.14), although the experiments performed made 
no attempt at identifying the wortmannin-sensitive species in the pathway. A role for a 
PI3-kinase y-like enzyme would be consistent with a recent report of agonist-mediated 
activation of p42/44^^^^ by the muscarinic m2 acetylcholine receptor expressed in 
COS-7 cells which appeared to signal via PI3-kinase y in a Gp y-dependent manner 
(Lopez-Ilasacac?fl/., 1997). In this cell system, PI3-kinase y was placed directly 
downsti'eam of Gpy leading to a pathway involving a tyrosine kinase. She, Grb2, mSos,
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Ras and Raf. However, the mechanism connecting the activation of the PI3-kinase to the 
tyrosine phosphoiylation of She was not investigated.
The EGFR tyrosine kinase was implicated by the inhibitory effect of tyrphostin AG 1478
on DADLE-mediated phosphoiylation of p44MAPK clone DOE (Figure 5.9). This
could imply that the ô opioid receptor can activate the p42/44^^PK pathway tlnough
activation of the EGFR tyrosine kinase in the absence of EGF as concluded previously
for other GPCRs (Daub etal, 1996). The majority of the data in this thesis would not be
inconsistent with this role for EGFR kinase in the ô opioid receptor-stimulated MAPK
pathway, apart from possibly the lack of effect of forskolin on DADLE-mediated
p 4 4 M A P K  phosphorylation when EGF-mediated activation was significantly attenuated
(see Figure 5.6). However, this might perhaps be explained by the ability of the ô opioid
receptor to mediate inhibition of adenylyl cyclase (Figure 4.5). The wortmannin-
sensitive step would appear to be upstream of the EGFR kinase (or on a parallel pathway)
as shown by the insensitivity of EGF-mediated phosphorylation of p 4 2 /4 4 ^ ^ ^  to
wortmannin at concentrations which inhibit DADLE-mediated phosphorylation of 
p/|/|MAPK^
The ability of DADLE to stimulate appaiently maximal phosphorylation of p44^^Pl^ in 
clone D2 in the presence of a concentration of tyiphostin A G1478 which significantly 
attenuates the EGF-mediated phosphorylation of p44^ P E  would perhaps suggest that 
the greater receptor expression level achieved in clone D2 permitted activation of a 
pathway distinct from the EGFR kinase to such an extent that full p44MAPK 
phosphorylation could be induced. Alternative kinases could be provided from the Src 
family of tyrosine kinases and/or by a PYK2-like kinase which have been implicated in 
the activation of p42/44^^P^ by some GPCRs (see Section 1.4.13.3 and 1.4.13.5).
The majority of the literature has implicated a genistein-sensitive kinase in the GPCR- 
mediated activation of p42/44^'^^^ and although genistein was apparently without effect 
in clone D2 and DOE (Figure 5.13) there could be a role for such a kinase under
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conditions in which the EGFR kinase is inhibited. The EGFR kinase is thought to 
mediate the signal from GPCRs to p 4 2 /4 4 ^ ^ ^  via She tyrosine phosphorylation and 
Grb2.mSos association (Daube/a/., 1996) and these other kinases could also perform 
such a role. It would therefore be of some interest to detennine whether a similar level of 
DADLE-stimiilated She tyrosine phosphorylation is achieved in tyrphostin AG1478- 
treated cells as was observed in uninhibited D2 cells (Mullaney etal, 1997) which might 
indicate if the tyrphostin insensitivity is the result of the direct substitution of another 
tyrosine kinase into the role of the EGFR or whether a distinct input into the pathway at a 
different level in the pathway is possible for the ô opioid receptor.
These results would therefore again raise the possibility of multiple inputs into the MAPK 
pathway by the ô opioid receptor as was discussed in relation to the observed co­
operative nature of p42/44^P^^ activation. Investigating the effect of tyrphostin 
AG1478 (and wortmannin) on the oc2A adrenoceptor agonist and LPA-mediated 
activation of p44MAPK jq determine if this appaient choice of pathways is available for 
these receptors, may suggest whether a lack of such alternative pathways explain the lack 
of co-operativity in the responses seen with these ligands.
The above conclusions suggest a possible model pathway of agonist-mediated activation 
of p42 /4 4 ^P ^  by the ô opioid receptor when expressed in Rati fibroblasts as shown in 
Figure 6.2. The data discussed here does not address the question of whether the 
wortmannin-sensitive step and the EGFR kinase lie on the same pathway or represent 
alternative/parallel pathways which are both required for full activation (at least in the 
absence of a large receptor overexpression) and have been drawn as they are for the sake 
of simplicity. It is not inconsistent with the data presented for the wortmannin-sensitive 
step to lie on the alternative pathway which was speculated to pennit full stimulation of 
p44MAPK jn the presence of tyrphostin AG1478 in the D2 clone. These aspects of this 
model could be tested from a more thorough study of the maximum inhibition possible by
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Figure 6.2 Model of p4 2 /4 4 ^APK regulation by the agonist-activated ô 
opioid receptor when expressed in Rati fibroblasts.
Possible model of activation of p42/44^PI^ by the agonist activated ô opioid receptor 
after heterologous expression in Rati fibroblasts in order to explain the effects of 
tyrphostin A G1478 and wortmannin on this pathway. See main text for details.
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tyrphostin AG1478 and wortmannin and the effect of both compounds when they are 
allowed to act together. Src and PYK2-like kinases and PKC are included in tins model 
only to demonstrate possible secondary inputs and their involvement in this regulation in 
these cells is purely speculative at present.
This thesis has described the regulation of p 4 2 /4 4 ^^^  in teims of receptor expression 
level and G-protein activation required for coupling, the relation between G-protein 
activation and duration of MAPK response, the possible involvement of multiple input 
points into the pathway and the cross-regulation and involvement of kinases of other 
signal transduction pathways. Although many of these observations could possibly be 
described as general for Gi-protein coupled receptors, there is certainly a degree of 
receptor (and possibly cell) specificity, the extent of which will require further 
investigation.
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